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Signaling molecules are critically important to regulate cellular processes. 
Therefore, their incorporation into engineered biomaterials is indispensable for the 
applications in tissue engineering and regenerative medicine. In particular, the 
functionalization of highly hydrated polymer networks, so-called hydrogels, with 
the signaling molecules, has been quite beneficial to provide multiple cell-
instructive signals. Following this strategy, the incorporation of sulfated 
glycosaminoglycans (GAGs) into such polymer networks offers unprecedented 
options to control the administration of signaling molecules via electrostatic 
interactions. Moreover, mathematical models can be instrumental in designing 
materials to tune the transport and adjust the local concentration of the signaling 
molecules to precisely modulate cell fate decisions. Accordingly, this study aims 
to systematically investigate the impact of different binary poly(ethylene glycol)-
glycosaminoglycan hydrogel networks on the transport of signaling molecules by 
developing and applying mathematical modeling in combination with 
experimental approaches. The gained knowledge was then applied to modulate the 
bioactivities of pro-angiogenic growths factor within the binary hydrogel and 
rationally design a new class of cytocompatible GAG-based materials for the 
controlled administration of pro-angiogenic growth factors. 
Firstly, systematic studies on the mobility of signaling molecules within GAG-
based polymer networks revealed differential effects of hydrogel network 
parameters such as mesh size, GAG content, and the sulfation pattern of the GAG 
building block on the transport of these signaling molecules. 
Secondly, the effect of the GAG content of the hydrogel and the sulfation pattern 
of the GAG building block on the bioactivity of hydrogel administrated vascular 
endothelial growth factor (VEGF) have been analyzed. Since VEGF is a GAG-
affine protein that plays a major role in angiogenesis, its ability to promote 
vascular morphogenesis has been investigated. The simulation and experimental 
results demonstrated the determining impact of the availability of free (unbound) 




polymer network on the formation of the endothelial capillary network within the 
hydrogel.   
Finally, a rational design strategy has been applied to extend a GAG-hydrogel 
platform to allow for a far-reaching control of its cell instructive properties. The 
resulting materials are independently tunable over a broad range for their 
mechanical properties and GAG content. The GAG content of the hydrogel 
matrices, in particular, was shown to modulate the transport of pro-angiogenic 
growth factors most. Moreover, the hydrogel also supports endothelial vascular 
morphogenesis. 
In conclusion, the in here followed approach of combining experimental results 
and mathematical modeling for predicting the transport of signaling molecules 
and the rational design concept for customizing GAG-based hydrogel networks 
provide the fundamentals to precisely modulate cell fate decisions within GAG-
based biohybrid polymer networks rationalizing their application for tissue 
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1. Introduction  
1.1 Motivation 
Soluble signaling molecules are critically important to regulate cellular processes 
such as cell survival, migration, differentiation, and proliferation, which 
orchestrate physiological phenomena including tissue repair and regeneration [1, 
2], angiogenesis [3-6], and immunomodulation [7, 8]. Therefore, incorporating 
such cell-instructive signals into hydrated polymer networks, so-called hydrogels, 
is highly indispensable for their applications in tissue engineering and 
regenerative medicines. The mobility of bioactive proteins within- and the 
subsequent release from the hydrogel may not only affect the activity of cells 
within the scaffold but may also determine the host responses at the site of 
implantation [9-13]. Despite the significant roles of signaling molecules in cell 
fate decisions, controlling their retention and activity within the tissue-engineered 
construct remains a significant challenge primarily because of their short half-
lives [14, 15] and narrow therapeutic windows [16, 17]. Therefore, engineering 
delivery strategies for soluble signaling molecules that could modulate the release 
and prolong their bioactivity are essential to precisely control cell fate decisions. 
Several studies have examined the development of delivery systems based on 
polymeric biomaterials to achieve tunable and sustainable delivery of the growth 
factors [4-6, 16, 18, 19] while minimizing the side effects of improper dosing 
[20]. Growth factors, a particular class of soluble signaling molecules, can be 
physically entrapped within the polymeric network to control their release rate 
from the polymer matrix. However, the extended-release of growth factors 
resulting from this approach will only last for a few hours to a day, depending on 
the thickness of hydrogel [126]. To overcome this, the covalent immobilization 
and engineering of growth factors with higher affinity for the matrix may be 
applied to prolong the retention within the polymer network. Their applications 
have been successfully reported [21-24]. Nevertheless, both approaches may alter 
the growth factor functionalities and require complicated procedures. 





engineered biomaterials can be explored to modulate the release kinetics and 
preserve the bioactivity of growth factors within engineered biomaterials [25]. 
Due to the presence of a heparin-binding domain, positively charged surface 
patches of the growth factors can reversibly interact with negatively charged 
GAGs through electrostatic interaction, thereby increasing their retention and 
stability [26]. Besides, the GAGs were also known to facilitate various growth 
factors binding to their receptor and potentiate the receptor activation, therefore, 
enhancing their overall bioactivity [27-29]. 
1.2 State of the art of modulation of the transport of 
signaling molecules in GAG-based materials 
The high-affinity interaction between GAGs and various soluble signaling 
molecules have inspired the utilization of GAGs as an affinity ligand for delivery 
systems of growth factors for various applications, including BMP-2 for bone 
regeneration [30], VEGF and FGF-2 for tissue vascularization [4-6], SDF1α for 
endogenous cells recruitment [19, 31], neurotrophin-3, NGF, and GDNF for nerve 
regeneration [32-34], and TGF-β for wound healing [35]. In order to achieve a 
desired cellular response upon the in vitro or in vivo applications of the GAG-
based-affinity system, several features of the materials can be tuned to control the 
mobility of encapsulated proteins and the subsequent release from the matrices 
(Figure 1.1). 
The chain lengths and the sulfation pattern of the GAG are essential for the 
growth factor binding and the ability of GAGs to enhance the stability of 
signaling molecules [36]. In particular, controlling the degree of sulfation of the 
GAG has been exploited to modulate the local affinity interaction between 
signaling molecules and GAG-based polymer matrices [37, 38]. For example, 
Attallah et al. have developed a starPEG-heparin hydrogel system with varied 
sulfation patterns through a cytocompatible Michael type addition crosslinking 
scheme between the thiol functionalized starPEG and maleimide-functionalized 
heparin [38]. Heparin derivatives with variable sulfation degree (N-, 6O-, and 
6ON-desulfated heparins) were generated and incorporated into the hydrogel to 





gradient and release of platelet-derived growth factor (PDGF)  from hydrogel 
matrices. Moreover, similar strategies have also been applied to control the release 
kinetics of FGF2 and VEGF from the starPEG-heparin hydrogel constructs using 
different crosslinking chemistry for network formation [6, 39]. Both overall and 
local sulfate density of the hydrogel was shown to modulate the rate of VEGF 
release in vitro. Moreover, the hydrogels with the lowest sulfate content were 
superior in promoting angiogenesis [6].  
Besides the local affinity, the overall affinity of GAG-hydrogels can also be tuned 
by adjusting the density of signaling molecule binding sites in the system. 
Depending on the structure and molecular weight of a particular protein and 
heparin, heparin may simultaneously bind several protein molecules [40]. 
However, as simplification, it is often assumed that one soluble signaling 
molecule bind to one heparin, i. e. in a 1:1 binding stoichiometry. This implies 
that the total heparin content of the hydrogel is directly proportional to the number 
of total protein binding sites in the gel.  
The strategy to adjust the heparin content of GAG-based materials has been 
successfully applied to modulate the release kinetics of many heparin-binding 
proteins [41-46] and enhanced the bioactivity of the molecules within engineered 
matrices. For example, Jha and coworkers developed bioinspired hyaluronic acid-
based hydrogels to aid stem cell transplantation therapy [42]. The incorporation of 
the heparin within the matrix enhanced the retention of the exogenously 
supplemented TGF-ß1 over 20 days. Besides, a tunable release could be achieved 
by modulating the concentration and molecular weight of heparin [43]. Similarly, 
the sustained release of bone morphogenetic protein-2 (BMP-2) from heparin 
containing hyaluronic acid microgels can also be achieved by varying the heparin 
content of the microgel from 1-10% (w/w) [41]. In a related study, heparin 
functionalization has been exploited to enhance the binding and retention of 
VEGF in polycaprolactone/ alginate scaffolds [45]. Heparin immobilization on the 
construct could modulate the VEGF binding and release and promote a more 





Adjusting the GAG content within a GAG based hydrogel is not always possible, 
especially within a system where the GAG is utilized as the major building block 
of the material [47, 48]. Incorporating small quantities of the GAG into such a 
kind of hydrogel is limited by the minimum solid content requirement that allows 
for the hydrogel formation. As a result, modulating the availability of free binding 
sites of the protein within the hydrogel network by merely changing the ratio of 
the protein loading to the GAG content can be used as an alternative strategy to 
modulate the release kinetics of proteins. This strategy has been previously 
applied to modulate the overall release of VEGF, FGF-2, PDGF-BB, TGF-ß, and 
IL-4 from heparin-based hydrogels [4, 6, 26, 35, 38, 39]. In general, more protein 
release could be observed as the loading concentration increases. However, this 
approach did not change the overall release efficiency of the system, as in the case 
of tuning the hydrogel intrinsic binding properties.  
 
Figure 1.1. Different strategies to modulate the transport of signaling molecules 
within GAG-based materials. Modified from [25]. 
 
In addition to modulating the affinity of signaling molecules to GAG, the mobility 
of proteins embedded within the GAG-based hydrogels can also be tailored by 
tuning the mesh size of hydrogels. In this approach, the extent of protein diffusion 
is governed by the steric interaction between the protein and polymer network. If 
the mesh size of the hydrogel is larger than the protein size, the protein diffusion 
is inversely proportional to the molecular size of the protein, similar to the protein 
diffusion profile in the solution [49]. The incorporation of enzymatically 





remodeling of polymer network by cell-secreted matrix metalloproteinases 
(MMPs) that enlarge the mesh size and subsequently induce a higher release of 
encapsulated molecular cargos. For example, Prokoph et al. have utilized this 
concept to modulate the release of SDF1α from starPEG-heparin hydrogel 
matrices to induce the recruitment of early endothelial progenitor cells (eEPC) 
into an ischemic tissue [19]. In vitro release studies of the SDF1α from the 
hydrogel have shown that the addition of the MMPs into the cleavable hydrogel 
could enhance the SDF1α release, especially within the first 24 H of the release 
studies. Moreover, tuning the degradability of the polymer network can further be 
applied by incorporating MMP-cleavable peptides along with the linkers of 
differing hydrolytic sensitivity to tailor the release of protein from the scaffold 
[50]. 
Many studies have shown that the incorporation of GAG within a synthetic 
polymer network enhances the retention of many therapeutically relevant growth 
factors [5, 19, 39]. However, maintaining a subtle balance between the retention 
and delivery of signaling molecules to the surrounding tissues or encapsulated 
cells can be crucial in determining cell fate decisions. As an affinity ligand, GAG 
determines the relative concentration of the matrix-bound and freely diffusing 
factor [32, 51-53], which can have different bioactivity [22, 54]. Combining all 
the GAG hydrogel network parameters into a mathematical model could be 
instrumental in designing materials that achieve the desired rate of morphogen 
transport [32, 55], to precisely modulate cellular responses [30, 56]. Besides, the 
model will also potentially speed up the discovery of biomaterials with tailored 
signaling molecule transport properties by testing different combinations of 
parameters in silico before experimental evaluation.  
The application of mathematical models to predict the transport of signaling 
molecules within GAG-based materials in the presence or absence of matrix 
degradation has been previously described [33, 53, 55, 57]. For example, 
Sakiyama-Elbert and Hubbell developed a mathematical model to describe the 
release of fibroblast growth factor 2 (FGF-2) from a fibrin matrix functionalized 
with the heparin [53]. Simulation results using the model allowed the 





minimize the passive release of the factor from the matrix. In a related study using 
the same delivery system, the effect of heparin content of the fibrin matrix to 
modulate the release of neurotrophin-3 (NT-3) for spinal cord injury was 
investigated [33]. The mathematical model suggested the optimal ratio between 
the heparin and the heparin-binding peptide that shifted the balance of the growth 
factor toward a matrix-bound state rather than a free heparin-bound state. In the 
study, the experimental release also confirmed the impact of heparin content on 
the overall release of NT-3. However, a direct comparison between the resulting 
experimental release and theoretical release was not presented.   
Similarly, Hettiaratchi et al. developed a computational model to predict the 
BMP-2 release from alginate-based hydrogels containing heparin microparticles 
(HMPs) in vivo [55]. The mathematical model suggested that the incorporation of 
HMPs lowered the BMP-2 released into surrounding tissues, and the release of the 
BMP-2 can be tailored by modulating the amount of HMPs in the construct. 
Nevertheless, the enhancement in the retention of growth factors through the 
incorporation of HMPs did not improve the materials' in vivo performance. The 
results of the studies also pointed out that additional parameters such as the 
competitive binding of the serum-borne proteins to the affinity ligands need to be 
considered when applying the engineered materials in vivo to achieve more 
predictable biological outcomes [58]. 
More recently, a mathematical model has also been applied to predict the release 
kinetics and short-range gradient of SDF1α from microparticles containing GAG 
that mimic cytokine releasing cells within a three-dimensional extracellular matrix 
[59]. The gradient of proteins developed from the particles was shown to be 
dependent on the concentration and affinity interaction facilitated by the GAG.  
Moreover, the functionality of the gradient to modulate cellular responses was 
demonstrated by a directed migration of hematopoietic cell line and primary 
murine hematopoietic stem and progenitor cells (Sca-1+CD150+CD48−) toward 
the SDF1α containing microparticles over periods of several hours. In a related 
study, the same approach has also been adapted to emulate paracrine signaling of 
TGFβ1 during wound healing [60]. The slow and sustained delivery of TGFβ1 





fibroblasts into myofibroblasts at a significantly lower concentration than the 
systemic delivery of signaling molecules.  
Mathematical models have been previously applied to guide the design of GAG-
based biomaterials for bone and neural tissue engineering [55, 57, 61]. However, 
their applications in vascular tissue engineering have not been reported. The 
vascular network is essential to supply the cells with the nutrients and oxygen as 
well as for the removal of metabolic waste to maintain the cell survival and 
functions beyond their diffusion limit in tissues (< 200 µm) [62-64].  As such, the 
ability to engineer functional microvasculatures is essential for the success of 
therapeutic vascularization and tissue engineering [65]. Within this context, pro-
angiogenic growth factors, including the vascular endothelial growth factor 
(VEGF), plays a pivotal role in regulating vascular functions and development by 
stimulating proliferation, migration, survival, and differentiation of endothelial 
cells  [66-72]. Previous studies on the VEGF gene therapy revealed that the newly 
generated vessel could be therapeutically beneficial only when they were stable 
indefinitely [73]. Accordingly, this could be achieved when the VEGF stimulation 
was provided for at least four weeks [74-76]. The GAG-based materials could 
offer powerful options to enhance the stability of pro-angiogenic growth factors 
and modulate their sustained administration [6, 77].  Thus, rational design 
strategies using the mathematical model that described the influence of each GAG 
hydrogel network parameters on the transport of the signaling molecules will 
potentially enhance the cell-instructive properties of the material to promote 
strong angiogenesis responses. 
GAGs can bind to a broad spectrum of proteins with different properties [7, 78]. 
Therefore, a systematic study on the transport of signaling molecules with various 
physicochemical properties in a fully defined and tunable GAG-based hydrogel 
platform would allow us to dissect the influence of each hydrogel network 
parameter on the transport of the growth factors.  Previously, we have developed 
the cell-instructive binary GAG-based-hydrogel system based on heparin and 4-
arm poly(ethylene glycol)-(starPEG) peptide conjugates [47]. The theory-driven 
material design concept has enabled the formation of hydrogels with different 





been extended to generate hydrogels with similar mechanical properties of 
varying sulfation patterns [110, 309]. The overall GAG content and the GAG 
sulfation pattern of the system can be varied to tailor the binding of various 
cytokines and growth factors of different physicochemical properties [38, 78]. 
Besides, the system is compatible with a direct encapsulation of human umbilical 
veins endothelial cells (HUVECs) and has been adapted as a 3D in vitro model of 
angiogenesis [3]. 
1.3 Aim of the work 
The thesis study aimed to systematically investigate the impact of different 
starPEG-GAG hydrogel network parameters on the transport of signaling 
molecules of different physicochemical properties by developing and applying 
mathematical modeling and combine it with experimental approaches. The gained 
knowledge should then be applied to control the vascular endothelial cell 
morphogenesis within already established starPEG-GAG-hydrogels and as an 
extension to rationally design a set of GAG-based hydrogels with well-adjusted 
network properties that significantly extend the current state of the art for the 
control of transport and biological activity of pro-angiogenic growth factors. 
To accomplish these goals, the project should be divided into three sections:  
 
1. Understanding of the transport and binding of signaling molecules 
within the existing binary starPEG-GAG hydrogel system 
2. Modulation of the bioactivity of pro-angiogenic growth factors to 
control the vascular endothelial cell morphogenesis within the binary 
starPEG-GAG hydrogel system 
3. Development of a ternary starPEG-GAG hydrogel system allowing for 
a fare-reaching control of the GAG content to enhance the 
administration of pro-angiogenic growth factors 
In this thesis, the impact of different network parameters of the binary starPEG-





pattern on the mobility and release kinetics of model proteins with different sizes 
and affinity to GAGs, will be first analyzed. Following the development of a 
mathematical model to analyze the diffusion and binding of signaling molecules 
within the polymer network, the impact of tuning the GAG content and GAG 
sulfation pattern of the hydrogel on the vascular endothelial growth factor 
(VEGF)-mediated endothelial cell vascular morphogenesis will be examined. 
Lastly, a ternary GAG-based hydrogel system will be developed to control the 
administration of pro-angiogenic growth factors by extending our previously 
established binary hydrogel system synthesis protocol [47]. The network 
characteristics, transport properties, as well as the applicability of the materials to 
support endothelial cell morphogenesis, should be evaluated. 
Taken together, this thesis project aimed to combine experimental and 
computational modeling approaches to systematically evaluate the influence of 
network properties of the GAG-based biohybrid hydrogels on the mobility of 
various signaling molecules with different properties, allowing for the rational 
design of hydrogels. This insight gained here may be applied to the design and 
translation of GAG-based biohybrid hydrogels for tissue engineering and 





2. Fundamentals  
2.1 Extracellular matrix and the cell signaling functions 
2.1.1 The extracellular matrix (ECM) structure and functions 
The extracellular matrix (ECM) is a dynamic structure around the animal cells 
providing the structural support, anchoring site, and biochemical signaling 
(Figure 2.1 ). Besides providing the mechanical cues to the cells, the ECM also 
controls the development, cellular morphogenesis, homeostasis, and 
differentiation of stem cells by regulating the availability of biomolecular signals 
and their receptors and the local physicochemical properties (pH and hydration) of 
the cellular microenvironment [80-83].  The ECM continuously undergoes 
remodeling due to a dynamic interplay between the cells and their environment, 
creating diversity in the structural and compositional of the ECM of different 
types of tissues [83, 84]. Several pathological conditions, such as cancer and 
abnormal scarring, are even characterized by their unique ECM composition and 
microarchitectures [83, 85]. 
2.1.1.1 The components of the ECM 
The ECM consists of a complex and organized cell-secreted meshwork of 
glycoprotein, polysaccharides/ glycosaminoglycans (GAGs), and proteoglycans. 
Collagen is the most abundant glycoprotein in the ECM, and it constitutes about 
more than 40% of the protein in the human body. Naturally, it forms a strong 
fibrous structure that provides mechanical support or attachment site to the cells. 
Twenty-eight different types of collagen have been identified. Each variant 
comprises an intertwined triple helix of polypeptide chains that exist as 
homotrimers or heterotrimers [86]. This triple helix structure particularly allows 
the collagen fiber to engage in different functions, including self-association, 
binding to the other ECM proteins, glycosaminoglycans (GAGs), and nucleic 






Figure 2.1. The extracellular matrix (ECM). The ECM is a complex meshwork 
containing structural and adhesion proteins, as well as highly hydrated 
proteoglycans. Adapted from [87] 
 
In the ECM, a collagen fiber is embedded within woven hydrated proteoglycan 
complexes. Proteoglycan distribution is varied within the tissues. Large 
proteoglycans, including aggrecan and versican, are secreted into the extracellular 
space; small proteoglycans such as decorin and lumican are located within the 
basement membrane, whereas proteoglycans like syndecans and serglycin are 
found on the cell surface and inside the cells, respectively [82]. The structure of 
proteoglycans composed of a core protein that is covalently linked to GAGs, long 
and linear negatively charged polysaccharides with disaccharide units. The 
hydrophilic nature of the GAG component of proteoglycans correlates well with 
its function to provide hydration and mechanical resistance to the tissues.  
GAGs can be classified into several main groups that differ in their degree of 
sulfation, chain length, and sugar composition of the disaccharides unit. These 
groups include hyaluronic acid (HA), chondroitin sulfate (CS), dermatan sulfate 
(DS), keratan sulfate (KS), heparan sulfate (HS), and the closely related family, 
heparin (Hep). Except for HA, all GAGs are sulfated. The degree of GAG 





affinities for different molecules within the ECM, such as the growth factors, 
chemokines, and other ECM proteins like laminin and fibronectin, and cell 
surface receptors; suggesting their role in various cellular processes [88-92]. 
Apart from the structural components, the ECM contains connector proteins, such 
as laminin and fibronectin, that facilitate the interactions between the structural 
elements and other components of the ECM or cells. Typically, the connector 
proteins are composed of multidomain of glycoprotein that serves as a binding site 
of other ECM proteins, signaling molecules such as vascular endothelial growth 
factors (VEGFs) [93] and the transforming growth factor-β1 (TGF-β1) [94], and 
the cell surface receptors [82]. Notably, the adhesive RGD sequence of fibronectin 
can be incorporated into cell-instructive materials to mediate the cell attachment 
on the surface- or within 3D polymeric networks.   
2.1.1.2  The functions of the ECM 
Cells respond to mechanical signals that originate from the external forces, cell-
cell, and cell-matrix interactions in a process called mechanotransduction [95, 96]. 
As described before, the cell perceives biomechanical signals in the ECM through 
integrin proteins. The binding of integrin to the ECM proteins triggers the 
activation of intracellular signaling pathways that induce the expression of genes 
involved in the regulation of cell proliferation, differentiation, and apoptosis [81] 
(Figure 2.2). Equally, the resident cells also constantly renew and remodel the 
ECM through synthesis, modification, reassembly, and degradation of 
surrounding  ECM components and the release of biomolecular signals that are 
immobilized in the matrix [97]. Subsequently, the released signaling molecules 
affect the nearby cells in an autocrine or paracrine manner, leading to diverse 
cellular functions. Overall, this suggests that the cross-talk between the 
biochemical and mechanical signaling allows integrating local signals that 







Figure 2.2. Cells respond to biophysical and biomolecular signals from the ECM 
and actively remodel their microenvironment. Physical and biochemical cues from 
the ECM are perceived by the cells by activating intracellular signaling pathways 
that trigger the gene expression, synthesis, and secretion of ECM components. 
Matrix remodeling initiated by the resident cells through the secretion of matrix 
metalloproteases (MMP) degrades the ECM and allows the release of growth 
factors that activate diverse cellular functions. Adapted from [97] 
 
2.1.2 GAG as the regulator of signaling molecule activity in the ECM 
2.1.2.1 Signaling function of GAGs 
Glycosaminoglycans have a profound effect on potentiating the growth-factor 
mediated cellular signalings.  In particular, heparan sulfate (HS) has long been 
recognized as a co-receptor of growth factors that facilitate the binding to the 
receptor tyrosine kinases and the resulting cellular responses.  As an example, the 
complex formation between the HS, FGF-2, and the FGF2 receptor (Figure 2.3A) 
could promote the dimerization of FGF/FGFR and, subsequently, activate the 
tyrosine kinase domain and downstream signaling pathways that modulate the cell 
motility, survival, and proliferation [98]. Besides,  glycosaminoglycan is known to 
interact with the integrin on the cell surface [99]. Such interaction could 





through the association between integrin cytoplasmic tail and adaptor proteins 
such as focal adhesion kinase and Src [100, 101] (Figure 2.3B).  
2.1.2.2 Protection and stabilization of growth factors 
Protecting the growth factors from thermal denaturation and degradation by 
proteases is another mechanism by which the GAGs enhance the bioactivity of 
proteins over time (Figure 2.3C). The stabilizing effects of polyanions, including 
the heparin or heparan sulfate against physical or enzymatic degradation has been 
previously documented on cytokines [102-104], and growth factors such as 
fibroblast growth factor (FGF-1) and FGF-2 [103, 105]. While the thermal 
denaturation can happen anytime, especially at a high temperature, the 
degradation of growth factors within the tissues may be elevated under certain 
physiological conditions such as the inflammation stage of the wound healing 
process. In this case, the GAG-based biomaterials could be instrumental in 
promoting tissue regeneration by protecting pro-regenerative cytokines from cell-
secreted proteases. In a recent study, Schirmer and co-workers have demonstrated 
that the heparin-based hydrogel could protect the encapsulated IL-4 against 
thermal denaturation and cleavage by protease’s model [26]. Moreover, the 
hydrogel also sustainability released the cytokine over two weeks, and as 
indicated by the ability to promote the activation of macrophages, the released 






Figure 2.3. GAG regulates the activity of soluble signaling molecules. (A) GAG 
enhances the FGF-2 binding to the receptor. (B) GAG mediates the association 
between the extracellular domains of the receptor of PDGF-BB to the integrin. (C) 
GAG protects the growth factors from thermal and proteolytic degradation. (D) 
During the angiogenesis, GAG maintains the formation of the VEGF gradient. (E) 
The affinity of VEGF isoforms to the GAG determine their gradient profiles 
within the ECM, which eventually shapes different vascular morphologies. Figure 








2.1.2.3 Formation of growth factor gradient 
The glycosaminoglycan controls the spatiotemporal presentation of soluble 
signaling molecules within the ECM.  This mechanism can be illustrated, for 
example, during the angiogenesis process. Angiogenesis involved the secretion of 
proteases that degrade the basement membrane, allowing the endothelial cells to 
migrate into the tissue and forming sprouting vasculatures. Subsequently, VEGF's 
gradient guides the migration of endothelial cells, controls their proliferation rates 
and initiates the vascular morphogenesis events (Figure 2.3D). Moreover, VEGF 
can be synthesized either as a longer isoform (VEGF189 and VEGF165) or 
shorter isoform (VEGF121) [106-108], which influence their ECM binding 
properties. The binding affinity of VEGF to the GAG not only guides the 
migration of endothelial cells but also shapes the overall morphologies of 
vasculatures (Figure 2.3E). VEGF165 and VEGF 189 have very restricted 
mobility and form a step VEGF gradient that orchestrates the formation of a large 
density of thin and highly branched vessels [108, 109]. On the other hand, the 
VEGF121 creates a shallow VEGF gradient in the ECM that lead to the formation 
of short, a small number of leaky vessels with a wide diameter [106, 109-112].  
2.2 Modelling the transport of signaling molecules in 
affinity-based systems 
Affinity-based growth factor delivery system modulates the release kinetics of 
embedded growth factors through the affinity interactions between the binding 
ligand and growth factor of interest. The binding ligand can be a protein, peptide, 
DNA, or glycosaminoglycans (GAGs), and typically linked to the hydrogel 
network through a covalent linkage [52, 113, 114]. Selecting the right binding 
ligand with a specific strength of interactions is essential to control the 
administration of bioactive molecules at a desired rate and dosage. For that, 
several methods, including isothermal titration calorimetry (ITC) [115], Surface 
plasmon resonance (SPR) [116], biolayer interferometry (BLI) [117], and 
microscale thermophoresis [118], have been developed to measure the strength of 





Table 2.1. Different methods used to quantify binding interactions. Data are from 
[115, 116, 119-127]. H, and S are enthalpy and entropy of binding, 
respectively. 
 
Method ITC SPR BLI MST 
KD range 10-6 to 10-9 
M 
10-3 to 10-12 M 10-6 to 10-9 M 10-3 to 10-12 M 
Thermodynamic data (H, G, 
S)? 
Yes Yes Limited Yes 
Kinetics data (ka/kd)? No Yes Yes No 
Immobilization? No Yes Yes No 
Modifications (e.g. fluorescent 
tag)? 
No No No Yes 
Concentration analysis No Yes Yes No 
Sample consumption High Low Low Very low 
Sensitivity Medium High Medium Low 
 
The affinity-based growth factor delivery system controls the release kinetics of 
encapsulated proteins by harnessing the reversible interaction between protein and 
ligand (Figure 2.4). A combination of intermolecular forces such as ionic 
interaction, hydrophobic or van der walls interaction, and hydrogen bonding 
usually facilitates binding a protein to the immobilized affinity-ligand. The rate 
formation and dissociation of the protein-ligand complex collectively are 
governed by the association and dissociation rate constant, respectively. The ratio 
between these values (KD= kd/ka) determines the strength of affinity interactions 
(KD). The KD value is also determined by the equilibrium concentration of free 
ligand, protein, the ligand-protein complex.  Overall, the changes in the 
concentration of protein within the polymer matrix can be modeled using the 
reaction-diffusion model [51, 52]. Accordingly, the transport of signaling 
molecules within an affinity-based system can be tuned primarily through 
adjusting the strength of affinity interactions, the concentration of binding ligand, 
the rate dissociation of the complex, initial protein loading concentration as well, 







Figure 2.4. Affinity-based growth factor delivery system. The binding ligand is 
immobilized within the polymer network allowing the reversible interaction with 
the encapsulated proteins — various intermolecular forces, including the ionic, 
hydrophobic, Van der Waals interactions, and hydrogen bonding, contribute to the 
formation of protein-binding ligand complex. The extent of complex formation is 
governed by their kinetics rate constants. The binding interactions, along with the 
diffusion process, can be modeled using the reaction-diffusion model. Multiple 
parameters that governed the transport of signaling molecules within the matrix 
are summarized. Figure modified from [119] 
 
The application of a mathematical model to predict the transport of growth factors 
within affinity-based systems has been previously described [33, 53, 55, 57]. For 
example, Sakiyama-Elbert and co-workers developed a mathematical model to 
describe the release of heparin-binding protein (FGF-2) from a fibrin matrix 
functionalized with the heparin [53]. In another study, Lin and Metters developed 
metal-chelating affinity hydrogels for the sustained delivery of recombinant 
protein containing Histidine tag [18, 128, 129]. Overall, their study emphasized 
that the protein release from the polymer matrices can be systematically controlled 
using ligands with a defined binding and rate constant. As such, metal ion-
mediated sustained protein release from these affinity hydrogels is governed by 
equilibrium protein-ligand binding affinity (dissociation constant, KD) as well as 
by the protein-ligand dissociation kinetics (dissociation rate constant, kd) [129]. In 
this case, while the equilibrium dissociation constant determined the initial rate of 






 More recently, the Shoichet group has developed an affinity-based delivery 
system for the fusion protein containing Src homology 3 (SH3) domains [52, 130-
132]. Computational [52],  and experimental studies on the release of SH3 fusion 
proteins including FGF-2 [132], insulin-like growth factor (IGF-1) [133],  
chondroitinase ABC [130], and ciliary neurotrophic factor (CNTF) [131], from 
methylcellulose- and hyaluronic acid/ methylcellulose hydrogels revealed that the 
release of these proteins could be precisely modulated over several days through 
adjusting the peptide affinities to the SH3 domain. Besides, simulation based on 
the reaction-diffusion model has also confirmed that the ratio of ligand to protein 
and hydrogel geometry could affect the protein release characteristics [52]. 
2.3 GAG-based biomaterials control the administration of 
pro-angiogenic growth factors  
2.3.1 GAG-based biomaterials as a controlled release system of pro-
angiogenic growth factors 
Pro-angiogenic growth factor administrations using GAG-based materials have 
been shown to promote pro-angiogenic effects in vitro and tissue vascularization 
in vivo (Figure 2.5A). For example, Peattiea et al. developed PEG-based 
hyaluronic (HA) hydrogels to deliver FGF and VEGF [134]. In vivo, the hydrogel 
functionalized with VEGF was shown to induce a higher vessel density and 
neovascularization than the hydrogel containing no growth factors, hydrogel 
functionalized with the FGF alone, or soluble growth factor treatments. Moreover, 
functionalization of the PEG-based matrices with heparin could also sustain the 
delivery of VEGF and maintain its bioactivity for a longer time [135]. The 
implantation of the VEGF-loaded gel in mice was shown to enhance a higher 
vascularization in the tissue surrounding the scaffold as compared to the unloaded 
hydrogels. A similar improvement over the tissue vascularization was also 
observed upon FGF delivery using a hybrid of chitosan-heparin hydrogel [136]. In 
a related study, HA-PEG hydrogel was modified with gelatin and heparin to 
control the release of various pro-angiogenic growth factors, including the Ang 





remarkable vascularization responses in vivo compared to the gels containing no 
growth factor. Overall, these studies suggest that the functionalization of 
engineered biomaterials with pro-angiogenic growth factors enhances tissue 
vascularization. 
The release of pro-angiogenic factors can be tuned by adjusting the GAG content 
and the GAG sulfation pattern of the hydrogel. As an example, Pike and 
coworkers modulate the release of FGF and VEGF from PEG-hyaluronic acid 
hydrogel matrices by varying the amount of incorporated heparin [77].  The 
growth factors can be sustainably released in vitro over 42 days by incorporating 
only less than 1% (w/w) of heparin, and the total amount of growth factor release 
decreased monotonically with increasing heparin concentration. Remarkably, the 
highest vascularization index was only observed when the hydrogels were 
functionalized with both heparin and growth factors. In a related study, the 
sulfation pattern of heparin could be selectively varied to tailor the binding and 
release of VEGF from starPEG-heparin hydrogels [6]. Both overall and local 
sulfate density of the hydrogel was shown to modulate the rate of VEGF release in 
vitro. However, in general, 6O- and N- sulfate groups are more pronounced in 
determining the amount of VEGF released from the system.  
Simultaneous multifactorial administration of angiogenic growth factors from the 
GAG-based polymeric matrices can be explored to synergistically enhance the 
bioactivity of the factors in vitro or in vivo. PEG-hyaluronic acid hydrogels have 
been previously applied to control the delivery of keratinocyte growth factor 
(KGF) and VEGF [138]. Combined delivery of both factors into ear pinnae of a 
mice model using the hydrogel could additively induce a greater extent of 
neovascularization than single growth factor delivery with the hydrogel or 
simultaneous bolus delivery of both factors. Similarly, Zieris et al. utilized the 
starPEG-heparin hydrogel system for the dual independent delivery of VEGF and 
FGF [5]. More recently, co-delivery of a chemokine, SDF1α, and lipid-based pro-
angiogenic factors, sphingosine-1-phosphate analog (FTY720), has also been 
explored to modulate the pro-regenerative potential of immune cells. PEG-
hydrogel functionalized with heparin and lipid chaperon of albumin allowed for 





2.3.2 GAG-based biomaterials as a 3D cellular encapsulation matrix for 
vascular tissue engineering 
The capacity of GAGs to regulate the activity of signaling molecules in the ECM 
has inspired their incorporation into vascular tissue engineering matrices (Figure 
2.5B). Typically, the GAGs also blend with the naturally derived biopolymer or 
fully synthetic polymer to enhance the cell-instructive and mechanical properties 
of the constructs [140, 141]. Several cell types, such as fully differentiated 
HUVECs [3, 141, 142], EPCs [143], and tissue-specific progenitor cells [42, 43, 
144, 145], have been reported to display their vasculogenic potential within the 
GAG-based materials. Their ability to form stable and lumenized vascular 
structures were also controlled by the presence of supporting cells, such as 
fibroblast, and smooth muscle cells, and mesenchymal stem cells [3]. For 
initiating the vascular morphogenesis, functionalization of the matrix with pro-
angiogenic growth factors such as VEGF, TGFβ, FGF-2, SDF1α, either 
individually or in combinations, is often required.  In addition to the biomolecular 
characteristics of the scaffold, the network properties of GAG hydrogels, such as 
matrix degradability, cell adhesiveness, and stiffness, were also shown to 
determine the extent of vascular network formation. The robust capillary-like 
structures developed within well-defined GAG-based materials will allow its 
further applications for drug discovery, tissue engineering, and studying vascular 
biology (Figure 2.5C).   
Heparin might be combined with the hyaluronic acid within a tissue engineering 
construct to synergistically harness the angiogenic properties of both materials. 
For example, Jha et al. utilized hyaluronic acid-based hydrogel supplemented with 
a low amount of heparin to aid cardiac progenitor cells (CPCs) transplantation 
therapies [42]. The adhesion peptide and stiffness of the hydrogel and the growth 
factor sequestering capacity were shown to affect the survival and engraftment of 
stem cells [42, 145]. The inclusion of heparin within the system also enhanced the 
function of CPCs in vivo to promote vascularization by coordinating the 
presentation of the encapsulated TGFβ and sequestration of various cell-secreted 
factors. The follow-up study also determined that the growth factor sequestration 





weight of the heparin [43]. The hydrogel with the highest affinity to the growth 
factors (with the highest heparin content and the largest molecular weight of 











Figure 2.5. The application of GAG-based materials to control the activity of pro-
angiogenic growth factors. (A) GAG-based material sustainably delivers pro-
angiogenic growth factors to promote angiogenesis in the damaged/ diseased 
tissues. (B) GAG-based materials can be applied as a cell instructive scaffold to 
generate robust microvasculature in vitro. (C) The microvascular network within 
the hydrogel can further be utilized as an anti-angiogenesis drug screening 
platform, implantable microvasculature for tissue engineering applications, or an 
in vitro culture model of vascular biology. Figure C-2 and C-3 are adapted from 









2.4. Modular starPEG-GAG hydrogels platform 
The extracellular matrix (ECM) provides cell instructive signals that control tissue 
formation and homeostasis. Particularly, glycosaminoglycans (GAGs), as one of 
the major components of the ECM, mediate various signaling functions of the 
ECM by presenting multiple soluble signaling molecules [104] and controlling the 
formation of morphogen gradients [147] (Figure 2.6). These fundamental roles of 
GAGs in the ECM ultimately regulate various important physiological processes 
in the body [88, 148-151]. In an attempt to recapitulate the instructive cell roles of 
the GAGs in living tissues, incorporation of GAG into the biomaterials are 
currently attracting considerable attention [152].  In addition to regulating the cell 
signaling function, the ECM also inherent various physical properties, structural 
heterogeneity, susceptibility to cell-mediated remodeling, and cell adhesion 
/attachment sites.  Therefore, GAG-based biomaterials can further be tailored to 
recapitulate these fundamental features of the ECM through the rational design 
and processing of polymer networks to control the presentation of soluble factors, 
network structures, cell adhesiveness, shapes, and degradability of the matrices.  
The in-situ encapsulation of soluble growth factors and cells within the MMP-
degradable PEG-Hep hydrogels can be achieved using a cytocompatible, a 
Michael-type addition reaction scheme. This would allow for the investigation of 
more advanced cellular processes under a defined 3D cellular environment [3, 47]. 
The cell-mediated degradation and subsequent VEGF delivery were previously 
shown to enhance cell spreading and endothelial cell morphogenesis on the 2D 
surface of starPEG-heparin hydrogel [47]. The follow-up studies revealed that 
multiple pro-angiogenic growth factors (VEGF, FGF-2, and SDF-1α) could 
synergistically enhance the formation of endothelial capillary networks in 3D [3]. 
Moreover, it has also been demonstrated that the co-culture of MSCs and 
HUVECs within RGD-modified, MMP-degradable, soft (~200 Pa) starPEG-Hep 
hydrogel matrix containing triple factors support the maintenance of a mature 
capillary network for at least a month in vitro. In an extension of that work, triple 
cultures of HUVECs, MSCs, and various breast and prostate cancer cell lines 





the platform has also been successfully applied to investigate the effect of 
different biochemical and biophysical properties of the matrix on the extent of  
renal tubulogenesis [154] and the hematopoietic stem cells cycling [155], 
highlighting the potential of the hydrogels for advanced organ culture models 
which could minimize the expensive and ethically challenging animal 
experiments [156]. 
The GAG-based hydrogel can entrap therapeutically relevant molecules and 
complexing the molecules through electrostatic interactions to control their local 
administration. Based on this property, starPEG-heparin hydrogel has been 
successfully adapted  to control the release of various heparin-binding growth 
factors, such as FGF-2 [2], VEGF [4], BMP-2 [79], SDF-1α [19], GDNF [157], 
NGF [158], TGF-β [35], IL4 [26], PDGF-BB [38], and EGF [159].  The relatively 
high gel heparin content also enabled multifactorial administration, such as for the 
combined delivery of FGF-2 and VEGF [5], and  FGF-2 and GDNF [157].  
The sulfation pattern of GAGs determines the GAG affinity for proteins, 
modulating the protein transport and bioactivity [160]. Therefore, the starPEG-
Hep hydrogel platform was adjusted to exhibit different affinities for soluble 
signaling molecules via the incorporation of N-desulfated, 6O-desulfated, or 2O-
desulfated heparin derivatives [39]. The rational design concept enables the 
formation of hydrogels with similar mechanical properties with different sulfation 
patterns [39, 79]. All the hydrogel containing desulfated heparin displayed 
anticoagulant activity. In vitro binding and release experiment of the VEGF from 
the hydrogel of different sulfation also revealed that VEGF release was unaffected 
by 2O-DSH, whereas 6O- and N-DSH enhance the VEGF release to a similar 







Figure 2.6. Modular starPEG-GAG biohybrid hydrogels. The starPEG-GAG 
hydrogel is tailored to recapitulate the fundamental characteristics of ECM, 
including the growth factor presentation, viscoelastic properties, provision of cell 




3. Materials and Methods 
3.1 Preparation of hydrogels 
3.1.1 Binary GAG hydrogel systems 
GAG component of the hydrogels, including maleimide-functionalized heparin 
(Hep) and heparin derivatives (6O- & 6ON desulfated heparin (6O-DSH & 6ON-
DSH, MW ~ 15 000) were in house synthesized. The hydrogels were prepared as 
previously described with slight modifications [47]. Briefly, thiol functionalized 
4-arm starPEG (starPEG-SH) (MW 10 000, Polymer Source, Inc., Dorval, 
Canada) and maleimide functionalized heparin/ heparin derivatives were 
dissolved in PBS at an appropriate molar ratio. To generate GAG-hydrogel with 
various mesh size/ crosslinking degree (molar ratio of starPEG to GAG), starPEG-
SH solution at a concentration in the range of 1.8–4.4 mM was mix with an equal 
volume of GAG to reach a final GAG concentration of 1.5 mM (solid content ~ 
3.2-4.4%). Similarly, the hydrogel with variable GAG sulfation patterns was 
produced with the final GAG content of 1.5 mM and prepared by reacting heparin 
or desulfated heparin with ~1.8 mM starPEG-SH (solid content ~ 3.2%). 
Furthermore, for the preparation of hydrogel with a lowered GAG concentration 
(0.5 and 1 mM), the Hep solution was mixed with 1.5 mM of starPEG-SH to 
produce hydrogels with a final solid content of ~2%. As a non-affine hydrogel 
control, pure PEG hydrogel was also prepared by reacting an equal volume of 3 
mM of starPEG-SH with maleimide-functionalized starPEG (starPEG-Mal) 
(JenKem Technology, Plano, USA) at a final solid content of 2.2-3.2%. In 
general, upon the mixing of gel components, the hydrogels were formed 
instantaneously within several seconds.  The pH of the starPEG-SH solution 
might be adjusted to 5.6 to have an efficient hydrogel component mixing allowing 
for the formation of homogenous hydrogel samples. 
3.1.2 Ternary GAG hydrogel systems  
A ternary system containing starPEG-SH, starPEG-Mal, and maleimide 
functionalized heparin was used to prepare GAG hydrogels with varied heparin 




concentration in the range of 1.5-1500 µM. All the hydrogel components were 
dissolved in PBS. Subsequently, starPEG-Mal and maleimide functionalized 
heparin were mixed at an appropriate molar ratio to produce polymer containing 
maleimide mixture.  The mixture was then combined with a starPEG-SH solution 
at an initial SH to maleimide molar ratio of 0.4-0.7 to produce hydrogels with 
different stiffness of a given heparin concentration (solid content of 2.6-4.5 %). 
The hydrogels could be pre-functionalized with growth factors by gentle mixing 
of the growth factor with the polymer containing maleimide mixture before 
adding the starPEG-SH component. Additionally, cell encapsulation during the 
gelation process was carried out by incorporating the cell suspensions into the 
polymer containing maleimide mixture. 
3.1.3 Synthesis of the starPEG-MMP cleavable peptide conjugate  
The synthesis of matrix metalloproteinase-cleavable peptide (MMP) with a 
sequence of Ac-CGGPQG-IWGQGGCG and its conjugation with four arms 
polyethylene glycol (starPEG, Mw= 16,500 g/mol ) was performed as previously 
described [8]. The starPEG-MMP conjugate was used for all the cellular 
experiments in place of non-cleavable starPEG-SH.  
3.2 Physical characterization of hydrogels 
3.2.1 Rheological and volume swelling measurements 
67 µL of the hydrogel mixture was allowed to polymerize between two 
hydrophobic coverslips with a diameter of 9 mm to produce free-standing 
hydrogel discs. After the polymerization, the cover glass was removed, and the 
hydrogels were scanned using FLA 5100 fluorescent scanner (Fujifilm, Tokyo, 
Japan) before and after overnight swelling in PBS with excitation 473 nm and an 
emission filter of 510 nm. The diameter of hydrogels was then determined by 
analyzing the fluorescence images using the Fiji (ImageJ, NIH). The gel 
volumetric swelling, Q, was determined by the following equation: 










where d0 and d are the initial and final diameter of the gel disk, respectively. 
Subsequently, the storage modulus of the swollen hydrogels was also measured 
using rotational rheometry with 25 mm parallel plate geometry in an Ares LN2 
(TA Instruments, Germany), as previously described [47]. The frequency sweeps 
were carried out at a shear frequency in the range of 10-1 rad s-1 to 100 rad s-1 with 
a strain amplitude of 2%. The mean values of the storage modulus were calculated 
from at least three independent hydrogel samples.  
3.3 Protein diffusion studies in hydrogels 
3.3.1 Fluorescent protein labeling and purifications 
Recombinant human VEGF165, VEGF121, EGF ( Peprotech, USA), and SDF1α 
(Miltenyi Biotec, Germany) were labeled with Alexa 488 NHS esters (N-
hydroxysuccinimide esters) (Thermo Fisher Scientific, Germany). Briefly, 
lyophilized proteins were dissolved in Milli-Q water, and an equal volume of   0.2 
M sodium bicarbonate buffer (pH 8.3) was added to reach a final protein 
concentration of 0.5-1 mg/mL. The Alexa 488 NHS esters were then added at dye 
to protein molar ratio of 10:1 and 1.5:1 for a large (VEGF165 and VEGF121) and 
small proteins (EGF and SDF1α), respectively. Afterward, the proteins were 
purified twice from the unreacted dyes using Zeba Desalting column with MWCO 
of 7 kDa (Thermo Fisher Scientific, Germany) following the manufacturer’s 
instruction. The final concentration of the protein and conjugated dyes were 
measured using NanoDrop™ 1000 Spectrophotometer  (Thermo Fisher Scientific, 
Germany) to determine the protein labeling degree. 
3.3.2 Fluorescence recovery after photobleaching (FRAP) 
FRAP measurement was used to evaluate the mobility of proteins within 
hydrogels or pure buffer. For the sample preparation, all hydrogel components 
were dissolved in PBS containing 0.1% BSA (Figure 3.1A). Fluorescently-
labeled proteins were incorporated into the hydrogels during the gelation process. 
For this, the proteins were mixed with the Hep, 6O-DSH, 6ON-DSH, or starPEG-
Mal at a final concentration of 5 µM. Afterward, the mixture was reacted with 
starPEG-SH to prepare hydrogel with varied mesh size, heparin content, and 




sulfation pattern as described above. To ensure that the diffusion coefficient 
measurement was carried out within the gel matrix and to specify the bleached 
spot's location within the scaffold, hydrogels were spiked with 1 mol% of ATTO 
647 maleimide (Atto-Tec, Siegen, Germany). For the FRAP measurement, 3 µL 
of the hydrogel mixture was spread onto a glass slide to generate hydrogel with 
~120 µm thickness, covered with 10 µL of buffer solution containing the same 
concentration of proteins as in the hydrogel, and sandwiched with another cover 
glass separated by an imaging spacer (Grace Bio-Labs SecureSeal, Sigma-
Aldrich). Afterward, FRAP was carried out with a Leica TCS SP5 confocal using 
a 10x magnification objective (HC PL Fluotar 0.30 NA). For each measurement, a 
time-series of 20 pre-bleach images with a resolution of 256 x256 pixels was 
recorded using an attenuated argon laser beam (80% output & 4% of 
transmission) every 141 ms (Figure 3.1B). A uniform disk with a radius of 20 µm 
in the middle of hydrogels was then bleached with high intensity of 488, 576, and 
495 nm lines of an argon laser at 100% transmission for ∼600 ms. 
Immediately after the photobleaching, a stack of 100 and 120 images was 
acquired at low laser intensity (4% of transmission) for every 141 ms and 1 s, 
consecutively, to measure the extent of fluorescent recovery within the bleached 
spot.  During all the experiments, the temperature was kept constant at 30 oC. The 
diffusion coefficients (D) were extracted from the fluorescent recovery curve, as 
described elsewhere [38, 161]. Briefly, the mean fluorescent intensity in the 
bleached spot, Ifrap(t), was normalized to the intensity of a reference region for 
every time point t, Iref(t).  Ifrap(t) was then normalized further by the intensity of a 
reference region, Iref(pre), and the bleached area, Ifrap(pre), before the 
photobleaching, using Equation 2 to correct for possible bleaching during the 













Subsequently, f(t) was normalized to a full scale, F(t) using Equation 3. Here, 
f(0) is the normalized fluorescent intensity of the bleached spot just after the 
bleaching, and f(pre) is the normalized fluorescent intensity before the bleaching. 




Characteristics diffusion time, τD and the mobile fraction, a, were then extracted 
from the least square fit of F(t) to the Equation 4, which is based on the 2D 











I0 and I1 represent modified Bessel functions of the first kind of zero and first 
order, respectively. Finally, the diffusion coefficient, D, was obtained from 





To analyze the hydrogels network properties, hydrogels with heparin content of 
1.5 mM were prepared in PBS with a molar ratio of starPEG/ heparin varied from 
0.63-1.5. Fluorescein isothiocyanate–dextran (FITC-dextran) with different 
molecular weights (FD10, FD20, FD70, FD150, and FD2000) (Sigma-Aldrich, 
Germany) was then embedded during the gelation process at a final concentration 
in the hydrogel of 0.5 mg/mL. Subsequently, the procedures for the FRAP 
experiments, as described above, were followed.  
To quantify the diffusion coefficient of proteins and dextran in the pure buffer, 10 
µL of protein and dextran solutions were used at a final concentration of 2.5µM 
and 0.5 mg/mL, respectively. 





Figure 3.1. FRAP experiment set-up. (A) FRAP sample preparations. The 
hydrogels were preloaded with proteins, immersed in PBS, and sandwiched in 
between two glass slides separated by an imaging spacer. In general, the FRAP 
experiment consists of the photobleaching of protein samples using a high-
intensity laser pulse and the monitoring of fluorescence recovery of the bleached 
spot until no further fluorescence recovery is observed. (B) The changes in the 
fluorescence inside the bleached spot before and after 120 s of the photobleaching. 
(C) The fluorescence intensity recovery curve of the bleached spot and the curve 
fit to a diffusion model for the quantification of a protein diffusion coefficient. 
 
3.3.3 The formation of fluorescent protein gradient in microfluidic 
devices 
As described in detail elsewhere [163], commercially available microfluidic chips 
were used to generate a biomolecular gradient within hydrogels. The microfluidic 
device contains three parallel channels, including the growth factor, hydrogel, and 
medium channels with a wide of 0.5, 1.3, and 0.5 mm, respectively (Figure 
3.2A). The growth factor and medium channels are separated from the hydrogel 
channel by trapezoid posts that prevent the hydrogel precursor from leaking out to 
the medium or growth factor channels during the hydrogel loading. 0.1 mm 
spacing between the structures allows for the biomolecules’ transport/ exchange 
between the hydrogel channel and the flanking growth factor and medium 






































































































flow of liquid within the device. Any hydrogel, including the in situ forming, 
starPEG-heparin hydrogels, can be loaded into hydrogel channels by injection.  
For the protein gradient characterization, the protein was labeled with Alexa-488 
(Please see section 3.3.1 for the protein labeling procedures), whereas the 
hydrogel was spiked with 0.1 mol % of ATTO-647. Moreover, for all the 
experiments involving this microfluidic device, 10 µL of hydrogel precursors 
were mixed thoroughly by pipetting it within a 500 µL Eppendorf tube. 
Subsequently, using a 20 µL micropipette, the mixture was injected into the 
hydrogel inlet until the solution reaches 2/3 of the gel channel length. The 
remaining solution was injected into the opposite hydrogels channel inlet until the 
front of the gel precursor was merged. The gels were allowed to polymerize for 5 
min, and the gel inlets were then sealed with adhesive plastic sealant. 
Subsequently, the hydrogel was washed with PBS/ 0.1% BSA by injecting 15 µL 
of the solution into the growth factor and medium channels.  
To initiate the gradient formation, 70 µL of 1 µM of fluorescently labeled protein, 
which is diluted with PBS/ 0.1% BSA solution, was injected into one of the 
growth factor channels, and an additional 50 µL of the growth factor solution was 
loaded from the opposite growth factor inlets. Similarly, a total of 120 µL PBS/ 
0.1% BSA solution were loaded into the medium channel, of which 70 µL and 50 
µL of the solution were injected from different ports. After adding the protein into 
the growth factor channel, the net diffusive transport of the protein from the 
growth factor to the medium channel initiated the formation of a protein gradient 
(Figure 3.2B).  
For the time-lapse microscopy, 20 µL of mineral oil (Sigma-Aldrich, Germany) 
was added onto each medium and growth factor ports to prevent evaporation 
during the imaging. The fluorescence images were captured using a Leica TCS 
SP5 confocal (Leica Microsystems, Germany) every 30 min for a total duration of 
72 H and subsequently used to analyze the spatial and temporal evolution of 
protein gradient.  





Figure 3.2. Generation of a biomolecular gradient within a microfluidic device. 
(A) The schematic of the microfluidic device used to generate a protein gradient. 
(B) The formation of a protein gradient across the loaded hydrogel. The 
fluorescence image represents the hydrogel and protein gradient formation after 
48 H of the protein loading. Scale bar 200 µm. 
 
3.5 Protein release studies from hydrogels 
10 µl of hydrogels with variable GAG concentration or sulfation degree were 
loaded with a final protein concentration of 1.5 µM and allowed to polymerize in 
0.5 mL conical microcentrifuge low protein binding tubes LoBind (Eppendorf 
Tubes, Germany). 400 µl of the release medium (Dulbecco's Modified Eagle 
Medium (DMEM; Gibco Life Technologies) supplemented with 0.1% BSA, 0.1% 
Procline, and 60 mM of HEPES buffer (Gibco Life Technologies) was then added 
to the samples and incubated at room temperature to initiate the release of protein 
from hydrogels. Release media was completely removed and exchanged with an 
equal volume of fresh media at t = 0.125, 0.25, .5, 1, 3, 6, 24, 96, 168, 264, and 
336 h. The collected media was split into two aliquots, stored and frozen at −80 
°C until the analysis. The amount of protein in the release media was quantified 
using enzyme-linked immunosorbent assay (ELISA) DuoSet kit (R&D Systems, 








































































3.6 Cell cultures 
Human umbilical vein endothelial cells (HUVECs) were isolated as previously 
described [164], cultured in Endothelial Cell Growth Medium (ECGM; 
Promocell, Heidelberg, Germany)  containing supplemental mix and 2% FCS on 
fibronectin-coated 75 cm2 culture flasks, and maintained at 5% CO2 and  37 °C in 
a humidified incubator. After reaching 80% confluency, the cells were detached 
using 0.5% trypsin-EDTA (Sigma-Aldrich, München, Germany) solution, 
collected, centrifuged at 1000 rpm, and reseeded at appropriate density until 
further usage. Cells from passage 2-6 were used for all experiments.  
3.7 In vitro assays 
3.7.1 Endothelial cell vascular morphogenesis 
To investigate the effect of GAG content on the endothelial cell morphogenesis 
within the binary hydrogel system, HUVECs were embedded within the hydrogels 
at a final heparin concentration of 0, 500, 1000, and 1500 µM. Besides, hydrogels 
with varied GAG sulfation patterns (Hep, 6O-DSH, 6ON-DSH) were prepared at 
a total GAG concentration of 1500 µM to study the influence of GAG sulfation 
patterns on the endothelial cell capillary morphogenesis. For these purposes, 
HUVECs were detached using Accutase (Sigma-Aldrich) for 5 min at 37 °C and 
resuspended in an ECGM medium containing a supplemental mix and 2% FCS at 
a final concentration of 40 x 106 cells/ml. Next, the starPEG-GAG hydrogels were 
prepared as described previously [3] with slight modifications.  
In brief, a degradable starPEG-MMP conjugate (MW 16,489) and heparin/ 
heparin derivatives-maleimide conjugate (MW 15,000) was dissolved in the 
HUVEC culture medium. Subsequently, the adhesive peptide CWGGRGDSP 
(cRGD, MW 990) was supplemented into the heparin at a 2:1 molar ratio. After 
that, the heparin-RGD mixture was (non-reactively) functionalized with 
VEGF165 (PeproTech, USA) at a final concentration of 0-20 µg/ml, and an equal 
volume of HUVEC suspension was then added to generate a cell-heparin 
conjugate mixture. For the formation of hydrogels, the cell-heparin conjugate 
mixture was mixed with the starPEG conjugate solution in a 1:1 volume ratio to 




form 20 μl of hydrogel droplets, which were cast onto hydrophobic µ-slides 8 well 
chambers (Ibidi, Germany). Following the in situ crosslinking, the gels were 
immediately immersed in the cell culture medium, and on day 3, the samples were 
fixed with 2% paraformaldehyde (PFA) for 10 min at RT and stained with 
fluorescence.  
For the spatial patterning of endothelial cell morphogenesis in microfluidic chips, 
hydrogels and the growth factor were loaded into the device as described before in 
section 3.3.3. The final cell concentration within the hydrogel was adjusted to 10 
x 106 cells/ml. The cells within the device were treated with 5 µg/mL of VEGF 
dissolved in basal medium (ECGM containing 0.5% FBS) either as a gradient or 
uniformly distributed within the hydrogels. The cells treated with the basal 
medium was included as a control. The progress of morphogenesis was then 
observed daily, and on day 3, the cells were fixed with 2% PFA and stained with 
the fluorescence.  
 
3.7.2 Endothelial cell chemotaxis 
HUVECs chemotaxis assay was performed on µ-Slide Chemotaxis (Ibidi, 
Germany).  This slide has been previously used for a long-term chemotaxis assay 
of various cells, including the immune cells, fibroblasts, and cancer cells under a 
two-dimensional (2D) or three-dimensional (3D) environment [165]. µ-Slide 
Chemotaxis contains three main chambers: observation and two large reservoirs 
area (Figure 3.3). The observation area is filled with the cell-laden hydrogels 
precursors, and the reservoir area can be filled with a cell culture medium only or 
in combination with a chemoattractant.  Here, the effect of the VEGF gradient on 
the chemotaxis of HUVECs in 3D was investigated. Two other conditions where 
the hydrogels were not loaded with VEGF or uniformly loaded with VEGF were 
used as a control.  For this purpose, cells were encapsulated within the hydrogels 
as described previously in section 3.7.1 except that all hydrogel components were 
dissolved in basal medium (ECGM supplemented with 0.5% FBS), and the 
heparin concentration in the hydrogel was fixed at 500 µM. The observation 
channel was filled with 6 µL of hydrogel precursors, whereas the reservoir was 




filled with 65 µL of medium with or without VEGF supplementation. No VEGF 
was added in the hydrogel or the reservoir chamber for the untreated control 
group, and all other compartments were filled up with the basal medium. For the 
gradient treated group, 5 µg/mL of VEGF was supplied at one of the reservoir 
chambers, while the other reservoir chamber was filled with the basal medium 
only. On the other hand, for the treatment with a uniform VEGF distribution, 
VEGF was preloaded within the hydrogel during the gelation process, and no 
additional VEGF was supplied into the reservoir chambers.  
Next, a live cell imaging was performed under 10x objective (HC PL Fluotar 0.30 
NA) using a bright field imaging mode of a Leica TCS SP5 confocal (Leica 
Microsystems, Germany) equipped with a humidifier and CO2 incubation. The 
image was captured every 15 min for up to 24 H. The XY coordinate of the cells 
for a particular field of view was extracted using manual tracking of Image J 
software. The cell migration parameters such as forward migration index (FMI), 
directness, accumulated distance, and the net migration distance between 6 and 16 
hours were then analyzed using IBIDI chemotaxis and migration tool software. 
The directed cell migration was considered to be statistically significant if the 
FMI parallel to the direction of the gradient (FMIII) is larger than the FMI 
perpendicular to the direction of the gradient (FMI┴)  and the p-value, P < 0.05 or 
if the FMIII and FMI┴ of the control group are around zero and the p-value, P > 
0.05. 
  





Figure 3.3. Schematic of µ-Slide Chemotaxis design for HUVECs chemotaxis 
assay. The cells are embedded within the hydrogel for the 3D cell migration 
experiment. 
 
3.8 COMSOL mathematical modeling and simulation 
A reaction diffusion-model was used to simulate the protein transport dynamics 
within GAG-based hydrogels. Notably, the model was applied to determine the 
concentration of free and bound protein within a hydrogel droplet, predict the 
protein release from hydrogels loaded within a conical microcentrifuge tube, and 
estimate the spatial and temporal changes of hydrogel-based protein gradients.  
Initially, this model was established by Crank [166] to describe the mass transport 
in an affinity-based controlled release system based on a simple binding kinetics 
and Fick’s laws of diffusion. A similar model has also been adapted and 
successfully applied in a peptide-based [52] and metal chelating affinity hydrogels 
[129] to model the release of recombinant proteins from the polymer networks.  
The binding ligand (GAG or GAG derivatives) in our system is covalently 
tethered within the hydrogel. Therefore, the freely diffusing protein is the only 
mobile fraction in the system. The protein reversibly binds to the GAG to form an 
immobilized protein-GAG complex, dissociate and diffuse through the hydrogel 
matrix. The equilibrium dissociation constant (KD) (Equation 6) is expressed as 
the ratio between the dissociation rate constant (kd) and the association rate 
constant (ka); the value determines the strength of affinity interaction between 




protein and GAGs that eventually govern the protein mobility within- and the 








Here, CP is the concentration of free protein, CG is the concentration of 
GAG and CPG is the concentration of protein-GAG complexes. The diffusion 
coefficient of protein within the hydrogels (Dgel) and release media (Dmed) were 
determined using FRAP, as described in section 3.3.2. In this case, the diffusion 
coefficient of affine-proteins within affine gel systems (GAG-containing 
hydrogels) was approximated by measuring the protein's diffusion within a non-
affine PEG-PEG gel with a comparable stiffness. On the contrary, the diffusion 
constant of non-affine proteins was measured directly within the affine hydrogel 
systems.  
The initial equilibrium concentration of free protein, GAG, and protein-GAG 
complexes within the hydrogel was determined according to the equations 
described as follows [167]: 
First, the equilibrium dissociation constant (Equation 7) can be rearranged to: 
 𝐶𝑃𝐶𝐺 = 𝐾𝐷𝐶𝑃𝐺 (7) 
At equilibrium, the free protein and GAG concentration can be calculated by: 
 𝐶𝑃 = 𝐶𝑃_𝑇𝑜𝑡𝑎𝑙 − 𝐶𝑃𝐺  and 𝐶𝐺 = 𝐶𝐺_𝑇𝑜𝑡𝑎𝑙 − 𝐶𝑃𝐺  (8) 
Here, CP_Total and CG_Total  are the initial protein and GAG loading concentrations 
in the gel precursors. Next, these equations were substituted into Equation 7 and 
rearranged to solve for 𝐶𝑃𝐺 giving rise to:  
 
 















Conversely, free protein concentration can also be defined as:  
 
𝐶𝑃  = 𝐶𝑃_𝑇𝑜𝑡𝑎𝑙  −








Afterward, a set of partial differential equations (Equation 11-14) was used to 
describes the diffusive transport and formation/ dissociation of protein-GAG 
complexes in the hydrogel (Equations 11–13) as well as the diffusive transport in 
the release media (Equation 14).  
Here, the change in the free protein concentration overtime happened as a result of 
association and dissociation from GAG, and the diffusion within the hydrogel 





2𝐶𝑃 − 𝑘𝑎𝐶𝑃𝐶𝐺 + 𝑘𝑑𝐶𝑃𝐺   (11) 
Similarly, the change in concentration of protein-GAG complexes overtime in the 




= 𝑘𝑎𝐶𝑃 𝐶𝐺 − 𝑘𝑑𝐶𝑃𝐺   (12) 





= −𝑘𝑎𝐶𝑃 𝐶𝐺 + 𝑘𝑑𝐶𝑃𝐺    (13) 
 
 




Finally, the change in the protein concentration in the release medium due to the 





2𝐶𝑃   (14) 
These equations were solved numerically using COMSOL Multiphysics 5.3a for 
different gel types and geometry as well as protein loading concentration. The 
dissociation rate constant of the model proteins from the heparin obtained from 
the literature was used as a starting point for the curve fitting to the experimental 
release of heparin-affine proteins. The best fit was obtained using the least-square 
method by systematic variation of KD. In general, the reaction-diffusion model 
was used to describe molecular transport in all simulations. Variations in the 
assumptions and parameters of the numerical simulations and details about the 
hydrogel geometry will be addressed, specifically in section 6.1.6. Besides, all the 
parameters required to generate each figure containing the simulation results are 
summarized in Table 6.1.  
3.9 Microscopy techniques and image analysis 
3.9.1 Fluorescence staining and immunocytochemistry 
To analyze the extent of tubular structure formation in a hydrogel. After fixation 
and washing with PBS, the samples were permeabilized using 0.1% TritonX-100 
for 10 min. Samples were washed and incubated with Hoechst 33342 (Life 
Technologies; 1:200) and ATTO 610-phalloidin (Atto-Tec,1:200) for two days at 
4 °C. Next, the samples were washed three times and stored in PBS at 4 °C, 
covered with foil until the imaging using a Dragonfly Spinning Disc confocal 
microscope (Andor Technology Ltd., Belfast, UK). At least three images were 
taken at different positions within each hydrogel sample. Fields for imaging and 
quantification were chosen randomly for all conditions. 
 
 




3.9.2 Image analysis   
To quantify the extent of tubular structure formation in 3D, 100 μm thick z-stacks 
of 5 µm intervals at 50 µm above the glass slide were analyzed with Imaris 
(Version 9.2.1, Bitplane AG, Zurich, Switzerland) utilizing a filament tracer 
module. Briefly, a threshold loops algorithm was used to generate a 3D 
skeletonized image of the tubular structures obtained from the phalloidin staining. 
All the creation parameters used for the fluorescent image segmentation are listed 
in Table 6.2. Next, the resulting skeletonized images were used to calculate the 
total area and number of branch points of vasculatures. The skeletonized images 
were then visualized as a cone with a scale of 0.5.  
3.10 Statistical analysis    
All experiments were carried out with 2-3 independent experiments. Statistical 
analysis and graphing were performed using the GraphPad Prism 6 (San Diego, 
California). A one-way analysis of variance (ANOVA) followed by Tukey’s 
multiple comparison post-hoc test was used to determine the significance level 
between the groups with different treatments.  All values represent the mean ± 
standard deviation for at least three independent samples. The difference between 












4. Results and discussion 
4.1. Molecular transport of signaling molecules in the 
binary GAG-based hydrogel systems 
4.1.1 Introduction 
Soluble signaling molecules such as growth factors (GFs) and cytokines regulate 
many biological processes, including cell proliferation, survival, differentiation, 
and migration [168, 169]. Therefore, understanding the molecular transport of 
signaling molecules, in particular, within cell-instructive polymer networks, such 
as hydrogels, is critically important for the rational design of engineered living 
matters [170]. The mobility of bioactive proteins within- and the subsequent 
release from the hydrogel may not only affect the activity of the cells within the 
scaffold but also determine the host responses at the site of implantation [9-13]. 
For these reasons, several attempts to control the diffusivity of proteins within 
hydrogels have been made, including the incorporation of glycosaminoglycans 
(GAGs) [7, 10, 16, 25, 171, 172]. Owing to its negative charge, GAGs mainly 
sequester a wide range of positively charged proteins through electrostatic 
interaction, enabling the applications of GAG-based materials for controlled 
growth factor release [5], cytokines sequestration [7], and 3D cell culture [3, 153-
155, 173, 174]. 
The mobility of signaling molecules within the polymeric biomaterials is 
controlled at the molecular level through its network properties. In general, the 
diffusivity of signaling molecules across the polymer networks is governed by the 
hydrogel mesh size. For the GAG-based hydrogels, the diffusion of such 
molecules is further affected by their binding to the gel matrix, which is primarily 
determined by the GAG volume density and affinity to the signaling molecules 
[28]. However, despite their critical roles, no studies have systematically reported 
the influence of different physical and biochemical parameters of the hydrogels on 
the mobility of embedded signaling molecules. The gained knowledge eventually 
can be essential for creating GAG hydrogels with a defined local growth factor 




concentration that could precisely modulate cell fates through the soluble factor-
mediated cell signaling. 
Mathematical modeling can facilitate the development and design of biomaterials 
for controlled delivery of growth factors/ cytokines from affinity-based delivery 
systems [52, 113, 129, 175-177], including GAG-containing matrices [32, 61, 
178]. However, most models developed so far have mainly investigated the role of 
affinity interaction between the proteins and affinity ligand while minimally 
taking into account the effect of steric interaction between the protein and 
hydrogels network [52]. Moreover, most of the models were developed based on 
ECM-derived matrices, which promiscuously bind to a diverse range of signaling 
molecules [34, 53, 61, 178-181] and suffer from a batch to batch variability, 
limiting the accuracy of the model prediction under various scenarios. 
Consequently, GAG-based biohybrid hydrogels with a fully defined composition 
and tunable biophysical and biochemical properties may be instrumental for 
studying the impact of the material properties on the transport of signaling 
molecules. 
We have previously developed an in situ forming, cell-instructive, biohybrid 
starPEG-heparin hydrogel system based on a bio-orthogonal Michael-type 
addition reaction [22]. The system's mechanical and biochemical properties can be 
decoupled, allowing one to study the impact of different hydrogel network 
parameters on the cell fate control independently [22, 50, 66]. In the present work, 
we aimed to elucidate the effect of mesh size, heparin concentration, and heparin 
sulfation pattern of the system upon the mobility of signaling proteins with 
varying molecular size and affinity to heparin. Moreover, we also developed a 
mathematical model based on a reaction-diffusion model to analyze the transport 
and release of embedded signaling molecules from the polymer networks.  
Herein, the binding of four relevant growth factors and cytokines, including EGF, 
SDF-1α, VEGF121, and VEGF165 to the GAG building blocks of the hydrogels 
were first characterized using microscale thermophoresis (MST) [182] (Section 
6.2.1). Subsequently, after the establishment of fluorescent recovery after 
photobleaching (FRAP) technique to measure the diffusivity of proteins within the 




hydrogel samples or pure buffer [183] (Section 6.2.2), the mobility of proteins 
within a set of hydrogels with various properties was systematically investigated. 
The effective diffusion coefficient of the model proteins in hydrogels with varied 
sulfation degree derived from the FRAP analysis was then validated with the 
experimental release.  Afterward, a reaction-diffusion model was developed and 
applied to predict the release of heparin affine proteins (VEGF165 and SDF1α) 
from the gel constructs (Section 3.3.8 & 6.1.4). Finally, the sensitivity analysis of 
different model parameters, including the GAG content and affinity to signaling 
molecules, on the VEGF165 release from the hydrogels was performed to 
understand the global transport phenomena of signaling molecules within GAG-
based materials. 
4.1.2 Protein mobility in GAG-based hydrogels 
4.1.2.1 Effect of protein physical sizes and affinity to GAG 
Four model proteins were chosen to represent small and large signaling molecules 
with a strong affinity to heparin (SDF1α and VEGF165) and no affinity to heparin 
(EGF and VEGF121). The affinity of SDF1α and VEGF165 to heparin derivative 
was first confirmed by MST analysis (Section 6.2.1). Despite the difference in 
their molecular size, both proteins displayed a comparable affinity (KD) to heparin 
(0.9 and 1.2 µM for SDF1α and VEGF165, respectively) (Figure 4.1A).  
To fully characterize the effect of protein size on their mobility within the 
hydrogels, we analyzed the protein diffusivity in solutions as well as in non-affine 
PEG/PEG gels and affine PEG/Hep gels. The storage modulus of these hydrogels 
was adjusted to be comparable to exclude the influence of steric interaction with 
the hydrogel network (Figure 4.1B).  FRAP analysis revealed that the mobility of 
proteins in solutions was inversely proportional to their molecular weight (Figure 
4.1C), similar to the mobility of VEGF pair (VEGF165 vs. VEGF121) in a pure 
PEG hydrogel. Surprisingly, the SDF1α diffused faster than the EGF in the non-
affine PEG gels despite the slightly larger physical size (8 kDa vs. 6.2 kDa, for 
SDF1α and EGF, respectively). The discrepancy could probably be attributed to 
the differences in the overall shape and compaction of their 3D structures. 




The diffusion of model proteins in an affine PEG/Hep hydrogel displayed an 
opposite trend as those in pure PEG/PEG systems. The mobility of small and large 
affine proteins (SDF1α vs. VEGF165) within the affine PEG/Hep hydrogel was 
quite similar (D = 4 µm2/s). In contrast, the in-gel diffusivity of the non-affine 
proteins within the affine hydrogel was affected by their molecular size. Similar to 
their diffusion in the non-affine gel, small non-affine EGF diffused through the 
hydrogel network faster than the larger non-affine VEGF121 with the diffusion 




Figure 4.1. Effect of protein physical size and affinity to GAG on the mobility of 
proteins.  (A) Physicochemical properties of the model proteins used in this study. 
The mobility of model proteins in an affine PEG/Hep and non-affine PEG/PEG 
hydrogel with a comparable stiffness/ mesh size was evaluated using FRAP. (B) 
A pictogram illustrating the effect of protein size and affinity to GAG on their 
mobility within PEG/Hep and PEG/PEG hydrogels, which are mostly affected by 
the electrostatic interaction between the protein and the GAG building block. (C) 
The diffusion coefficient (D) of the model proteins in solution or hydrogels as 
determined by FRAP. Data represents mean ± SD (n = 3), ‘ns’ stands for not 








4.1.2.2 Effect of hydrogel mesh size  
The hydrogels' mesh size can be tailored to regulate the transport of embedded 
signaling molecules [8, 16]. Since the stiffness of hydrogel is correlated to the 
mesh size, we varied the stiffness of the gels by adjusting the molar ratio of 
starPEG to heparin while keeping the heparin content constant to investigate the 
effect of hydrogel mesh size on the mobility of signaling molecules independently 
from their heparin content (Figure 4.2A-B). This rational design strategy was 
previously shown to allow for decoupling the effect of starPEG-Hep hydrogel 
mechanical properties from the biomolecular characteristics [47]. 
It is hypothesized that decreasing the mesh size of hydrogels could increase the 
steric interaction between the free proteins and the hydrogel network, therefore 
slowing their mobility within the gel matrix (Figure 4.2A). Three different 
hydrogels with stiffness varied from ~0.2-6 kPa were generated while keeping the 
gel heparin concentration around 1500 µM. Based on the rubber elasticity theory 
[2], this range of stiffness corresponds to the gel mesh size of 9-28 nm (Figure 
4.2B and section 6.2.3), which is significantly larger than the hydrodynamic 
diameter of the model proteins used in this study (Figure 4.1A).  
FRAP analysis showed that small or large heparin-affine proteins' mobility was 
not affected by the hydrogel mesh size. The diffusion coefficient of SDF1α and 
VEGF165 in the starPEG-heparin system was quite similar; each felt within the 
range of 4 µm2/s (Figure 4.2C). In contrast, the diffusivity of non-affine proteins 
(EGF and VEGF121) was influenced by hydrogel mesh size. It was shown that 
the effect of mesh size was more pronounced on the protein mobility of VEGF121 
than for the smaller EGF. Accordingly, the increase in the mesh size of hydrogel 
from 9 to 11 nm significantly raised the diffusivity of the VEGF121 by ~ 30%. In 
contrast, the diffusivity of EGF only increased by ~ 20% if the mesh size of 
hydrogel was enlarged to ~ 28 nm. Probably, the VEGF121 experienced a 
stronger steric hindrance in the hydrogel network due to the larger size, even with 
a slight decrease in the mesh size of hydrogels. 





Figure 4.2. Effects of hydrogel mesh size on the mobility of proteins. The 
mobility of model proteins in PEG/Hep hydrogels at a pre-define crosslinking 
degree with an overall GAG concentration of 1500 µM. (A) A pictogram 
illustrating the effect of adjusting the mesh size of hydrogel on the steric 
interaction between the free protein and the hydrogel network, which negatively 
correlates to the in-gel mobility. (B) Tunable mechanical properties/ mesh size of 
hydrogels can be obtained by varying the molar ratio of starPEG to heparin. (C) 
The diffusion coefficient (D) of the model proteins in hydrogels as determined by 
FRAP. Data represents mean ± SD (n = 3), ‘ns’ stands for not significant, *P<0.5, 
**P< 0.01, ***P<0.001. 
 
4.1.2.3 Effect of GAG concentration 
starPEG-GAG hydrogels containing fully sulfated heparin were used as a model 
system to investigate the effect of overall GAG concentration on signaling 
molecules' mobility.  As previously described, the gel system could maintain a 
constant heparin content of approximately 1500 µM independent of their stiffness 
[47]. However, based on our rational design strategies, the overall solid content, 
crosslinking degree, and GAG building block can be adjusted further to prepare 
hydrogel variants with tunable biochemical characteristics (GAG content/ 
sulfation degrees) of comparable mechanical properties  [47] (Figure 4.3A). As 
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shown in Figure 4.3B, the hydrogel with variable heparin content and pure PEG 
gel control can be produced with overall stiffness of ~200Pa. With this storage 
modulus, the hydrogels were estimated to have a mesh size of about 30 nm, which 
is significantly larger than the hydrodynamic radius of proteins used in this study 
(Figure 4.1A). It is hypothesized that decreasing the hydrogel's GAG content 
could increase the free protein fraction within the system. Therefore, it could 
enhance the overall mobility of signaling proteins within the hydrogel.  
Based on our FRAP analysis, we showed that the inclusion of heparin into the 
hydrogel could significantly lower the mobility of heparin affine proteins (Figure 
4.3C). The diffusivity of the SDF1α significantly decreased from ~ 80 µm2 /s in 
pure PEG/PEG system to ~ 15 µm2/s or lower (≤ 5 factors) in the heparin-
containing hydrogels. A similar trend was also observed for the VEGF165; the 
mobility of the protein in PEG/Hep hydrogel with the lowest heparin content 
decreased by approximately 40% compared to the PEG/PEG hydrogel. Although 
VEGF165 and SDF1α displayed a comparable affinity toward heparin, the 
mobility of VEGF165 declined to a less extent than SDF1α in the PEG/Hep 
hydrogel. This observation could have resulted from its higher molecular weight 
that already exerts a more substantial steric interaction with the hydrogel network.  
While gradually adjusting the heparin content of the PEG/Hep hydrogels further 
from 500 to 1500 µM could still significantly decreased the mobility of heparin 
affine proteins, the mobility of small or large non-affine proteins (EGF and 
VEGF121, respectively) was not affected.  The diffusivity of non-affine proteins 
within the hydrogels was comparable despite the variation in the heparin content, 
and the magnitude was inversely correlated to their molecular size (~ 20 and 60 
µm2 /s, for large and small non-affine proteins, respectively). This result 
suggested that the mesh size of the hydrogels was comparable. Thus, a similar 
extent of size filtering effects controlled the mobility of these proteins. 





Figure 4.3. Effect of GAG concentration on the mobility of proteins. The 
mobility of model proteins in PEG/Hep hydrogels with a total GAG concentration 
of 0, 500, 1000, and 1500 µM. (A) A pictogram illustrating the effect of tuning 
the GAG concentration of hydrogels on the free protein concentration, which 
positively correlates with the in-gel mobility. (B) Comparable mechanical 
properties/ mesh size of the hydrogels with variable GAG content. (C) The 
diffusion coefficient (D) of model proteins in the hydrogels as determined by 
FRAP. Data are presented as mean ± SD (n = 3), ‘ns’ stands for not significant, 
*P<0.5, **P< 0.01, ***P<0.001, ****P<0.0001 
 
4.1.2.4 Effect of GAG-sulfation pattern  
Next, we investigated the mobility of signaling molecules within the hydrogels 
with varied GAG sulfation patterns.  Heparin was selectively desulfated at the 6-
O- (6O-DSH), or both at the N-, and 6-O-  (6ON-DSH) positions and 
functionalized with maleimide moieties to produce heparin derivatives which are 
reactive toward thiol-functionalized starPEG [38] (Figure 4.4A). The hydrogels 
with variable sulfate content of ~100% (PEG/Hep), 67% (PEG/6O-DSH), and 
33% (PEG/6ON-DSH) relative to the fully sulfated heparin can be produced with 
a comparable stiffness of ~ 250 Pa, allowing us to decouple the impact of GAG 
sulfation from the gel matrix stiffness on the transport of signaling molecules 
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(Figure 4.4B). As described in section 6.2.1, heparin-binding proteins' affinity to 
heparin was regulated in a sulfation-dependent fashion with a declining affinity 
toward decreasing the sulfation degree of heparin. Therefore, we expected that 
lowering the heparin sulfation degree could enhance the amount of free protein 
within the hydrogel, increasing their effective diffusion coefficient. 
In general, the diffusivity of non-affine proteins (EGF and VEGF121) within the 
hydrogels was not affected by the GAG sulfate content, and the diffusion rate was 
controlled primarily by the molecular weight (Figure 4.4C). Accordingly, the 
larger VEGF121 diffused with a diffusion coefficient of ~18 µm2/s while the 
smaller EGF diffused at a faster rate of 60 µm2/s in all hydrogel types tested, 
confirming the similarity of the mesh size of hydrogels with a variable of GAG 
sulfation patterns. 
While non-affine proteins' mobility was not dependent on the heparin sulfation 
patterns, the mobility of heparin affine proteins was inversely correlated to the 
GAG sulfate content (Figure 4.4C). However, a specific sulfate group of heparin 
seems to have a more noticeable impact on a given heparin-affine protein's 
mobility.  For instance, the diffusivity of SDF1α significantly declined from ~ 30 
µm2/s in PEG/6ON-DSH hydrogel to ~ 9 µm2/s in PEG/6O-DSH, suggesting the 
critical role of N- sulfate group for the SDF1α binding to heparin. Although we 
saw a lower diffusion coefficient of the SDF1α in PEG/Hep compared to that in 
the PEG/6O-DSH gel, no significant difference was observed. Interestingly, the 
influence of 6O and N sulfate on the mobility of VEGF165 showed the opposite 
trends as those on the SDF1α. VEGF165 diffused nearly 3-fold faster in PEG/6O-
DSH gel than in the PEG/Hep gel. Moreover, the VEGF165 diffusivity in 
PEG/6ON-DSH gel behaved similarly to that in the PEG/6O-DSH hydrogel. 





Figure 4.4. Effect of GAG sulfation pattern on the mobility of proteins. The 
mobility of model proteins in PEG/6ON-DSH, PEG/6O-DSH, and PEG/Hep 
hydrogels with an overall GAG concentration of 1500 µM. (A) A pictogram 
illustrating the effect of tuning the sulfation pattern of the GAG building block on 
the free protein concentration, which positively correlates with the in-gel mobility 
of the proteins. (B) Comparable mechanical properties of hydrogels with variable 
sulfation pattern and the respective theoretical sulfate content relative to the 
PEG/Hep hydrogel. (C) The diffusion coefficient (D) of the model proteins in the 
hydrogels as determined by the FRAP. Data are presented as mean ± SD (n = 3), 
‘ns’ stands for not significant, *P<0.5, **P< 0.01, ****P<0.0001. 
 
4.1.3 Protein release from GAG-based hydrogels  
The release of model proteins from a set of GAG hydrogels with varied overall 
sulfate content (PEG/Hep, PEG/6ON-DSH, PEG/PEG) was investigated. 
Subsequently, the experimental release profiles of the proteins were fitted to a 
mathematical model, which is based on the reaction-diffusion model to obtain 
their translational diffusion coefficient within the hydrogel network. Here, the 
resulting diffusion coefficient is called an effective diffusion coefficient because it 
considers the binding and unbinding of the proteins to (from) the hydrogel 








comparable to the diffusion coefficient obtained from the FRAP experiments. As 
described previously in section 4.1.2.4, PEG/Hep and PEG/6ON-DSH hydrogels 
were expected to have an approximately 100% and 33% sulfation degree, 
respectively. In addition to this, the PEG/PEG gel containing no sulfate was used 
as a control. Together, all the gel variants could represent GAG-based matrices 
with variable affinity to soluble signaling molecules. 
The release of SDF1α, VEGF165, EGF, and VEGF121 from the hydrogels was 
analyzed throughout 360 H (Figure 4.5, left panel). Depending on their sulfate 
content, all hydrogels showed an initial burst release of heparin affine proteins 
within the first 24 H, followed by nearly constant slow linear release throughout 
360 H (Figure 4.5A-B). The release of VEGF165 and SDF1α from the hydrogels 
with the highest sulfate content only reached almost 1% of the initially loaded 
amounts even after two weeks, indicating the proteins' strong affinity to the 
hydrogel scaffold. Decreasing hydrogels' sulfate content to 33% (PEG/6ON-DSH) 
enhanced the affine proteins' release by almost two factors, independent from their 
physical sizes, suggesting the important role of negatively charged sulfate groups 
for the binding of proteins to the GAG backbones. Remarkably, even if the 
remaining sulfate content of the PEG/6ON-DSH hydrogel was already as low as 
33%, the overall protein release from this gel was still relatively low (≤5%). The 
considerably higher GAG concentration than the protein loading amount in this 
gel matrix (1500 µM vs. 2.5 µM) might counteract the impact of its reduced 
affinity on the protein release, allowing them to still behave as a molecular sink of 
cationic proteins. 
Moreover, the release rate of small or large affine proteins from the pure 
PEG/PEG system was significantly much higher than from the GAG-containing 
hydrogels, with nearly 70% of the protein released was observed after 48 H. 
Notably, the release of both affine and non-affine proteins from the PEG/PEG 
hydrogels never reaches 100%, even up to two weeks of the release studies, 
despite the protein repellant properties (Figure 4.5A-D).  
While the affine-proteins displayed a low release from the PEG/HEP or the 
PEG/6ON-DSH hydrogels after 360 H, the release of non-affine proteins (EGF 




and VEGF121) was quite similar for all examined hydrogel formulations (Figure 
4.5C-D). Like the release of affine proteins from the PEG/PEG hydrogels, the 
non-affine protein attained a maximum release close to 60% of the initial loading 
amount within 48 H in any hydrogel types tested. This result could be explained 
by the absence of electrostatic interaction between the proteins and hydrogel 
building blocks. Therefore, the proteins only experienced a hindered diffusion 
caused by the hydrogel network, which only delays their release for a short period 
[16].  
The release experiments are generally accepted as the gold standard and most 
available methods to compare biomolecules' transport in different gel systems. For 
this reason, we compared the effective diffusion coefficient of proteins in the 
hydrogels obtained from the FRAP with those from the experimental release 
(Section 4.1.2.3-4 and Figure 4.5). For all cases, the obtained values from release 
experiments were almost twice as high as ones from the FRAP measurements.  
However, similar trends in the diffusion coefficient of the proteins in different gel 
formulations were obtained from both methods. While the diffusivity of heparin-
affine proteins declined as the hydrogel's sulfate content decreases, the non-affine 
protein diffusion remained constant irrespective of the hydrogel sulfate 
composition. Also, similar to the trends obtained from the FRAP measurements 
(Figure 4.1.2.1), the impact of protein size and affinity on their mobility within 
the hydrogel can also be determined using the diffusion coefficients derived from 
the release studies. Small and affine protein (SDF1α) diffused faster than large 
and affine protein (VEGF165) in the non-affine gel system (PEG/PEG), while 
their diffusivity was quite similar in the GAG-containing hydrogels (PEG/Hep or 
PEG/6ON-DSH). Besides, small non-affine proteins (EGF & VEGF121) were 
also observed to diffuse much faster than the bigger counterpart in all hydrogels 
tested (Figure 4.5C-D, right panel).  





Figure 4.5. The release characteristics of model proteins from binary GAG 
hydrogels containing different GAG sulfation patterns. (A) The release of SDF1α, 
(B) VEGF165, (C) EGF, (D) VEGF121 from PEG/Hep, PEG/6ON-DSH, 
PEG/PEG hydrogels for a period of 360 H at room temperature. For all 
conditions, the hydrogels were pre-loaded with 2.5 µM of proteins. The release 
curve for each protein was then fitted with a Fickian diffusion model to extract the 
proteins' effective diffusion coefficient in hydrogels. The resulting diffusion 
coefficient (D) was then compared to those obtained from the FRAP experiments. 









4.1.4 Modelling the transport of protein within GAG-based hydrogel 
systems 
To evaluate the applicability of the reaction-diffusion model to predict the release 
of proteins from the GAG hydrogel with varied sulfation, the experimentally 
determined release curve of two heparin-binding proteins, including VEGF165 
and the SDF1 throughout 360 H was fitted to the model using the least-squares 
method (Figure 4.6). The simulation could approximate the KD value of the 
protein-GAG complex within the hydrogel (Figure 4.6 and Table 4.1). 
Subsequently, the KD values obtained from the MST were compared to those 
obtained from the release experiments. 
In general, the reaction-diffusion model could not describe the release profile of 
both VEGF165 and SDF1 at early time points (Figure 4.6). Especially, the 
model underestimated the protein release within the first 24 H. However, at 100 H 
or longer, the experimental release of both proteins was in good agreement with 
the simulation. Notably, the model could better predict proteins' release from the 
PEG/Hep gel than from PEG/6ON-DSH gel.  
 
 
Figure 4.6. Experimental release (data points) and the resulting least-squares best 
fit of the data using the reaction-diffusion model (solid line) of VEGF165 and 









Table 4.1. Affinity constants of the VEGF165 and SDF1α to the heparin or 
heparin derivatives as determined by microscale thermophoresis (MST) and the 
release simulation based on the reaction-diffusion model (model) from the GAG 
hydrogels with variable sulfation. 
Protein GAG KD_MST [M] KD_Model [M] 
VEGF165 
Hep 9.00 x 10-7 2.13 x 10-6 
6ON-DSH 3.33 x 10-5 6.67 x 10-6 
SDF1α 
Hep 1.20 x 10-6 2.21 x 10-6 
6ON-DSH ND 5.48 x 10-6 
 
4.1.5 Sensitivity analysis of different COMSOL model parameters on 
the release characteristics of protein from hydrogel 
To understand the effect of each model parameters on the release of heparin affine 
protein from the hydrogels, the release of VEGF165 from starPEG-heparin 
hydrogels loaded at the bottom of the microcentrifuge tube was simulated (Please 
see section 6.1.6.1 for the detailed geometry of the system). The influence of 
different hydrogel network biochemical properties, including the total 
concentration of heparin, the affinity of heparin to protein, the dissociation rate 
constant of protein from the heparin, and the impact of protein loading 
concentration was investigated (Figure 4.7).  The detailed parameters used for the 
simulations for each graph were listed in Table 6.1. 
According to the simulations, the initial growth factor concentration did not affect 
the overall release of VEGF from the hydrogel, especially at a high concentration 
of heparin (1500M) (Figure 4.7A). In such conditions, VEGF's release increases 
only from 1% to 6% over two weeks, when the protein loading concentration 
was raised to 1500 M. However, this concentration is physiology irrelevant. 
Therefore, increasing the growth factor concentration was not the best choice to 
enhance the release from hydrogels as the burst leakage of the growth factor, 
especially those with a narrow margin of safety, may cause severe side effects.  
Interestingly, we could fine-tune the release rate of protein from hydrogel by 
varying the initial protein loading concentration only when hydrogels' heparin 




content was lowered by 100 times to 15 M. Notably, the overall release 
efficiency was higher for the gel prepared with a low heparin content. Moreover, 
over two weeks, the total protein release could also be adjusted from 30% to 80% 
by merely changing initial protein loading from 1.5 to 150 M. 
Altering heparin's affinity to protein was also shown to effectively control the 
protein release from hydrogels (Figure 4.7B). The protein release could be varied 
from 30% to 80% at low heparin content only by modulating heparin's affinity. 
The strategy to modulate protein affinity to GAG has been previously described, 
such as removing certain sulfate groups of the heparin that determine the specific 
binding to a particular protein [6]. Although decreasing the GAG building block's 
affinity to the protein of interest could also modulate their release from the 
hydrogel containing high heparin content, the overall release amount was still 
low. The protein's cumulative release only increased to 8% at high heparin content 
when the heparin's affinity declined by ten factors. This indicated that hydrogels 
containing high content/ density of binding ligands, even those with a low affinity 
for the signaling molecules, are suitable more as a sequestration biomaterial than a 
controlled delivery system of bioactive proteins. 
The affinity of GAG to signaling molecules is determined by the ratio of 
dissociation and association rate of the protein to GAG. As several combinations 
of the association (ka) and dissociation rate constant (kd) of the protein-GAG 
interaction pair results in the same value of KD (KD = kd/ka), we then examined 
whether these rate constants could influence the protein release from the hydrogel. 
The impact of kd on the protein release was investigated at a high and low heparin 
content (Figure 4.7C). In both cases, varying the dissociation rate constant from 1 
x10-2 – 1x 10-5 /s did not change the overall release of VEGF. Remarkably, 
decreasing the dissociation rate constant (increasing the resident time) at given 
strength of affinity interaction (KD) could lower the overall protein release only 
when physically irrelevant rate constant (1x 10-9) for a typical GAG-protein 
interaction was used for the simulation. Besides, this effect was proportional to 
the heparin concentration of the hydrogel. At high heparin content, decreasing the 
rate constant to 1x 10-9 decreased the total release by almost ten factors whereas, 




at a low heparin content, the same rate constant only declined the entire release by 
two factors.  
Finally, since adjusting the affinity or initial growth factor concentration did not 
significantly affect VEGF's overall release when the heparin concentration is high, 
we extended our simulation to understand the effect of gel heparin concentration 
on the protein release (Figure 4.7D). For the simulation, the heparin was varied in 
the range of 1.5 to 1500 M while the affinity of heparin to growth factor was 
either set to low (KD = 21300 nM) or high (KD = 2130 nM). Remarkably, the 
VEGF release could be finely tailored from as low as 1% to as high as 80% over 
two weeks by varying the hydrogel's heparin content at both KD values. In 
general, the gel heparin content was inversely proportional to the amount of 
protein release. Overall, incorporating a graded amount of heparin into the GAG 
hydrogels seems to be a more robust strategy to gradually adjust the release of 
protein from the gel matrix than modifying the heparin affinity to the signaling 
molecules.  





Figure 4.7. COMSOL simulations of the VEGF165 release from GAG hydrogel 
systems. The effect of different input parameters of the COMSOL model, 
including (A) the initial protein loading concentration, (B) the protein affinity to 
GAG,  and (C) the dissociation rate constant (kd) of the protein,  on the release of 
the protein from hydrogels containing a high (1500 µM) and a low (15 µM) 
heparin concentration. (D) The effect of heparin concentration of the hydrogel on 
the protein release at a strong (KD = 2130 nM) and weak (KD = 21300 nM) 
protein-GAG affinity interactions. The initial VEGF concentration was 2.5 µM for 










4.1.6 Discussion and summary 
The capacity of GAGs to control the mobility and retention of cytokines/ GFs 
within polymer networks has been widely applied in biomaterial research to 
control physiological processes, including wound healing, stem cell renewal, and 
differentiation, and tissue vascularization [7, 19, 43, 155]. However, the impact of 
GAGs incorporation into the biomaterial on the cellular responses is often 
difficult to predict because of the GAG-protein interactions that could suppress 
and enhance biological signaling depending on the context of presentation [28, 36, 
185-188].  Accordingly, signaling molecules' interactions with GAG resulted in 
their partition within the polymer network into a matrix-bound and free factor. 
Such separation eventually controls their retention within the gel matrices and 
influence the bioactivity [54]. Therefore, one potential approach to effectively 
predict the effect of GAG on the cell fate control within such materials is to apply 
a mathematical model that estimates the total amount of growth factors retained 
within the polymer matrices and the fractions that can be delivered to the cells.  
In this part of the thesis, we investigated the role of different biophysical and 
biochemical parameters of GAG-based hydrogels on the transport of selected 
signaling molecules that differ in their molecular sizes and binding affinity to the 
GAG. Using our previously established tunable starPEG heparin hydrogels 
systems [38, 47], we could dissect the impact of steric (hydrogel mesh and protein 
size) as well as the affinity interactions (which depends on the heparin 
concentration & GAG-sulfation degree) between the polymer network and model 
proteins, including VEGF165, VEGF121, SDF1α, and EGF, upon their in-gel 
mobility. Finally, a mathematical model based on the diffusion of signaling 
molecules or in combination with their binding to GAG building block was 
developed to interpret the overall processes governing the diffusivity within the 
hydrogels matrix and their subsequent release from the system. Thus, our 
systematic study could potentially serve as guidelines for designing materials that 
could precisely induce desirable cellular responses through growth factors-based 
biological signaling. 




Modulation of steric interactions between the hydrogel network and embedded 
signaling proteins through adjustment hydrogel mesh size is a common strategy to 
control the in-gel mobility or the release kinetics of proteins from polymer 
matrices [16, 189]. The relative difference between the protein and hydrogel mesh 
size dictates the magnitude of the steric hindrance. Hydrogel mesh size can be 
modulated either by the concentration and the chemistry of polymer and 
crosslinker or by introducing external stimuli [16]. In this study, the GAG-
hydrogels' mesh size was gradually adjusted by changing the molar ratio of the 
starPEG to heparin while keeping the heparin concentration constant [47]. This 
strategy effectively generated hydrogels with mesh size ranging from 8-30 nm of 
similar biochemical characteristics, making them suitable to control the mobility 
of many therapeutically relevant cytokines and GFs [7, 38]. Molecular diffusivity 
studies using FRAP revealed that the mobility of non-affine proteins within the 
GAG-hydrogels was primarily influenced by the protein's molecular weight and 
the hydrogel's mesh size (Figure 4.2). Similar to the mobility of these proteins in 
a pure buffer/ in a non-affine gel system (PEG/PEG), we found that smaller non-
affine protein (EGF) diffuse faster than the bigger ones. These effects could be 
clearly explained by the higher steric hindrance that the larger proteins 
experienced as it diffuse through the hydrogel network in comparison to the 
smaller proteins. Similarly, increasing the steric constraint within the starPEG-
heparin hydrogels by decreasing the hydrogel mesh size could restrict the 
diffusivity of both small (EGF) and large (VEGF121) non-affine proteins.  
In contrast, the diffusion of heparin-affine proteins (VEGF165 & SDF1α) was not 
significantly affected by their molecular size. We believe that the impact of 
overall electrostatic interactions between positively charged affine proteins and 
the high density of negatively charged heparin (750:1, heparin/ protein molar 
ratio) at pH 7.4 surpassed the effect of steric interaction between the proteins and 
the hydrogel network. In line with this, our previous finding reported that 
starPEG-heparin hydrogel could efficiently sequester a significant amount of 
many different cationic proteins in vitro and in vivo [7]. Similar effects of the 
protein size and charge on their in-gel mobility have also been documented in 
self-assembling peptide hydrogels [9, 189]. Here, the release of the bovine serum 




albumin (BSA) and trypsin inhibitor as representative of small and large, 
negatively charged protein models, respectively, was studied.  Accordingly, the 
larger protein exhibited a more prolonged-release than, the smaller ones at a pH 
where the electrostatic interaction between the protein and nanofiber was 
negligible [189]. On the contrary, the release of positively charged cytokines 
(βFGF/ basic fibroblast growth factor & BDNF/ brain-derived neurotrophic 
factor) from a variant of the peptide hydrogel that has a net negative charge was 
comparable despite the difference in their molecular weight [9]. 
The mobility of proteins in affinity-based delivery systems, including the GAG-
based hydrogel, is affected by the steric interactions with the hydrogel network 
and their affinity interactions with the binding ligand, which depends on the 
concentration of ligand and the strength of interaction [16, 52].  Based on this 
concept, recently, we have introduced GAG-hydrogels with varied GAG-sulfation 
patterns to modulate the affinity of the encapsulated Platelet-Derived Growth 
Factor (PDGF) and control the release kinetics from hydrogels [38]. In the present 
study, we varied the heparin content along with hydrogels' crosslinking degree to 
maintain a similar gel stiffness.  
The results of our study showed that the mobility of affine proteins decreased as 
the hydrogel heparin content increased (Figure 4.3). This finding is similar to 
what Jha and coworkers reported for the diffusion of TGFβ1, another heparin-
binding protein, in heparin-containing hyaluronic acid hydrogels [43], where the 
amount of added heparin did correlate to a substantial decrease in the mobility of 
proteins. Similarly, the increase of gel heparin content in a PEG-hyaluronic acid 
hydrogel was demonstrated to decrease VEGF's mobility and the subsequent 
release from the polymer matrices [77]. 
Unlike the impact of heparin concentration, the effect of specific GAG-sulfation 
pattern on the diffusion of heparin-affine protein within the hydrated polymer 
network seems to be more exclusive for a particular affine protein. We showed 
that the removal of 6O-sulfate from the heparin building block did not 
significantly affect the mobility of SDF1α, but it significantly enhanced the 
mobility of VEGF165 (Figure 4.4).  In line with this finding, previous studies 




investigating the interactions between the growth factors or cytokines and heparin 
have also demonstrated a preferential protein interaction with a distinct sulfate 
group of heparin for the efficient binding [36, 167, 190-193]. For example, the N- 
and 6O- sulfate of heparin was known to a greater extent mediate the heparin-
binding of VEGF165, whereas the interaction with the SDF1α mainly involved 
the 2O- and N- sulfate group [190, 193]. Overall,  the results of the study 
suggested the potential application of our hydrogel as a defined 3D in vitro model 
to recapitulate growth factor presentation/ transport in the ECM.  
The release of GAG-affine proteins from the hydrogel was inversely correlated to 
the sulfation degree of GAG building blocks, similar to their in-gel diffusivity 
trend measured by the FRAP method (Figure 4.5). Contrary to this, the release of 
non-affine proteins was not affected by the hydrogels' GAG sulfation. 
Interestingly, both the GAG-affine and non-affine proteins did not reach a 
complete release from the pure PEG/ PEG hydrogel despite the absence of affinity 
interactions. In line with this finding, Koutsopoulos and coworkers have also 
documented the release of proteins from a peptide-based-hydrogel scaffold that 
rarely reached 100%  irrespective of the protein sizes and affinity peptide fibers 
[189]. Accordingly, the hydrogel network domain's entanglement might limit the 
free movement of encapsulated macromolecules within the hydrogel matrix, 
which eventually precluded their complete release from the system. Also, the 
growth factors usually possess a short half-life both in vitro and in vivo [15, 194, 
195]. Thus, it was possible that during the release studies, proteins were denatured 
or forming aggregates preventing their detection by the ELISA or the release from 
the gel constructs [52, 196, 197]. 
Fluorescence recovery after photobleaching (FRAP) was a robust technique to 
quantify protein diffusion within various systems [183]. However, its applicability 
to analyze the diffusion process underlying the release of therapeutically relevant 
proteins from an affine GAG-based hydrogel system has yet to be proven. In this 
study, we observed similar trends of the diffusion coefficient of model proteins in 
the hydrogels with varied sulfation obtained either from the FRAP measurement 
or release experiment (Figure 4.5). In general, the values of diffusion constants 
derived from the release curve were consistently higher than those acquired from 




the FRAP, which is in good agreement with the previous studies on the diffusion 
of macromolecules within crosslinked-polymeric networks [161]. One possible 
explanation for such discrepancies might be attributed to the differences in the 
experimental setups [198-200]. Alternatively, the relatively higher protein 
concentration used for the FRAP measurement than the release experiment [201], 
might cause protein aggregation that would slow down the protein diffusion. 
Moreover, the slow scanning speed of the confocal microscope might also allow 
the diffusion to happen during the photobleaching stage of the FRAP 
measurements. These conditions could further contribute to the underestimation of 
diffusion coefficients obtained from the FRAP [202], especially when both slowly 
and rapidly diffusing protein fractions exist within the hydrogel [161]. 
Overall, the FRAP can be adapted as an alternative to the release experiments to 
evaluate the relative contribution of different GAG-hydrogel network parameters 
on the transport of embedded signaling molecules because the determined 
diffusion coefficient values were correlated well with those obtained from release 
studies. Considering the speed and precision of the FRAP measurement, both 
methods can complement each other to rapidly evaluate the potential of new 
GAG-based/ GAG-inspired materials for controlling the administration of growth 
factors or other bioactive molecules.  
A mathematical model can be instrumental for guiding the design of a cell-
instructive hydrogel with desired growth factor transport characteristics. Here, we 
applied a reaction-diffusion model to understand the binding and diffusion process 
within the GAG-based hydrogel system and predict the release kinetics of 
signaling molecules (Figure 4.6).  In general, the model underestimated the 
protein release within the first 24 H, especially those from hydrogels containing 
6ON-DSH. However, at later time points, the experimentally determined release 
of both proteins well agreed with the simulation. Two different protein 
populations that were not considered in the model may exist within the hydrogel: 
weakly and strongly binding proteins. The weakly binding protein was released 
much faster at early time points, whereas the strongly binding protein population 
sustainability was released from the hydrogel matrix over a more extended period.  




Consequently, as the model only accounts for single protein species with a strong 
affinity to the GAG, it could better capture the protein release dynamic at later 
time points. Additionally, for the PEG/ 6ON-DSH hydrogel with a low sulfation 
degree, much more weakly bound proteins may also present in the gel matrix. 
Together, these reasons might explain the model's poor curve fitting result to the 
experimental release of proteins from the PEG/ 6ON-DSH hydrogel. Moreover, 
the convective flow that speeded up the gels' protein release during the buffer 
replacement step of the experiments might also exist, especially at initial time 
points when the procedure was done more frequently. In this study, the buffer 
exchange was done more often at the beginning of release studies to capture the 
protein release dynamic, especially from the pure PEG/PEG gel, where the 
diffusion was relatively fast.  For future studies, the time scale to analyze affine 
proteins' transport in the GAG-based hydrogel system needs to be adjusted 
independently. As such, the release media should be exchanged less frequently to 
minimize the convective flow that complicates the subsequent analysis using the 
reaction-diffusion model. 
Despite these shortcomings, the developed computational model could still 
provide valuable information to predict the total protein release from the GAG 
hydrogel with varied sulfation patterns. The developed model could also estimate 
the KD value characterizing the interaction between the protein and GAG 
crosslinked within the hydrogel based on the experimental release. In general, the 
resulting KD values obtained from the release experiment were positively 
correlated to those obtained from the MST measurement (Table 4.1).  Besides, 
the variation in the KD obtained from both methods felt within the same order of 
magnitude of variability range of the KD values determined using different 
methods [115, 116, 127, 182]. Overall, we could see a positive correlation 
between the KD values derived from the model and the overall amount of protein 
release from the hydrogel, except for the interaction between the SDF1α and 
6ON-DSH, where the KD value could not be determined using MST.   Besides, the 
KD values also decreased with increasing sulfation degree of GAG building block 
of hydrogels. Therefore, the reaction-diffusion model that we developed here is 




instrumental to directly quantify the strength of interactions between the protein 
and GAG immobilized within a biomaterial.  
The model that we developed based on the binding and diffusion of molecules 
within the hydrogel might also serve as a guideline to design and characterize the 
biomaterial. By utilizing the KD of the interaction between the protein and linear/ 
soluble GAG measured using methods such as SPR [116], ITC [115], or BLI 
[117], it is possible to predict the release of proteins from the GAG-based 
hydrogels quantitatively. The adjustment of input parameters of the model, 
including the growth factor loading, GAG content, GAG affinity to the proteins 
(e.g., GAG sulfation patterns), and the gel geometry, can further be applied to 
predict the transport of protein within and out of the gel matrices in a more 
complex in vivo or in vitro scenario. 
Sensitivity analysis of GAG-hydrogel network parameters revealed that adjusting 
the GAG content of hydrogel was the most effective way to modulate the release 
of GAG-affine proteins (Figure 4.7). The effect of protein loading concentration, 
GAG affinity to the signaling molecules, and the dissociation rate constant of the 
GAG-protein complex did not significantly influence the release of GAG-affine 
proteins, especially at a high concentration of GAG. Regioselective desulfation or 
the introduction of additional sulfate moieties to the GAGs regulates their affinity 
for signaling molecules and thereby could be applied to modulate the retention 
and release kinetics of proteins from engineered matrices [38, 203]. However, the 
complicated procedures and the difficulty in achieving a tunable release of the 
growth factors from the materials may limit their usage. As demonstrated by the 
simulations results, heparin's affinity to the protein could also dynamically control 
the release of growth factor from the matrices at the low heparin concentration. 
Therefore, combining selective heparin desulfation and tuning the hydrogels' 
heparin concentration may provide valuable options to precisely tailor the release 
rate of signaling molecules for various applications. 
Previous studies investigating the influence of binding rate constant on the release 
kinetics of protein from affinity-based growth factor delivery systems have 
reported conflicting results. Some studies suggested that the dissociation rate 




constant is essential for determining the release of proteins from the gel matrix 
[129], while other studies have shown the opposite [178]. Here, we found that 
altering the dissociation rate constant did not change the overall release of protein 
as long as a physically relevant rate constant value for a typical GAG-protein 
interaction was used. Therefore, for the subsequent simulation employing this 
model, it is unnecessary to utilize the exact value of rate constant between the 
protein and heparin or heparin derivatives to predict the release from scaffolds. 
This knowledge is particularly useful, especially when the rate constants' values 
are not available/ failed to be determined using available methods.  
Taken together, in this section of this thesis,  fluorescent recovery after 
photobleaching has been successfully optimized and implemented to analyze the 
transport of signaling molecules within the binary GAG-based hydrogels. Our 
systematic study on the mobility of proteins revealed the key parameters of the gel 
network that govern the transport of signaling molecules. A mathematical model 
that describes the binding and diffusion of signaling molecules within the GAG-
based hydrogel has also been developed utilizing the data derived from the protein 
diffusion and binding studies under various scenarios. Overall, the obtained 
results allow for the customization of signaling protein transport in GAG-based 











4.2 Tuning the activity of pro-angiogenic growth factor 
within binary GAG-based hydrogels 
4.2.1 Introduction 
The vascular network is essential to provide the cells with a continuous supply of 
nutrients and oxygen. Previous in vitro studies revealed that the formation of 
vascular structures involves the interplay between endothelial cells, supporting 
cells [3], and biophysical and biomolecular cues of the scaffold such as matrix 
degradability [66, 204], stiffness [3, 205], cell adhesiveness [206], and 
functionalization with pro-angiogenic growth factors [3, 140]. Among the 
previously identified pro-angiogenic growth factors, vascular endothelial growth 
factor (VEGF) is the key player of in vivo angiogenesis. The factor controls 
multiple aspects of vascular function and development by stimulating 
proliferation, migration, survival, and differentiation of endothelial cells [69-72].  
However, the VEGF has a relatively short half-life [14, 15, 207], and a narrow 
therapeutic window [17, 208]. Therefore, maintaining the delivery of bioactive 
VEGF within- and out of the scaffold can be instrumental for the application in 
vascular tissue engineering. 
Incorporation of sulfated glycosaminoglycans (GAGs) has been widely applied 
for the sustained delivery of signaling molecules from engineered biomaterials [4-
6].  This methodology offers a powerful means to modulate the retention and 
release kinetics of heparin-binding proteins because the negatively charged GAGs 
can reversibly interact with the molecules through their positively charged 
surfaces. The affinity of GAG to a given signaling molecule, and the overall GAG 
content, determine the relative concentration of free and matrix-bound factor 
within the hydrogel [32, 51-53]. Therefore, adjusting the overall GAG content of 
the polymer network as well as the GAG sulfation pattern to modulate the GAG 
affinity to signaling molecules have been widely applied to control the 
administration of signaling molecules, including the VEGF from the GAG-based 
scaffolds [6, 38, 43]. The effect of GAG content and GAG sulfation patterns of 
GAG-based matrices on the bioactivity of the released VEGF has been previously 
investigated [4-6, 77]. However, the influence of both parameters on the activity 




of gel embedded VEGF to control cell fates within cell-instructive polymer 
networks has not been systematically studied.  
To unravel the impact of  GAG content and GAG sulfation patterns of the 
hydrogel on the transport and bioactivity of VEGF, herein we applied a previously 
introduced platform of binary GAG based-hydrogel made from heparin and four-
arm poly(ethylene glycol)-(starPEG) peptide conjugates (Figure 4.8A-B) [47]. As 
described before, the overall GAG content and GAG sulfation pattern of the 
system can be varied to tailor the overall space charge density and local charge 
density of the GAG component, respectively, to modulate the binding of various 
cytokines and growth factors (Figure 4.8C-D) [78]. Besides, the system is 
compatible with a direct encapsulation of human umbilical veins endothelial cells 
(HUVECs) and has been adapted as a robust 3D in vitro model of angiogenesis 
[3]. As the VEGF plays a vital role in the early regulation of angiogenesis [12, 
209, 210], controlling extracellular availability is critically important to direct the 
tubular morphogenesis of endothelial cells. 
In this study, hydrogels containing different heparin (Hep) content (0,500,1000, 
and 1500 µM) or heparin derivatives with varied sulfation patterns were first 
prepared and thoroughly characterized for their swelling and mechanical 
properties.  A mathematical model to predict free and bound VEGF availability 
within the gel matrices was then developed and experimentally validated. 
Furthermore, we investigated the relevance of free VEGF availability and specific 
heparin (derivatives) sulfation patterns on the formation of HUVEC tubular 
structures within the hydrogels. Finally, by utilizing the microfluidic technique, 
we also demonstrated the effect of a graded distribution of VEGF on the HUVEC 









4.2.2 Physical properties of hydrogels 
Heparin (Hep) was regioselectively desulfated at 6O- position to generate 6O-
desulfated heparin (6O-DSH), or both at 6O- and N- position to synthesize 6ON-
desulfated heparin (Figure 4.8A). This strategy enabled the generation of heparin 
derivatives with a sulfation degree of 67% and   33%, respectively, relative to 
the fully sulfated heparin (Hep). Subsequent functionalization of Hep or its 
derivatives with maleimide moieties further allowed for an efficient reaction with 
thiol-containing starPEG through Michael type addition scheme to form a 
hydrogel with a stable thioether bond in the presence of biological fluid (Figure 
4.8B). Due to the reaction's specificity, the crosslinking reaction is also 
compatible with a direct encapsulation of cells or various growth factors during 
the gel formation.  
To modulate hydrogels' affinity for given signaling molecules, the GAG-building 
block with a variable sulfation degree can be selectively chosen for the in-situ 
cross-linkable hydrogel formation to generate hydrogel with variable local sulfate 
density (Figure 4.8C). Besides, the heparin content of hydrogels was also varied 
by adjusting the overall solid content (Figure 4.8D). This strategy is rationally 
applied to adjust the number of protein binding sites within the system, 
modulating the binding and transport of signaling molecules. 
Endothelial cell morphogenesis within engineered materials is controlled both by 
the presence of pro-angiogenic growth factors and the scaffold's mechanical 
properties, such as stiffness [3, 143, 211]. As described before, the formation of 
endothelial capillary structures within starPEG-heparin hydrogel can be achieved 
in a soft hydrogel with a storage modulus of 200 Pa [3]. Therefore, to investigate 
the effect of heparin content and heparin sulfation patterns on the VEGF-mediated 
vascular morphogenesis, a set of hydrogels with the various heparin content or 
heparin-sulfation degree was prepared with this stiffness range (Figure 4.8E-F).  
For investigating the effect of heparin content on the transport and bioactivity of 
VEGF within the scaffold, hydrogels containing fully sulfated heparin were 
produced with a total GAG concentration in the range of 500-1500 M (Figure 
4.8E). Besides, pure PEG hydrogel was used as a control. We could prepare 




hydrogels with a stiffness of approximately 200 Pa by adjusting the overall solid 
content in the range from 2-3.6% and the molar ratio of starPEG to heparin. 
Volume swelling measurement of all hydrogels indicated an increase in the 
volume of only less than 30% from its original, with the highest swelling was 
observed for the hydrogel containing the highest heparin content (1500M).  
Next, to understand the effect of GAG affinity on VEGF's bioactivity, hydrogels 
containing fully sulfated heparin, 6O-desulfated heparin, and 6ON desulfated 
heparin were prepared at a total GAG concentration of 1500 M. All the hydrogel 
with varied GAG sulfation patterns could be produced with a 200 Pa stiffness by 
merely altering the GAG building block choice while fixing the total GAG 
content constant (Figure 4.8F). Interestingly, similar to the hydrogel prepared 
with a low GAG content (Figure 4.8E), slightly lower volume swelling was 
observed for the hydrogels containing GAG building block with the lowest 
sulfation degree compared to the fully sulfated heparin. These results might be 
attributed to the decrease in hydrogel hydrophilicity due to the reduced volume 
density of sulfate groups.  





Figure 4.8. The formation and physical properties of the GAG-based hydrogel 
with adjustable local and overall sulfate density. (A). The building block of 
hydrogels consists of thiol-functionalized starPEG (starPEG-SH), maleimide 
functionalized heparin (Hep)/ heparin derivatives, which were selectively 
desulfated at 6O- (6O-DSH), or 6O- and N- position (6ON-DSH). (B) The 
starPEG-SH can be instantaneously reacted with maleimide-functionalized 
heparin to form a hydrogel network containing a stable thioether linkage. (C) 
Variation in hydrogels' local sulfate density can be achieved by incorporating 
heparin/ heparin derivatives with different sulfation degrees. (D) The overall 
heparin content of hydrogels can also be adjusted to control the overall sulfate 
density. (E) Stiffness and volumetric swelling of the hydrogels with varied 
heparin content. (F) Stiffness and volumetric swelling of the hydrogels with 










4.2.3 VEGF release from hydrogels with varied GAG content and GAG 
sulfation patterns 
The effect of heparin content of hydrogels and the sulfation pattern of GAG on the 
release of VEGF165 was evaluated throughout 360 H. Due to the biorthogonal 
crosslinking scheme, the protein can be encapsulated during the gel formation 
[212]. All hydrogels were adjusted to have a similar stiffness to specifically 
dissect the impact of both parameters on the protein release. 
The release of VEGF from PEG-PEG hydrogel displayed a significant initial burst 
(Figure 4.9A). More than 60% of the initially loaded protein was released within 
the first 24 H. At 72 H, the VEGF release reached a maximum amount (~ 70%), 
and no more protein release occurred at later time points.  
Nevertheless, in all hydrogels with varied heparin content, more than 97% of the 
loaded VEGF can be retained throughout 360 H (Figure 4.9B). The hydrogels 
could also maintain a sustainable release of VEGF with a minimal burst release. 
The release of VEGF165 can be gradually adjusted by varying the heparin 
concentration. Decreasing the hydrogel's heparin content from 1500 µM to 500 
µM could enhance the overall VEGF release by a factor of three, which is 
proportional to the total decrease in the heparin content.  
Similarly, hydrogel containing different GAG sulfation also displayed variation in 
the release profile (Figure 4.9C). Sulfation degree of the GAG-building block 
inversely correlated to the amount of VEGF release from the hydrogel. The VEGF 
release rise from ~1% to ~2.5% when the GAG building block was switched from 
fully sulfated heparin (Hep) to 6O-desulfated heparin. Incorporation of 6ON- 
desulfated heparin further enhanced VEGF release to more than 4% throughout 
360 H. Although 6ON-DSH contains only ~30% of the sulfate group of the 
heparin, 96% of the proteins were retained within this hydrogel even after two 
weeks, which is significantly higher than the amount remaining in the PEG-PEG 
hydrogel. This result indicated that the desulfated heparins maintain a higher 
affinity for the VEGF than the PEG, which was reported to be inert [213]. 
To understand if the release of VEGF from the hydrogel is governed both by the 
diffusion of protein through the hydrogel network and the binding to the GAG 




building block, the experimental release data was fit to the reaction-diffusion 
model [52], in COMSO Multiphysics. The curve fitting resulted in an estimated 
strength of an interaction between the VEGF and GAG or GAG derivatives within 
the crosslinked polymeric network. A similar model has been previously applied 
in several affinity-based systems [52], including the GAG-based materials [32, 33, 
53]. Several parameters, including the free diffusion coefficient of protein in the 
hydrogel (Dgel), dissociation rate constant of the protein-GAG interactions (kd) as 
well as the GAGs and initial protein loading concentration after the hydrogel 
swelling, were required for the curve fitting (Table 6.1).  It is important to note 
that the curve fitting of the VEGF release from PEG/PEG hydrogel mainly 
required the diffusion coefficient of protein in the gel since no protein affinity to 
the PEG building block was assumed. 
Interestingly, the reaction-diffusion model could describe the release profile of 
proteins from all gel formulations. The resulting KD values obtained from the 
curve fitting for each GAG-derivatives were listed in Figure 4.9D. VEGF's 
binding strength to the GAG crosslinked within the hydrogel was inversely 
correlated to the GAG building blocks' sulfation degree. In general, the obtained 
KD values are lower than those obtained using microscale thermophoresis for a 
linear GAG in solutions. However, the values are still within the variability range 
of the KD values of protein-GAG interaction measured using various techniques 
[167, 193].  





Figure 4.9. GAG content and GAG sulfation patterns modulate the release of 
VEGF from hydrogels. (A) The release of VEGF from hydrogel with varied 
heparin content. (B). The release of VEGF from hydrogel containing variable 
GAG sulfation patterns. (C) The release of VEGF from non-affine pure PEG/PEG 
hydrogel. The release experiment was conducted at 37o C in endothelial growth 
medium (EGM) supplemented with 0.1% BSA over 360 H. The data points and 
solid lines indicate the experimental release and resulting curve fit to the reaction-
diffusion model, respectively. Data represent mean ± SD (n ≥ 3). (D) Comparison 
between the binding constant of VEGF to the GAGs obtained from the microscale 
thermophoresis and the curve fitting of experimental release. 
 
4.2.4 Effect of GAG concentration and sulfation pattern on the 
formation of vascular structures of endothelial cells within hydrogels 
The VEGF is the major growth factor that controls proliferation, migration, 
survival, and differentiation of endothelial cells [70-72, 214]. Previously, it has 
been incorporated into the starPEG-GAG hydrogel to initiate the capillary-like 
structure formation [3]. Here, we investigated the role of GAG content and GAG 
sulfation on the extent of VEGF-induced endothelial cell vascular morphogenesis. 
As described before, the HUVECs and VEGF can be directly encapsulated into a 
droplet of hydrogel during the gel formation and eventually form vascular 
structures within three days [3] (Figure 4.10 A-B). After three days, the cells 








acquired in the middle of the hydrogel, skeletonized, and subsequently analyzed 
for the vessel area and branching (Figure 4.10D).  
 
Figure 4.10. Schematic view of in vitro assay of endothelial morphogenesis 
within the hydrogel. (A) Uniform encapsulation of HUVEC and VEGF within a 
hydrogel droplet. (B) After three days of culture, HUVEC capillary-like structures 
were formed. (C) Fluorescence image of HUVEC vascular structures within the 
hydrogel, DAPI was used as a nuclear counterstain, and the actin filament was 
visualized using ATTO-633-phalloidin. (D) The skeletonized image obtained 
from the fluorescence image using the Imaris software was used to quantify the 
number of branching and the total vessel area of HUVEC capillary networks. 
 
We have shown that the VEGF induced metabolic activity of HUVECs on 2D at a 
concentration of 1-100 ng/mL, in a dose-dependent manner (Figure 6.7A). 
Similarly, others have also reported that 10 ng/mL (260 pM) of VEGF was 
sufficient to induce the proliferation of HUVECs [193]. However, our previous 
work reported that a much higher concentration of VEGF (at least 5 µg/mL) was 
needed to prime endothelial cell vascular morphogenesis in the starPEG-GAG 
hydrogels [3]. Therefore, we hypothesized that free VEGF availability is crucial 
for the induction of proliferation and metabolic activity of endothelial cells within 
the hydrogels. A numerical simulation based on the reaction-diffusion model was 
performed utilizing the KD obtained from the release experiment (Figure 4.9D) to 
determine the amount of free factor exposed to the cells after the gelation (0 H) 
A B 
C D 




and at 72 H when the endothelial capillary-like structures were formed (Figure 
4.11).  
According to the simulation, free VEGF concentration is inversely proportional to 
the hydrogel's GAG content. At t= 0 H, the pure PEG gel has the highest free 
VEGF content ( 250 pM), whereas the corresponding concentration within the 
hydrogel containing 500, 1000, and 1500 µM of heparin was found to be 170 pM, 
110 pM, and 60 pM, respectively. After 72 H, a significant portion of the VEGF 
was already released from the PEG/PEG gel. In contrast, all hydrogels 
functionalized with the GAG retained almost all the loaded VEGF.  
Similar trends were also observed in the hydrogels with varied sulfation patterns, 
the hydrogel with the highest GAG sulfation maintain around 60 pM of free 
VEGF, and the values increase to around 160 pM and more than 200 pM for the 
hydrogel with 67% and 33% of GAG sulfation degree, respectively. Even after 72 
H, all hydrogels with varied GAG sulfation also maintain a similar amount of free 
factor compared to 0 H, with the amount of free VEGF in the media inversely 











Figure 4.11. COMSOL simulation of the free VEGF concentration in hydrogel 
droplets with varied GAG content and GAG sulfation. (A) Schematic view of the 
hydrogel droplet for endothelial cell culture and the cross-section view at the 
middle part of the hydrogel. (B) The color map shows the distribution of free 
VEGF in media and hydrogels with varied GAG content (left panel) or varied 
GAG sulfation of fixed GAG content (right panel) just after the formation of the 
hydrogels (0 H) or 72 H after the incubation with media. The gels were pre-loaded 
with 5 µg/ml of the VEGF. The color legend represents the free VEGF 
concentration in nM. The free factor with a concentration of 200 nM or higher is 
shown with the same color (dark red) as indicated by the * sign. 
 
Next, the effect of GAG content and GAG sulfation on the bioactivity of VEGF to 
regulate vascular morphogenesis within the hydrogel was examined. VEGF's 
initial loading was varied from 0-20 g/mL to further modulate the free VEGF 
concentration within the hydrogels. The hydrogel containing the lowest GAG 
content displayed a superior formation of endothelial cell tubular structures at any 
VEGF loading concentration than any other hydrogels tested (Figure 4.12A). The 
total vessel area and the number of branch points of the vascular network in the 
hydrogel with 500 µM of GAG were significantly higher than for the hydrogels 
with 1000 M or 1500 M of GAG (Figure 4.12B-C). In general, the extent of 
vascular morphogenesis decreased as the GAG content of the hydrogel increased. 
This effect was directly correlated to the amount of free VEGF within the 
hydrogel.  
Furthermore, the amount of VEGF loading enhanced the formation of 
vasculatures in a concentration-dependent manner. In particular, we observed a 
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greater extent of vascular structure formation in the hydrogel with the low and 
medium GAG content as more VEGF was loaded into the gels. Interestingly, the 
hydrogel with the lowest GAG content also required a less VEGF concentration to 
induce an extensive vascular network formation. Although 1 g/ml of VEGF was 
enough to induce vascular morphogenesis in the hydrogel with the lowest GAG 
content, increasing the VEGF loading up to 20 µg/mL in hydrogels with the 
medium or high GAG content could not promote a similar extent of 
vascularization. Interestingly, while the pure PEG hydrogel contained the highest 
amount of free VEGF compared to any other hydrogels, a minimum of vascular 
morphogenesis was observed within this hydrogel. Similar to the VEGF 
bioactivity in culture medium (Figure 6.7B), probably the activity of VEGF in the 
PEG hydrogel also decreased over time since a slight increase in the vascular 
structure formation was seen when the VEGF loading was raised to 5 and 20 
g/mL (Figure 12A).  
Similar to the effect of VEGF in the hydrogel with varied GAG content, the 
VEGF enhanced the vascular morphogenesis in a concentration-dependent 
manner in any hydrogels with varied GAG sulfation patterns (Figure 4.13A). 
Increasing the free factor concentration by removing the 6O sulfate or 6O and N 
sulfate from GAG enhanced HUVEC tubular structures' formation. Compared to 
the hydrogel with the fully sulfated GAG, the hydrogel containing 6O-DSH or 
6ON-DSH produced vasculatures with a larger area and higher number of branch 
points (Figure 4.13B-C).  Interestingly, at a lower VEGF loading concentration of 
1 and 5 µg/mL, hydrogel containing 6O-DSH induced a superior vascular 
structure formation compared to the one with 6ON-DSH, despite the higher 
estimated free VEGF in the 6ON-DSH hydrogels. However, increasing the VEGF 
loading to 20 g/ml resulted in no significant difference between the vasculature 
area in both types of hydrogels. Notably, in the absence of VEGF, the hydrogel 
containing the GAG with the lowest sulfation promoted larger vessel area 
formation than those with higher GAG sulfation. 





Figure 4.12.  Effect of heparin content of the hydrogel on the endothelial cell 
capillary morphogenesis at various VEGF loading. (A) Representative 
skeletonized images of endothelial vascular structures formed within the 
hydrogels with varied heparin concentration (0, 500, 1000, and 1500 µM) over 
three days. One image per condition was chosen arbitrarily to represent different 
hydrogel conditions. Fixed samples were stained with phalloidin and DAPI, and 
Imaris software was used to process and skeletonize the fluorescence images. (B) 
Total vessel area of the vascular structures. (C) The number of branch points of 
the endothelial network. Scale bar = 200 µm. Data represents mean ± SD (n = 5-8 
cultures), ‘ns’ stands for not significant, ****P<0.0001.  
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Figure 4.13. Effect of GAG sulfation pattern of the hydrogel on the endothelial 
cell capillary morphogenesis at various VEGF loading. (A) Representative 
skeletonized images of endothelial vascular structures formed within the 
hydrogels containing GAG building blocks with varied sulfation degrees (33, 67, 
& 100 %) over three days. One image per condition was chosen arbitrarily to 
represent different hydrogel conditions. Fixed samples were stained with 
phalloidin and DAPI, and Imaris software was used to process and skeletonize the 
fluorescence images. (B) Total vessel area of the vascular structures. (C) The 
number of branch points of the endothelial network. Scale bar = 200 µm. Data 
represents mean ± SD (n = 5-8 cultures), ‘ns’ stands for not significant, ** 
P<0.01, *** P<0.001, ****P<0.0001.  
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4.2.5 Spatial patterning of cellular activity within hydrogel matrices 
4.2.5.1 Patterning of endothelial cell morphogenesis in response to angiogenic 
growth factor gradients 
GAG binds to various positively charged growth factors, restricts their diffusive 
transport, and initiates a growth factor gradient in the ECM [215, 216].  Hydrogel 
prepared with the lowest GAG content and functionalized with a uniform 
distribution of VEGF could support a remarkable vascular network formation. To 
test the applicability of material to direct the spatial organization of endothelial 
cell tubular structures within the hydrogel, the VEGF was presented as a gradient 
using microfluidic devices as previously described [163].  The microfluidic 
platform contains three parallel channels for loading medium containing growth 
factors, the hydrogel precursors, and the medium alone.  
To characterize the VEGF gradient's spatiotemporal profile, fluorescently labeled 
VEGF was loaded into one of the side channels and allowed to diffuse into the 
hydrogel for 72 H. The fluorescent images revealed the spatial differences in the 
fluorescent intensity across the hydrogel channel (Figure 4.14A). Immediately 
after adding growth factors into the source channel, significant protein 
accumulation was observed near the medium-gel interface. Even after the 72 H of 
the protein uptake, the gradient of VEGF remained visible. The simulation of the 
spatial and temporal profile of the VEGF gradient using the reaction-diffusion 
model revealed that the gradient only spans within the first 300 m from the 
source of growth factors and remained stable throughout 72 H (Figure 4.14B). In 
good agreement with the simulation results, the fluorescent protein gradient 
spanned within the first half of the hydrogel channel from the source of growth 
factors. The gradient was not depleted after 72 H, although no medium flow was 
applied to the medium nor the growth factor channel (Figure 4.14C).  
To examine the effect of the VEGF gradient on the spatial formation HUVEC 
tubular structure, HUVECs were embedded within the hydrogel and subsequently 
exposed to medium only, the gradient of VEGF, or homogenously distributed 
VEGF (Figure 4.14D). After three days of culture under these conditions, the 




extent of vessel area near the sink channel, the source channel, as well as within 
the hydrogel channel were quantified (Figure 4.14E). As such, the hydrogel 
treated with the medium only did not support any vascular structures' formation. 
On the other hand, the hydrogels containing the gradient of VEGF supported a 
higher density of tubular structures toward the higher concentration of VEGF 
(Figure 4.14F). Moreover, when the VEGF was homogeneously distributed 
within the hydrogel, the extent of the tube-like structure formation in the source 










Figure 4.14. The gradient of VEGF modulates the spatial organization of 
endothelial cell vascular structures within the hydrogel. (A) fluorescence images 
representing the gradient of fluorescently labeled VEGF formed within the 
microfluidic device throughout 72 H. (B) The theoretical gradient profile of 
VEGF (C) The experimental gradient profile of fluorescently labeled VEGF. (D) 
The experimental set-up to investigate the effect of the VEGF gradient on the 
spatial organization of HUVEC vascular structures. The endothelial cells loaded 
within the hydrogel are either treated with no VEGF, the gradient of VEGF or 
homogenously distributed VEGF. (E) Skeletonized images of endothelial vascular 
structures resulting from VEGF treatment of different spatial presentations over 
three days. One image per condition was chosen arbitrarily to represent different 
hydrogel conditions. Fixed samples were stained with phalloidin and DAPI, and 
Imaris software was used to process and skeletonize the fluorescence images. (F) 
Quantification of the total area of HUVEC vascular structures at a different 
location within the hydrogel channel. The source area is defined as the half 
portion of the hydrogel channel closed to the VEGF source, whereas the sink area 
is defined as the half portion of the hydrogel channel closed to the medium 
channel containing no VEGF. Scale bar = 200 µm. Data represents mean ± SD (n 










4.2.5.2 3D chemotaxis of endothelial cells in response to angiogenic growth 
factor gradients 
The formation of new vasculatures involves a series of steps initiated by the 
degradation of the ECM and followed by a directed endothelial cell migration 
toward non-vascularized tissues, cell proliferation, and the formation and 
stabilization of vascular lumens [217]. The VEGF is a potent chemoattractant that 
functions to modulate cell motility [218]. Herein, the effect of the VEGF gradient 
on the endothelial cell chemotaxis within the hydrogel was investigated. Two 
main conditions where the VEGF was either distributed homogeneously or 
presented as a gradient within the hydrogel were tested. As a control, the 
migration pattern of the HUVECs in the absence of VEGF was also examined.  
Accordingly, the HUVECs treated with the VEGF gradient displayed as strong 
chemotaxis toward the source of VEGF (Figure 4.15A). The HUVECs exposed to 
the VEGF gradient displayed a greater forward migration index (chemotaxis 
index) than the untreated cells or the ones treated with uniform distribution of 
VEGF (Figure 4.15B). In the presence of VEGF, the cells also migrated farther 
and more efficiently compared to the non-treated cells, as indicated by the higher 










Figure 4.15. Endothelial cell chemotaxis in response to the VEGF gradient. (A) 
Representative trajectory plots of the HUVECs treated with various VEGF 
presentations. (B) Analyzed cell migration parameters, including a forward 
migration index, directness, net migration distance, and accumulated distance. 
 
4.2.6 Discussion and summary 
Strategies to maintain the stability of VEGF and the retention within polymeric 
biomaterials include covalent immobilization [23, 219], engineering growth factor 
variants with higher affinity for particular matrices [21], and incorporation of 
GAGs into the polymer networks [4, 6]. While the first two approaches might 
compromise the functionality of the growth factors, the later offers unprecedented 
options to control the bioactivity of VEGF due to the ability of the GAG to 
enhance protein stability and to facilitate the growth factor binding to the 
receptors [7, 22, 29, 54, 220-222]. However, maintaining a subtle balance of 
retention and cellular delivery of the growth factors can be crucial in determining 
the cell fate decisions. The fraction of free and bound factor within GAG-based 
material is determined by the affinity of growth factor to the GAG building block 
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and the total content of GAG within the system. Controlling the sulfation degree 
of GAG has been previously explored to modulate the growth factors' affinity and 
thereby determine the release from polymer networks [6, 38, 39]. However, the 
influence of the hydrogels' GAG content and GAG sulfation patterns on the 
bioactivity of gel-embedded VEGF was not yet determined. 
In this part of the thesis, we investigated the role of GAG content and GAG 
sulfation patterns of the starPEG-GAG hydrogel system on the VEGF-mediated 
endothelial cell vascular morphogenesis [47]. Hydrogels with varied GAG content 
and GAG sulfation were prepared and characterized for their physical properties. 
Analysis of VEGF release from the hydrogel using a mathematical model 
revealed the VEGF transport dependency on the binding and diffusion of the 
molecules within the polymer network. Finally, mathematical modeling and 
HUVEC tubular morphogenesis studies in hydrogels with varied GAG content 
and GAG sulfation patterns revealed the relevance of free VEGF availability and 
specific GAG sulfation patterns on the formation of tubular structures of 
endothelial cells. Moreover, the VEGF gradient was shown to modulate the 
chemotaxis of endothelial cells and the spatial organization of the emerging 
tubular structures within the hydrogel. 
The ability to tune the mechanical and biochemical properties of the scaffolds is 
essential to dissect the influence of GAG content as well as GAG sulfation 
patterns on the cell-fate control. The rational design concept has enabled the 
independent modulation of the starPEG-heparin hydrogels' mechanical properties 
from their heparin concentration and the GAG building block sulfation patterns 
[38, 39, 47, 79]. Supporting this finding, we could produce a set of soft hydrogels 
with varied GAG sulfation (Figure 4.8). Besides, for the first time, we 
demonstrated that the heparin content of the starPEG-GAG could also be tuned 
while maintaining their similar stiffness by merely adjusting the molar-ratio of 
starPEG to heparin of the hydrogel precursors. The capacity to decouple the GAG 
content and the GAG sulfation of hydrogels from the mechanical properties will 
broaden the applicability of the materials for dissecting their relevance on the 
organ or disease development such as cancer, in which the stiffness, GAG 
sulfation, GAG content of the ECM played essential roles [223].  




The GAG volume density of hydrogels modulates the transport of signaling 
molecules. In the present study, we expanded the starPEG-GAG hydrogel 
system's tunability to allow for the formation of hydrogels with varied heparin 
concentrations. This strategy could further improve our hydrogel platform's 
versatility to control the diffusivity of signaling proteins at various levels. The 
effect of heparin content on the in-gel mobility of heparin-affine proteins, here as 
we demonstrated using the VEGF165, was also correlated with the release from 
the hydrogel matrices (Figure 4.3 & Figure 4.9B). Similarly, we have observed 
less VEGF released from the hydrogel as more heparin was incorporated into the 
hydrogel. In line with this finding, the modulation of the VEGF's retention and 
release rate from various hydrogels,  including PEG-hyaluronic acid hydrogel 
matrices, and polycaprolactone-alginate scaffolds, could also be achieved by 
tuning the heparin content of the system [45, 77].  
GAG sulfation patterns determine the affinity for signaling molecules, thereby, 
governs the transport of growth factors within GAG-based materials [38]. The N- 
and 6O- sulfate of heparin was known to a greater extent, mediate the binding of 
VEGF165 to heparin [190, 191, 193].  In line with this, the diffusivity of 
VEGF165 in the hydrogels containing 6O-DSH and 6ON-DSH was significantly 
higher compared to that in the hydrogels containing Hep (Figure 4.4). 
Furthermore, the degree of GAG sulfation inversely correlated to the amount of 
VEGF release from the hydrogel (Figure 4.9C). The hydrogel containing 6O-
DSH significantly released more VEGF than that containing fully sulfated Hep. 
Furthermore, the VEGF release slightly increased when the hydrogel's GAG 
building block was changed from 6O-DSH to 6ON-DSH heparin, which further 
confirmed the importance of both 6O- and N- sulfate for the VEGF binding to 
heparin or heparin derivatives. Similarly, the influence of 6O desulfation of 
heparin on the VEGF release from the starPEG-GAG hydrogels of different 
crosslinking schemes has also been reported before [6]. However, no significant 
differences were observed between the release of VEGF from the GAG hydrogel 
containing 6O-DSH and 6ON-DSH. The discrepancy might be explained by the 
differences in the hydrogel thickness as well as the loading amount and 
entrapment procedures of VEGF, which could affect the initial distribution within 




the hydrogel, the absolute amount of release, and the subsequent detection by the 
ELISA. Interestingly, only less than 10% of the proteins were released throughout 
360 H from the hydrogel containing 6ON-DS despite the low sulfate content. The 
remaining negative charges on the GAG derivative due to the carboxylic acid and 
residual sulfate groups and the molar excess of GAG compared to the protein 
loading in the hydrogels (100: 1, GAG/ protein molar ratio) collectively might 
explain this observation. 
A mathematical model could be instrumental in designing materials that achieve 
the desired rate of morphogen transport [32, 55], to precisely modulate cell fate 
decisions [30, 38]. Notably, the mathematical models have been previously 
applied to predict the transport characteristics of growth factors within GAG-
based materials in the presence or the absence of matrix degradation [33, 53, 55, 
57]. In most of these studies, the experimental release confirmed the impact of the 
heparin to growth factor ratio on the overall release of the growth factor. 
However, a direct comparison between the theoretical and the resulting 
experimental release was not presented. In this study, VEGF's release from the 
hydrogel with varied GAG content and GAG sulfation can be well described 
using a reaction-diffusion model. The decrease in the heparin sulfation resulted in 
a weaker interaction between the protein and GAG within the hydrogels. Besides, 
the estimated binding strength of the VEGF to the GAG crosslinked within the 
hydrogel was comparable to the value determined by the MST for the growth 
factor interaction with the linear GAG in solution (Figure 4.9D). This indicates 
the applicability of the model for the quantitative prediction of different GAG-
binding proteins' transport by merely providing necessary input parameters. For 
example, the diffusion coefficient of the protein in the hydrogel as can be 
determined by molecular diffusion techniques, and the binding constant value 
(KD) of the protein to the linear GAGs as can be measured using methods such as 
SPR [127], ITC [115], or BLI [117].  
Apart from that, here, the mathematical model was also developed to investigate 
the transport of signaling molecules within biohybrid GAG-based hydrogels with 
predefined constituents. Therefore, it would allow us to precisely determine all 
possible molecular interactions between the growth factors and the gel 




components (e.g., GAG units).  In contrast, previous studies developed the model 
to predict the transport of signaling molecules in GAG-based biopolymer-derived 
matrices [33, 53, 55, 57]. In such matrices, the inherent affinity of the biopolymer 
components for a broad spectrum of growth factors [181], and their batch to batch 
variability would make it difficult to accurately estimate the strength of 
interactions between the factors and the GAG building blocks. Furthermore, to 
improve the accuracy of the model predictions in more complicated in vivo 
settings, we also envisioned considering parameters such as the competitive 
binding of serum-borne proteins to affinity ligands [58] and the altered GAG 
affinity after the chemical modifications [224] in our mathematical model. 
In the context of VEGF administration, the GAG content of polymer networks 
determines the overall VEGF retention and the available amount that can 
stimulate the embedded cells. We hypothesized that only the unbound VEGF 
could bind to the endothelial cell surface receptor and subsequently trigger the 
VEGF-dependent vascular morphogenesis. Therefore, we applied the 
mathematical model to predict the amount of VEGF that forms a complex with 
the GAG and the one that freely diffuses within the hydrogel network.  
Despite the high retention of VEGF ( 90%) in all hydrogels containing heparin 
(Figure 4.9), only the hydrogel with the lowest heparin concentration displayed 
an extensive endothelial network formation (Figure 4.12). Based on our 
simulation results, the hydrogel containing 500 µM of heparin maintains the free 
VEGF concentration of about 170 pM for at least up to 3 days of culture without 
the supplementation of growth factor in the media (Figure 4.11). This 
concentration is comparable with the VEGF dose required to prime endothelial 
network formation in the standard tube formation assays (520 pM)  [225]. The 
enhancement in the cellular delivery of free VEGF with decreasing GAG content 
of hydrogels probably played a significant role here since the concentration of 
bound VEGF in all hydrogels containing heparin was comparable and 
significantly higher than 260 pM (117 nM, data not shown). However, out of our 
set of gels,  only the material containing the lowest heparin content supported the 
vascular morphogenesis. (Figure 4.12). It is important to note that increasing 
VEGF loading in the hydrogel with the high or medium heparin content to 20 




g/mL did not enhance vascular morphogenesis as much as in the hydrogel with 
the lowest heparin content despite the elevated free VEGF concentration. Heparin 
is known to promiscuously bind to various growth factors [7], probably the 
bioavailability of endogenously secreted factors that also regulate the 
vascularization was affected by the excess amount of heparin in the hydrogel with 
a medium or high concentration of heparin. 
The effect of VEGF availability on the formation of tubular structures of 
HUVECs strongly depends on the specific GAG sulfation pattern. According to 
the simulation, complete removal of the heparin (as in the pure PEG/PEG gel) or 
the substitution of fully sulfated Hep with the 6ON-DSH could significantly 
increase the availability of free VEGF to a greater extent than in the hydrogel with 
6O-DSH (Figure 4.13). However, we could not see a similar extent of endothelial 
tubulogenesis in these hydrogels. Heparin has been recognized to prolong the 
half-life of the heparin-binding proteins in culture by increasing their stability [26, 
226]. Moreover, as previously demonstrated for heparin-binding BMP-2, N-DSH, 
and 6ON-DSH were not as effective as the native heparin in preserving the 
bioactivity of BMP-2 against thermal denaturation [227]. Therefore, we 
hypothesized that the N-sulfate group of heparin is essential to modulate vascular 
morphogenesis by maintaining VEGF activity. The capacity of the starPEG-GAG 
hydrogels to enhance the activity of VEGF could also explain the relatively low 
concentration of free VEGF required to stimulate endothelial vasculatures 
formation within these hydrogels. In particular, the hydrogel with the lowest 
heparin content could stimulate the endothelial cell vascular morphogenesis at a 
lower free VEGF concentration (40 pM, data not shown) whereas in other 
hydrogel systems containing no growth factor sequestering moieties, a 
significantly higher VEGF  concentration (≥ 50 ng/mL (1300 pM)) was required 
[66, 228, 229].  
Finally, the ability to localize the VEGF activity to spatially control the formation 
of endothelial capillary-like structures was evaluated within the hydrogel with the 
lowest GAG content due to its superiority in supporting the vascular 
morphogenesis.  Previously, spatial patterning of the vascular tube formation 
within the hydrogels could be achieved through light guided photocrosslinking 




[230], and controlling the RGD ligand presentation [231]. In our study, we 
harnessed the natural capacity of the GAG to restrict the mobility of pro-
angiogenic growth factors within the ECM [106, 107], to modulate the 
distribution across the polymer network. Simulation-based on the reaction 
diffusion-model enabled the prediction of the spatial and temporal distribution of 
VEGF within the hydrogels (Figure 4.14B-C). We have shown that presenting 
the VEGF as a gradient within the GAG-based hydrogel matrices allowed for the 
spatial control over the directed endothelial cell migration in 3D as well as the 
local formation of endothelial vascular structures within the hydrogels (Figure 
4.14D-F & Figure 4.15). Further modulation on the hydrogel's transport 
properties, for example, through the use of GAG with different binding affinity to 
the VEGF, could modulate the gradient profiles within the hydrogels that further 
control the spatial organization of cellular fates. Moreover, the application of 
computational modeling to predict the transport of growth factors within 
hydrogels in silico can rationally guide the design of materials with precise 
regulation over the presentation of growth factors.  
Overall, we have shown the impact of GAG content and GAG sulfation patterns 
of biohybrid hydrogels on cellular morphogenesis by modulating the local 
availability of signaling molecules. In the elaborated example, computational 
modeling allowed for the prediction of transport and bioavailability of VEGF 
within the biomaterials. The gained knowledge could further be applied for the 











4.3. Cell-instructive ternary hydrogel system with 
variable GAG content  
4.3.1 Introduction 
Soluble signaling molecules control a diverse range of cellular responses and 
orchestrate the formation of tissues and the developmental processes [20]. In 
particular, pro-angiogenic growth factors stimulation is essential for the 
physiological formation of in vivo vasculatures [232]. Therefore, engineering 
delivery strategies that could sustainably maintain their local concentration within 
a therapeutic window could be instrumental for therapeutic vascularization or 
vascular tissue engineering [65]. Glycosaminoglycan-based hydrogel offers 
unprecedented options to modulate the retentions as well as the activity of pro-
angiogenic factors due to the ability of GAGs to reversibly bind positively 
charged surface patches of the growth factors through electrostatic interactions 
[25, 26] (Figure 4.16A). 
Recent progress in tuning the administration of pro-angiogenic growth factors 
within the GAG-based polymeric network has been made to precisely modulate 
cellular responses [4-6, 19]. For example, Zieris et al. varying the initial growth 
factor loading of the starPEG-heparin hydrogel to control the release of VEGF 
and FGF-2 from the hydrogel matrices [5]. In related work, a matrix-
metalloproteinases cleavable peptide has been incorporated into the hydrogels to 
mediate polymer network degradation in response to cell-secreted proteases, 
which could further enhance the growth factor release [19, 50]. More recently, 
selectively desulfated heparins have also been applied to modulate various growth 
factors' binding affinity to the GAGs and control their release from the scaffold [6, 
38, 39, 78]. The tunable release can be achieved either by adjusting the local 
sulfate density of the GAG or the overall hydrogel sulfate content [6]. However, 
removing a specific sulfate group from the GAG might affect the activity of the 
molecules to stabilize various GAG-binding proteins [227]. Besides, the chemical 
procedures to selectively remove specific sulfate group of the GAG was also 
complicated [227].  




Incorporating a graded amount of fully sulfated GAG into the cell-instructive 
polymer networks can be applied as an alternative strategy to modulate the 
binding, as well as the transport of pro-angiogenic growth factors. Besides, 
simulation using the reaction-diffusion model described in section 4.1.5 also 
revealed that adjusting the hydrogel's GAG content is the most effective strategy 
to control the release of GAG-affine proteins from the hydrogel matrix. Notably, 
modulation of the retention and release rate of heparin-affine proteins from 
various hydrogels,  including PEG-hyaluronic acid hydrogel matrices [43], and 
polycaprolactone-alginate scaffolds [45], has been demonstrated by tuning the 
amount of incorporated heparin. Despite the effectiveness of this approach to 
achieve a tunable release of the growth factor, the ability to decouple the GAG 
content from the mechanical properties of GAG-based biomaterials is often 
difficult to achieve, especially when the GAG is used as the major building block 
of the scaffold [47, 233, 234]. In such a system, producing a hydrogel with a low 
GAG content is limited by the minimum solid content for the hydrogel 
crosslinking reaction to occur. 
To address this challenge, here we developed a set of ternary GAG-based 
materials with a precise adjustment over GAG content to control the 
administration of pro-angiogenic growth factors. The materials were formed by 
extending a previously established binary GAG-based hydrogel synthesis protocol 
[47]. Specifically, the hydrogel was prepared by combining thiol-terminated 
starPEG units, maleimide-functionalized GAG, and maleimide-terminated 
starPEG units in different ratios through a Michael type addition crosslinking 
scheme to freely modulate the heparin content over a broad range of gel stiffness 
(Figure 4.16B-E). In this study, the hydrogel materials with varied heparin 
content were thoroughly characterized for their network and transport properties, 
as well as the applicability of the matrices to support endothelial cell vascular 
morphogenesis. Besides, the GAG content of the hydrogel was also tuned to 
modulate the gradient of GAG-affine proteins. Overall, the new GAG-based 
materials that we developed here could pave a new way to precisely control the 
administration of pro-angiogenic growths rationalizing their future applications as 
advanced 3D cell culture platform and tissue engineering matrices. 





Figure 4.16. Ternary GAG hydrogel systems with tunable GAG content and 
mechanical properties. (A) In the extracellular matrix (ECM), cellular fate is 
controlled by the GAG's ability to modulate the presentation of signaling 
molecules through electrostatic complexation. (B) The building blocks of ternary 
hydrogel systems consist of thiol-functionalized starPEG, maleimide-
functionalized starPEG, and maleimide-functionalized GAG. (C) The network of 
ternary hydrogel systems formed by Michael-type addition (click) reaction 
between the thiol and maleimide terminated polymers. (D) The stiffness/ mesh 
size of the hydrogel can be customized by adjusting the overall solid content or 
the molar ratio of thiol to maleimide-containing polymers. (E) The GAG content/ 
overall sulfate density of the gel can be varied while maintaining a comparable gel 











4.3.2 Physical properties of ternary hydrogels 
Rational design strategies of the binary starPEG-heparin hydrogel have enabled 
the development of hydrogel materials with a stiffness in the range of 0.2-8 kPa at 
a relatively invariant heparin content of 1500 µM [47]. To further modulate the 
transport of signaling molecules, binary hydrogels with a heparin concentration in 
the range of 500-1500 µM were formed by altering the solid content and 
crosslinking degree of the hydrogel. However, as we decreased the heparin 
content of the hydrogel, a more crosslinking degree (ratio of starPEG-SH to 
heparin) was required to initiate the gel formation (Figure 6.8). For example, 200 
Pa hydrogel with a heparin concentration of 1500 µM could be formed at a 
crosslinking degree of 0.63. In contrast, a comparably stiff hydrogel with a 
heparin concentration of 500 µM was formed only at a higher crosslinking degree 
of 1.5. Furthermore, we did not observe gelation at heparin concentration below 
500 µM because of the low solid content of the reacting solution (< 2%). 
We included starPEG-Mal as the third component of the ternary hydrogel to 
maintain a similar solid content between different gel preparations allowing us to 
decouple mechanical properties and heparin content of the hydrogels (Figure 
4.17A). Accordingly, hydrogels with heparin content of 0-1500 µM can be 
prepared with variable stiffness in the range of 0.2-4 kPa by merely adjusting the 
total solid content. Interestingly, hydrogels with similar stiffness but varied in 
their heparin content displayed a similarity in the volumetric swelling with a 
softer hydrogel swells relatively more than the stiffer ones. (Figure 4.17B). 





Figure 4.17. The physical properties of ternary hydrogels with variable GAG 
content. (A) The Stiffness and (B) the volumetric swelling of the hydrogel at 
various solid content. 
 
4.3.3 Mobility of heparin affine proteins within- and the release out of 
ternary hydrogels 
The in-gel mobility of heparin affine proteins (VEGF165 and SDF1α) within the 
ternary hydrogels with varied heparin content was investigated using FRAP. It is 
hypothesized that as the heparin content of the hydrogel decreases, more unbound 
proteins exist, resulted in the enhancement of the mobility of affine proteins. 
FRAP measurements were carried out in the hydrogels with the stiffness of ~2.5 
kPa. Based on the rubber elasticity theory [2], hydrogels prepared with this 
stiffness were estimated to have a mesh size of 10 nm, which is significantly 
larger than the molecular size of the VEGF165 and SDF1α. The similarity in the 
stiffness of the hydrogels containing variable heparin content also allowed for the 
dissection of the effect of heparin content on the mobility of these proteins 
independently from the impact of steric interaction within the polymer network 
(Figure 4.18A-B). 
In general, the mobility of large and small heparin affine proteins was affected by 
the hydrogels' heparin volume density (Figure 4.18C). For example, VEGF 
diffusivity increased from ~ 4 µm2/s in the hydrogel with the highest heparin 
content to nearly  20 µm2/s  in the hydrogel with the lowest heparin concentration. 
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Interestingly, the effect of decreasing the heparin content of hydrogels was more 
pronounced on the mobility of SDF1α as compared to the VEGF165. The 
mobility of SDF1α was raised by ~15 factors in the hydrogel with the lowest 
heparin content, whereas the mobility of VEGF165 increased by only five factors. 
The lower steric interaction might explain that the small affine protein diffused 
faster than the larger ones in the hydrogel with the lowest heparin content. 
Similarly, as shown in pure PEG-PEG gels, which show a minimum protein 
binding, the diffusivity of SDF1α was significantly higher than the VEGF165. 
The effect of varying GAG content of hydrogels on protein release was also 
investigated (Figure 4.18D). The release of VEGF165 and SDF1α from the 
PEG/PEG gel displayed a burst release and reached a maximum after 24 hours. 
Interestingly, no additional protein release was observed even after 360 H. The 
release of both proteins from the pure PEG/PEG gel also did not reach 100%. 
Nearly only 50%  and 85% of the VEGF165 and SDF1α, respectively, was 
released from the gel constructs after 360 H.  
Incorporating a graded amount of heparin into the hydrogel modulated the release 
of VEGF165 and SDF1α. In the hydrogel with the highest heparin content  (1500 
µM), only less than 1% of the VEGF165 or SDF1α was released after two weeks. 
In contrast, the hydrogel with the lowest heparin (1.5 µM) content significantly 
released a higher amount of proteins, with nearly 20% of the proteins was released 














Figure 4.18. The GAG content of ternary hydrogels modulates the in-gel mobility 
and release of GAG-affine proteins. (A) A schematic illustrating the effect of 
GAG content of ternary hydrogel on the free protein concentration within the 
hydrogel network, which positively correlates to the diffusivity of proteins. (B) 
Comparable stiffness/ mesh size of ternary hydrogel with varied heparin content 
(C) The diffusion coefficient (D) of VEGF165 and SDF1α  within the hydrogels 
with different heparin content as determined by FRAP. (D) The release of 
VEGF165 and SDF1α  from ternary hydrogel with varied heparin content. Data 












4.3.4 The gradient of signaling molecules within ternary hydrogels 
The ability of GAG hydrogels to modulate the gradient of signaling molecules 
with different properties was evaluated using a microfluidic platform. 
Accordingly, the gradient of large or small heparin-affine proteins could be 
maintained stably over 48 H without a continuous replenishment of growth factors 
(Figure 4.19A). Fluorescent microscopy revealed that the heparin-affine proteins 
were mostly accumulated near the hydrogel and growth factor channel interface. 
The resulting gradient was steep and only spanned across half of the gel channel 
even after 48 H (Figure 4.19B). In opposite to these observations, the gradient of 
non-affine EGF was depleted quickly. In less than 6 H, the protein already 
reached an equilibration within the hydrogel. Interestingly, although the 
VEGF121 did not have an affinity toward heparin, the gradient could still be 
observed after 48 H. However, the gradient profile spans at a much broader range 
than those of the affine proteins. 
The experimental gradient profile of proteins within the GAG hydrogel was also 
compared with the simulation-based on a reaction-diffusion model (Figure 
4.19B). In good agreement with the theoretical modeling, the gradient of affine 
proteins was developed quite slowly and only spaned near the growth factor's 
source. Based on the simulation, the gradient of SDF1α and VEGF165 only 
developed within the first 600 µm and 300 µm, respectively, from the hydrogel 
channel over 48 H.  
Similarly, the gradient of non-affine proteins can also be approximated using the 
same model by only considering the free diffusion coefficient within the hydrogel. 
In particular, the EGF was shown to diffuse rapidly into the hydrogel, and the 
gradient was nearly depleted after 6 H of the protein uptake. In line with the 
experimental data, a similar EGF gradient profile can be predicted accurately 
using theoretical modeling. In contrast, the experimental gradient of VEGF121 
could not be described with the simulation results. Experiment results showed that 
the gradient of VEGF121 evolved slowly and remain visible after two days. Based 
on the model prediction, the gradient of VEGF121 should have only lasted for less 
than 24 H due to the minimal interaction with the heparin. However, dynamic 




light scattering analysis showed the formation of VEGF121 aggregates with a size 
up to a few µm shortly after the dilution in the medium (Figure 6.9). The protein 
aggregations might retard the diffusion of VGEF121 from the source to the sink 
channel. Hence, as the hydrogel's mesh size was within the range of nm, µm-sized 
aggregate remained to persist in the hydrogels and visible as a stable gradient.  
In an attempt to modulate the spatiotemporal profile of heparin affine protein 
gradients in the hydrogel, the heparin content of ternary hydrogels was varied 
from 0-1500 µM (Figure 4.20). In the absence of heparin, both VEGF165 and 
SDF1α diffused rapidly into the hydrogel and formed a gradient that lasted only 
for a few hours (Figure 4.20A). Nearly after 6 H of the protein uptake, the 
gradient of proteins was utterly depleted. Remarkably, the gradient of affine 
proteins could be gradually adjusted by increasing the hydrogel's heparin content 
with a shorter-range, and a steeper gradient profile was observed as more heparin 
was loaded into the hydrogels. The stability of gradients was also varied with 
increasing heparin content. Time-lapse microscopy demonstrated that the 
hydrogel with the heparin content of 15 µM maintains a long-range gradient of 
heparin affine proteins that lasted for up to 24 H (Figure 4.20B). In contrast, 
hydrogels with heparin content of 150 µM or higher could stably maintain a short-
range gradient of the growth factors even up to 48 H. 
Mathematical modeling was also applied to predict the gradient of heparin-affine 
proteins in a set of hydrogels with a graded amount of heparin after 48 H of the 
protein uptake (Figure 4.20B). While the gradient of VEGF165 in all hydrogels 
preparations was in good agreement with the simulation, the experimental 
gradient of SDF1α exhibited a slightly different profile from the simulated ones, 
especially for the hydrogel with a heparin content of 150 and 15 µM. In contrast 
to the model prediction, the experimental gradient of SDF1α in these hydrogels 
displayed a steeper profiler and evolved more slowly. This discrepancy might 
indicate protein aggregations, which could be affected by the intrinsic properties 
of proteins, as this case was not observed for the VEGF165. 





Figure 4.19. The gradient of signaling molecules with different molecular sizes 
and affinity to the GAG. (A) Fluorescence images representing the gradient of 
various fluorescently- labeled proteins (SDF1α, VEGF165, EGF, and VEGF121) 
established using the microfluidic device within the hydrogel containing 1500 µM 
of heparin throughout 48 H. (B) The theoretical and experimental gradient of 









Figure 4.20. The GAG content of ternary hydrogels modulates the gradient of 
GAG-affine proteins. (A) Fluorescence images representing the gradient of 
various fluorescently- labeled proteins (SDF1α, VEGF165, EGF, and VEGF121) 
established using the microfluidic device within ternary hydrogels containing 0-
1500 µM heparin throughout 48 H. (B) The theoretical and experimental gradient 
of proteins within the hydrogels after 48 H. 
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4.3.5 Endothelial cell capillary morphogenesis within ternary hydrogels  
Previously, the binary GAG-based hydrogel has been shown to support 
endothelial cell vascular morphogenesis in vitro [3]. Here, we also evaluated the 
applicability of ternary hydrogels for the 3D culture of endothelial cells. HUVECs 
cultured in ternary hydrogels with heparin content of 0-500 µM initiated the 
formation of capillary-like structures approximately three days after the cultures 
(Figure 4.21A). The variation in the heparin content of hydrogels was shown to 
modulate the vascular morphogenesis within these hydrogels. Accordingly, 
ternary hydrogels containing 5 µM of heparin promoted a more extensive vascular 
structure formation than ones functionalized with 50 µM of heparin or higher 
(Figure 4.21B). Moreover, this gel also induced a higher vascularization in 
comparison to the pure PEG hydrogel control.  
The extent of vascular morphogenesis in the ternary hydrogels was also compared 
to the binary gel containing 500 µM heparin. HUVEC tubular structures were 
observed in ternary gels with variable heparin volume density. However, 
HUVECs formed a larger total vessel area in the binary hydrogel with 500 µM 
heparin than the ternary hydrogels with any heparin content tested. As a result, 
future works may aim to optimize other parameters of the ternary gel network, 
such as the molecular weight of the PEG component, to enhance the 
vascularization of the hydrogels. 
 





Figure 4.21. The ternary hydrogel system supports endothelial cell vascular 
morphogenesis. (A) Capillary-like structures of endothelial cells formed within 
the hydrogels containing varied heparin concentrations after three days of culture. 
One image per condition was chosen arbitrarily to represent different hydrogel 
conditions. Fixed samples were stained with phalloidin and DAPI. After the 
confocal imaging, Imaris software was used to process and analyze the 
fluorescence images. Scale bar = 200 µm. (B) Total vessel area of the endothelial 
cell vascular structures. 
 
 
4.3.6 Discussion and summary 
Tissue formation is a complex process involving the interplay between physical 
and biomolecular cues of the extracellular matrix [235]. In particular, the in vivo 
formation of blood vessels requires the cell-instructive signals provided by pro-
angiogenic growth factors [209, 236, 237]. Various strategies have been 
developed to control the administration of pro-angiogenic growth factors to 
stimulate the vascularization of diseased tissues or engineered living matters [45, 
219, 238-240]. However, in the field of tissue engineering, maintaining a 
sustained delivery of bioactive growth factors remained challenging.  
To overcome this, polymeric biomaterials have been exploited to incorporate 
glycosaminoglycans (GAGs) to maintain the sustained delivery and long-term 
bioactivity of growth factors [25]. Various GAG-based hydrogels have been 
developed for the controlled administration of pro-angiogenic growth factors [4, 
6, 46, 77, 137, 239, 241-243]. In general, network properties of the system, 
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including the GAG content, sulfation pattern of the GAG building blocks, 
degradability of the network, as well as the growth factor loading concentration, 
could be adjusted to modulate the retention and release. Nevertheless, no studies 
have reported the development of GAG-based materials with tunable mechanical 
properties over a broad range of GAG concentration.  
In this study, the ternary hydrogel system based on the heparin-maleimide, 
starPEG-maleimide, and starPEG-thiol, was developed by extending our 
previously established binary hydrogel platform [47], to precisely customize the 
administration of pro-angiogenic growth factors. The hydrogel with tunable 
mechanical properties was developed to incorporate heparin in the concentration 
range of 0-1500 µM (Figure 4.17). Tuning the heparin content of hydrogel was 
shown to modulate the in-gel mobility and release of pro-angiogenic growth 
factors as well as the formation of gel-based growth factor gradients. Moreover, 
the system was also shown to support endothelial cell morphogenesis. 
Previously, hydrogels with variable GAG content have been developed to control 
the administration of soluble signaling molecules [48, 137, 244-246]. 
Nevertheless, in most studies, the influence of heparin content on the overall 
network properties of hydrogels was not investigated. In this study, rational 
design strategies have been successfully applied to developed ternary hydrogel 
system with variables GAG content and tunable mechanical properties. Compared 
to the previously established binary hydrogel system [47], the ternary system 
allowed for the formation of hydrogels at much lower heparin concentration while 
retaining tunable mechanical properties.  
The ability to tune the mechanical properties of the materials independently from 
the heparin content is particularly beneficial for investigating the effect of heparin 
content on the cellular process in which the matrix stiffness plays a significant 
role. For example, osteogenic differentiation of mesenchymal stem cells was 
primarily induced by a stiff substrate, whereas neurogenic differentiation occurs 
on a more compliance matrix [247]. Similarly, GAG-based hydrogels might be 
applied to stimulate vascularization in tissues with different stiffness. The design 
of a controlled release system with mechanical properties matching to the 




implantation sites could minimize foreign body responses and rejection of 
implants [248]. Therefore, ternary hydrogels with a programmable heparin 
content and mechanical properties could provide precise delivery of pro-
angiogenic factors while minimizing deleterious immune responses. 
Modulating the heparin content of the ternary hydrogel was shown to control the 
mobility of heparin-affine proteins within hydrogel networks and the release out 
of the matrices (Figure 4.18). The burst release of SDF1α and VEGF165 could be 
attenuated through the incorporation of ~1.5 µM of heparin (≤ 1% of the hydrogel 
polymer content). Besides, the sustained release of growth factors can be achieved 
for at least over two weeks, which is in line with previous findings [43, 45, 77]. 
Other than adjusting the heparin content, incorporating heparin with different 
molecular weight and sulfation patterns may further be applied to tailor the release 
of heparin-affine proteins from the ternary hydrogel network [6, 38, 43].  
The ability to tune the heparin content of ternary hydrogels over a wide range is 
essential to precisely customize the hydrogel network relevant for particular 
applications. For example, the hydrogel containing a low amount of heparin is 
suitable more as a controlled release system of growth factor, whereas those 
contain a high amount of heparin could rather be applied as cytokine scavenging 
materials [7]. Furthermore, local as well as overall sulfate density of the hydrogel 
may also be adjusted to control the binding of cytokines with different properties 
[78]. 
Soluble signaling gradient is essential to regulate various physiological processes, 
including cell migration, homeostasis, angiogenesis, and development [249]. 
Therefore, various strategies such as source-sink methods have been developed to 
recapitulate the formation of biomolecular gradients in engineered biomaterials 
for studying such process in vitro [250, 251]. The resulting gradient could be 
maintained stably for a long period, such as through the covalent immobilization 
of growth factors or flow applications [252, 253]. However, such approaches 
could compromise the protein functionalities and may be expensive due to the 
requirement to continuously perfuse the growth factor feeding solution. 




In this study, the glycosaminoglycan-based hydrogel was utilized to generate 
signaling molecule gradients by harnessing the natural affinity of GAGs to 
various cationic growth factors. The hydrogel could stably maintain the gradient 
of heparin-affine proteins but not the non-affine proteins for at least 48 H (Figure 
4.19). Here, the ternary hydrogels with varied heparin content subsequently 
allowed for the modulation of the gradient of heparin-affine proteins. Notably, 
decreasing the heparin content of hydrogel was shown to change the resulting 
profile of protein gradient from a steep and short-range toward a shallow and 
long-range (Figure 4.20). Besides, computational modeling based on the reaction-
diffusion model has also been developed to predict the establishment of growth 
factor gradient within hydrogels.  The parameter of the model, such as the GAG 
content, affinity of growth factor to GAG building blocks, and the geometry of 
hydrogel, can be adjusted to allow for the prediction of the growth factor gradient 
profile under various scenarios. 
Finally, the capacity of ternary hydrogel matrices to support 3D cultures of 
endothelial cells was examined (Figure 4.21). The ternary hydrogel was shown to 
be cytocompatible, as demonstrated here, by the ability to promote endothelial 
cell morphogenesis. The concentration of heparin within hydrogels needs to be 
rationally adjusted to maintain high retention and bioactivity of growth factors 
within the polymer matrix while at the same time could still provide an adequate 
amount of free factors to stimulate cellular responses. We have shown that the 
hydrogels containing heparin as low as 5 µM induced a greater extent of 
vascularization than those with higher heparin concentration or pure PEG 
hydrogel. The gel matrix's functionalization with 1.5 µM of heparin was sufficient 
to maintain 80% of growth factor retention within the polymer network for several 
days. Moreover, as shown in section 4.2, the presence of a low concentration of 
heparin could sufficiently maintain a high concentration of free growth factor 
within the hydrogel. Therefore, we speculate that the superiority of ternary 
hydrogel containing 5 µM of heparin could be attributed to the balance of local 
retention and availability of the free factor, as well as the preservation growth 
factor activity within the scaffold.  




Nevertheless, the ternary gel containing 5 µM of heparin could not support a 
similar vascularization as much as the binary hydrogel with 500 µM of heparin, 
despite the elevated free factor concentration. Parameters other than the free factor 
concentration may play a more critical role in regulating the vascular 
morphogenesis within the hydrogels. For example, the inclusion of starPEG–Mal 
in the ternary hydrogel might increase the local physical constraints and decrease 
the degradability of the polymer network. Besides, biopolymer-derived matrices 
with known angiogenic properties, such as collagen and fibrin gels, consist of 
components with a large molecular weight (≥ 70 kDa), allowing the creation of a 
matrix with a larger mesh size in comparison to our gel system with a smaller 
PEG (10 kDa) as the major building block [254-257]. Therefore, future studies 
can potentially be done to investigate the effects of polymer molecular weight on 
the extent of capillary structure formation within the hydrogel. In particular, 
systematic approaches using the design of experiment (DOE) to simultaneously 
analyze different combinations of ternary hydrogel network parameters [258, 
259], might be utilized to identify matrix conditions that promote the formation of 
endothelial vascular structures. 
In conclusion, we have developed the ternary hydrogel system, which is tunable 
for the mechanical properties over a broad-range of heparin content. The 
modulation of the gel's heparin content was shown to be superior for controlling 
the administration of heparin-affine pro-angiogenic growth factors. Combining 
rational design strategies to tune the hydrogel network and mathematical 
modeling for predicting the transport of signaling molecules, we could potentially 
apply the resulting materials as versatile tissue engineering matrices and advanced 




5. General discussion 
5.1 Summary and conclusion 
 
Figure 5.1. A systematic study of the mobility of signaling molecules and the 
mathematical modeling rationally guide the design of GAG-based biomaterials to 
precisely modulate the cell fate decisions. 




This thesis aimed to systematically investigate molecular transport and binding of 
signaling molecules with different properties in a binary starPEG-GAG hydrogel 
system [47], by combining mathematical modeling and experimental approaches. 
The fundamental principles underlying the transport properties of the signaling 
molecules were then applied to modulate the morphogenesis of endothelial cells 
into vascular structures within the hydrogel and rationally design a set of GAG-
based materials with tunable network properties that could significantly enhance 
the current state of the art for the modulation of the hydrogel-based administration 
of pro-angiogenic growth factors. 
5.1.1 Molecular transport and binding in the starPEG-GAG hydrogels 
Understanding the molecular transport and binding of various signaling molecules 
within the starPEG-GAG hydrogels is essential for the rational design of the 
material to control the formation of cell-instructive gradients and the local 
morphogen concentration (Figure 5.1). Many studies have investigated the impact 
of GAG hydrogel network parameters, including the mesh size, GAG content, and 
the GAG sulfation on the mobility of growth factors relevant for particular 
applications [4-6, 43]. However, none of them has systematically investigated the 
influence of each parameter on the mobility of the signaling molecules of different 
properties.  
To address these issues, we first investigated the impact of mesh size, GAG-
content, and the sulfation pattern of GAG building block of the binary starPEG-
GAG hydrogels on the mobility of representative signaling molecules that differ 
in their molecular weight and GAG-affinity including the VEGF165 (MW 38.2 
kDa, pI 8.3), VEGF121 (MW 28 kDa, pI 6.4), SDF1α (MW 8 kDa, pI 10), and 
EGF (MW 6.2 kDa, pI of 4.6) (Section 4.1). Rational design strategies for 
polymer networks have enabled the decoupling of mechanical properties 
(stiffness, mesh size) from bimolecular characteristics (GAG content and the 
GAG sulfation pattern) of the hydrogel, allowing for the investigation of the 
influence of each hydrogel network parameter on the mobility of the signaling 
molecules independently. Molecular diffusion studies revealed that the mobility 
of GAG-affine proteins is primarily controlled by the GAG content and of GAG 




sulfation pattern, whereas the mobility of non-affine proteins is governed by the 
mesh size of the hydrogel. Together, this part of the thesis study significantly 
improved our current understanding of different ways of modulating the mobility 
of signaling molecules with different properties within the GAG-based biohybrid 
hydrogels. 
To precisely customize the transport of the different signaling molecules within 
the GAG-based materials, we developed a mathematical model that describes the 
binding and diffusion process of the molecules within the hydrogel network. 
Previously, the reaction-diffusion model has been applied to design GAG-based 
materials with desired growth factor transport properties [32, 33, 53, 55]. The in 
vitro and in vivo applications of the model have been demonstrated. However, 
there was no reported experimental validation on the accuracy of the model to 
describe the transport characteristics of signaling molecules within the materials. 
Moreover, most of the models also developed for the biopolymer derived matrix 
[33, 53, 57], which was shown to have an inherent affinity toward a broad 
spectrum of the signaling molecules [181] — therefore adding up more 
complexities on establishing a reliable mathematical model 
In this study, for the first time, the reaction-diffusion model was developed to 
predict the transport of signaling molecules within fully synthetic starPEG-GAG 
hydrogels. Experimental release studies of the GAG-affine proteins (VEGF165 
or SFD1α) confirmed the applicability and accuracy of the model prediction for 
the overall release profile of the proteins from hydrogels displaying completely 
different geometries (i.e., a hydrogel loaded at the bottom of the microcentrifuge 
tube or a free-standing droplet of hydrogel). Similarly, theoretical modeling 
could also capture the spatial and temporal dynamics of signaling molecule 
gradients within the starPEG-GAG hydrogel that have been established using 
microfluidic techniques. Thus, the applicability of the mathematical model that we 
have developed here to predict the molecular transport within the GAG hydrogel 
could be validated with the experimental results, rationalizing its further usage for 
the prediction of transport of signaling molecules for more advanced in vitro or in 
vivo applications. 




Overall, systematic studies on the mobility of the signaling molecules within the 
GAG-based hydrogels allow for the determination of various GAG hydrogel 
network parameters that govern the signaling molecules' mobility. In combination 
with the mathematical modeling, the results allow for the customization of 
transport of soluble signaling molecules within GAG-based biohybrid hydrogels 
for a broader context in the field of tissue engineering and regenerative medicines. 
5.1.2 Modulation of the activity of pro-angiogenic growth factor within 
the starPEG-GAG hydrogels 
The ability to precisely modulate the spatiotemporal activity of signaling 
molecules within cell-instructive polymer networks is critically important for the 
resulting application in tissue engineering. In particular, VEGF is known to be the 
major pro-angiogenic growth factor that regulates the early process of 
angiogenesis. Therefore, controlling the extracellular availability within the 
polymer network could have a tremendous effect on the extent of vascular 
morphogenesis within the matrices. The effect of GAG content and the GAG 
sulfation pattern of GAG-based matrices on the released VEGF bioactivity has 
been previously investigated [4-6, 77]. However, the influence of both parameters 
on the bioactivity of VEGF to control the cellular fate within the cell-instructive 
polymer network has not been systematically studied.  
To unravel this, the mathematical model that we developed in the first part of the 
thesis was utilized to predict the effect of the GAG content and the GAG sulfation 
pattern on the availability of free VEGF within the hydrogel (Section 4.2). 
Simulation results going along with endothelial vascular morphogenesis studies 
within the hydrogel with varied GAG content and GAG sulfation pattern 
concordantly revealed the dependency of the vascular network formation on the 
concentration of free VEGF within the system. Interestingly, despite a 
significantly higher concentration of the free factor within the hydrogel containing 
6O-DSH or 6ON-DSH, the hydrogel crosslinked with 6O-DSH building blocks 
supports a more extensive branching and a larger area of endothelial vasculatures 
compared to the hydrogel containing 6ON-DSH building block. This indicates the 
critical role of the N-sulfate group of the GAG in mediating the formation of the 




endothelial capillary network within the hydrogel, such as their thermal 
stabilizing effect on the growth factors [227]. Moreover, in line with the 
simulation prediction on the spatial distribution of free VEGF, the presentation of 
VEGF as a gradient promotes a local formation of endothelial vasculatures and 
significantly induce more directed cell migration toward the source of the 
growth factor.  
Taken together, the accuracy of the model prediction on the local availability of 
the signaling molecules, as well as their spatial distribution within the polymer 
network, could provide relevant information on the resulting pattern of cellular 
fate within the scaffold. In particular, within the context of the study, the 
simulation results on the growth factor transport and availability within the GAG-
based hydrogels significantly improved our current understanding of how the 
GAG-content and the GAG sulfation pattern modulate the cellular responses 
within the three-dimensional matrices. 
5.1.3 Cell-instructive ternary hydrogels with variable GAG content 
Our detailed analysis of the influence of each GAG hydrogel network parameter 
on the subsequent release kinetics of VEGF from the hydrogel matrices revealed 
that adjusting the GAG content of the materials is the most efficient way of 
modulating the release kinetics from the polymer matrices. While utilization of 
selectively desulfated GAG derivatives such as 6O-DSH, N-DSH, or 6ON-DSH 
could modulate the binding and the release of signaling molecules from the 
polymer matrices [6, 38], the incorporation of fully-sulfated heparin is known to 
be more beneficial due to the capacity to protect and stabilize a plethora of 
signaling molecules [26, 227]. 
Accordingly, in the last part of the thesis study, ternary hydrogels with variable 
GAG content were developed by extending the currently established synthesis 
protocol of the binary GAG-based hydrogel system [47] (Section 4.3). 
Specifically, the ternary hydrogel incorporates the thiol-functionalized starPEG, 
maleimide-functionalized starPEG, as well as maleimide-functionalized heparin 
to freely vary the heparin content of the hydrogel over a broad range of 
concentrations. As such, hydrogels with variable heparin content in the range 




from 1.5-1500 M have been synthesized while maintaining a comparable 
stiffness and volumetric swelling. Besides, the hydrogel's stiffness can further be 
controlled by modulating the overall solid content of hydrogels.  
The ternary hydrogel system with variable GAG content is tunable for its 
transport properties. Molecular diffusion, as well as release studies utilizing the 
pro-angiogenic growth factors (VEGF165 and SDF1α), demonstrated the strong 
correlation of their in-gel mobility as well as their release behavior on the heparin 
content of the particular hydrogels. Moreover, the gradient of the heparin affine-
proteins (VEGF165 and SDF1α) established within the hydrogel could also be 
modulated by varying the overall heparin content of the hydrogel, whereas the 
gradient of non-affine proteins (EGF) was not affected by the presence of heparin.  
Subsequent analysis of the endothelial cells embedded within hydrogels with 
variable heparin and constant VEGF content revealed the matrix's suitability to 
support 3D endothelial cell morphogenesis and a heparin content-dependent 
cell response. The hydrogel with a low heparin content (5 µM) promoted a higher 
vascularization than the hydrogel containing no heparin (pure PEG/PEG gel) or a 
higher heparin content. The superiority of the hydrogel containing 5 µM of GAG 
could probably be attributed to the subtle balance between retention, protection, 
and the enhancement of VEGF availability within the matrices.  
Overall, the ternary hydrogels with variable heparin content could serve as a 
versatile platform to enhance the current state of the art of modulating the 
transport of pro-angiogenic growth factors. The cytocompatibility and tunability 
of the hydrogel's network properties allow its potential applications as an 
advanced three-dimensional scaffold for precision medicine and tissue 
engineering applications. 
 




5.2 Future perspectives 
5.2.1 Advanced modeling transport and binding of protein within the 
starPEG-GAG hydrogels 
The prediction of the transport and the local concentration of signaling molecules 
within polymer networks are essential for the rational design of GAG-based 
materials that precisely modulate cell fate decisions. Additional parameters can be 
considered within the reaction-diffusion model developed and applied in this 
thesis to improve the accuracy of predicting the transport of signaling molecules 
within polymeric hydrogel materials.  
Protein binding sites  
The number of binding sites of protein at the GAG is crucial for predicting the 
protein's transport within the GAG-based hydrogels. In many cases, the 1:1 
binding ratio between the protein and the heparin is only an assumption and might 
not be valid since for FGF-2 as an example, depending on the molecular weight, 
each molecule of heparin can have more than two binding sites [40]. Therefore, 
further studies should aim to quantify the binding sites of particular signalings 
molecule to different GAG molecules. In this context, the generation of ternary 
hydrogels with strongly varying GAG content might allow for quantifying the 
number of protein binding sites within the hydrogel as the most relevant 
parameter. As such, a ternary hydrogel containing a low amount of heparin can be 
titrated with a series of solutions containing a different concentration of protein. 
The protein concentration at the maximum binding can be used to determine the 
protein binding sites' concentration in the hydrogel, allowing the estimation of the 
number of protein binding sites per GAG molecules. 
Competitive binding 
Heparin binds to a large variety of positively charged proteins. Notably, for 
applications of the heparin-based hydrogels in vivo, the presence of serum 
proteins with known affinity for the heparin, such as apolipoproteins and 
thrombospondins, might interfere with the binding of signaling molecules to the 
hydrogel matrix [58]. The competitive binding of the serum proteins to the 




heparin building block could influence the binding of signaling molecules to- and 
their release from the hydrogel matrices. As such, future experiments to measure 
the affinity constants of signaling molecules to GAGs could be done in the 
presence of serum in order to enhance the accuracy of model simulations and the 
resulting biological performance of the materials in vivo. 
Binding in 3D matrices 
The majority of the available binding data for the signaling molecules to GAGs 
originates from analyses of individual molecules. However, GAG-protein 
interactions within charged, hydrated polymer networks typically is dependent on 
the spatial distribution of charges/ affinity centers that might also influence 
specific (spatially matching) electrostatic interactions between the GAG and 
proteins. The crosslinking degree of the hydrogel may influence the signaling 
molecule diffusion away from the GAG building blocks, therefore increases the 
probability of the molecules for re-binding to the GAGs. Similarly, the high 
density of the negative charge within the hydrogel could cooperatively enhance 
the overall binding capacity of the gel matrix to the signaling molecules, i.e., 
providing an unspecific contribution to the binding. In contrast, the crosslinking/ 
covalent modification of the GAG with the synthetic polymer can mask the 
protein binding sites. All these variables increase the complexities of studying the 
binding interaction between the protein and GAG within the hydrogels. 
Therefore, a direct assay to estimate the binding affinity between the protein 
and the GAGs crosslinked within the hydrogel could be instrumental in 
obtaining more realistic binding data. This can be done, for example, by 
comparing the actual amount of proteins that bind to the hydrogel (as analytically 
determined by the ELISA) with the mathematical model for the protein binding 
[260].  
5.2.2 Signaling molecule gradients 
On-demand switch of the gradient profile  
In this study, gradients of soluble signaling molecules have been created using a 
microfluidic device. The resulting gradients have been successfully demonstrated 
to control endothelial cell vascular morphogenesis and chemotaxis. However, 




many cellular processes, such as immune cell migration in response to chemokine 
gradients, occur within a short time scale [261]. Therefore, the ability to rapidly 
alter the gradient profile of the signaling molecules within our GAG-based 
hydrogel system is instrumental in expanding the system's applicability to 
recapitulate such process in vitro. The high content of the heparin in our gel 
system is valuable in maintaining a stable long–term gradient of the growth 
factors. However, the currently established protocol only allowed for the 
formation of short-range and steep gradient of the heparin-affine proteins, 
including chemokines such as SDF1α within the hydrogel after several days. As a 
result, the technique is limited by the inability to systematically analyze the short 
term behavior of many cells within the hydrogel. To overcome this, the signaling 
molecule may be mixed with anionic polyelectrolytes such as soluble heparin 
during the establishment of the gradient in the microfluidic device. The 
competitive binding between the soluble heparin and the heparin crosslinked 
within the hydrogel will enhance the growth factors diffusion into the hydrogel 
and speed up the formation of long-range growth factors gradients. Parameters 
such as the concentration of soluble heparin, the application of flow, and the 
affinity of the gel matrix to growth factors may be adjusted to provide the on-
demand switch of gradient profile.  
Localized signaling molecules gradient  
Advances in the development of tissue models and organoids are essential for 
their therapeutic applications or to study the developmental process in vitro [262, 
263]. In particular, the gradient of soluble signaling molecules plays a significant 
role in mediating various biological processes, including the neural tube axis 
specification of vertebrates and the wing disk formation of drosophila [264-267]. 
The mechanism of gradient generation in vivo involves clustering of cells, named 
signaling center, that secret of morphogens that diffuse away and creates a spatial 
profile of concentration, the gradient [250]. Based on that, the generation of a 
localized and short-range gradient of morphogens within engineered biomaterials 
can be applied to investigate such a process in vitro. While gradients of the 
signaling molecules within bulk hydrogels have been successfully applied and 
developed here, the usage of GAG-based microparticles can further be applied 




to provide a sustained and localized release of morphogens. The ability to tune 
the GAG content as well the mathematical model that we developed here can then 
be applied to optimize the gradient profile from the microparticles to pattern the 
spatial organization of organoids, e.g., organoid models such as kidney or neural, 
allowing the generation of robust organ and disease model in vitro. 
5.2.3 Network properties and applications of ternary hydrogels 
Finally, rational design strategies have been applied to develop ternary hydrogels 
with variable heparin content. Accordingly, hydrogels with varied heparin content 
of comparable stiffness can be produced by maintaining similarity in the solid 
content. However, the individual polymer component, and the ratio between 
reactive groups of the hydrogel precursors, need to be parametrized to understand 
their impact on the overall network properties such as hydrogel swelling and 
stiffness. To address this issue, empirical equations that allow for predicting and 
tuning the hydrogel network properties based on the solid content, thiol 
concentration, and the maleimide to thiol ratio may be obtained using a design 
of experiment (DOE) approach [258, 259]. This strategy might not only improve 
the understanding of existing GAG-based material properties but also help to 
expand the hydrogel platform towards a fully synthetic sulfonated system. 
Together, this information will be essential to provide an optimized hydrogel 
network for a broad range of applications in the tissue engineering field. 
The ternary hydrogel with varied heparin content was shown to be 
cytocompatible and support the endothelial cell morphogenesis. The system can 
be applied further as an in vitro model for tissues that naturally display 
variations in their GAG content. In particular, the articular cartilage consists of 
layered structures from the superficial to the calcified zone, which is characterized 
by an increase in the GAG content and compressive strength [188]. Therefore, a 
ternary hydrogel with tunable GAG content and physical properties may be used 
to engineer the articular cartilage in vitro. Moreover, in combination with the 
recently published approaches to print in situ crosslinked hydrogels system, the 
zonal variation in the cartilage structures may be recapitulated in a high-resolution 
manner [268]. 




In conclusion, the systematic study on the mobility of signaling molecules within 
GAG-based hydrogels revealed fundamental principles that govern the transport 
of such key mediators within the ECM-mimicking material. Besides, the 
mathematical model that has been developed here for the prediction of transport 
processes and the local concentration of signaling molecules within the polymer 
matrices further enhanced the design concept of customizing the GAG-based 
hydrogel network that could precisely modulate cell fate decisions. Furthermore, 
the proposed experiments could lead to further development and application of the 
mathematical model and the advancement of the GAG-based biohybrid materials 





6.1 Supplementary materials and methods 
6.1.1 Determination of protein binding affinity to GAG and GAG 
derivatives 
Microscale thermophoresis (MST) was used to quantify the strength of 
interactions between the proteins and GAG or GAG derivatives, as previously 
described [182, 269]. In this method, the model proteins were labeled with a 
reactive dye, NT-647, using Monolith NT Protein labeling kit RED-NHS 
according to the manufacturer’s instructions (NanoTemper Technologies). 
Briefly, proteins were dissolved in a labeling buffer and mixed with the 
fluorescent dyes at a 1:1 molar ratio with a final concentration in the range of 2-20 
µM. The mixture was then incubated at room temperature for 30 min in the dark. 
The protein was purified from the unreacted dye using gel filtration columns 
(Sephadex G25, GE Healthcare). The protein concentration and purity were 
monitored using NanoDrop™ 1000 Spectrophotometer (Thermo Fisher Scientific, 
Germany) by measuring the absorption at 280 nm and 650 nm for proteins and the 
dye, respectively.  
Afterward, GAG or GAG derivatives were titrated from 15.25 nM to 1000 µM in 
PBS containing 0.05% Tween 20 and 0.1% BSA and mixed with 4-8 nM of 
labeled proteins in a 1:1 volume ratio. The mixture was then briefly centrifuged 
for 5 min at 15000 g and 4 oC. Next, the sample mixture was loaded into 
hydrophobic capillaries (NanoTemper Technologies), and the thermophoresis 
measurement was carried out at 22 oC in the Monolith NT.115 Pico instrument 
(NanoTemper Technologies) using excitation and MST power of 20% and 40%, 
respectively. Four independent measurements were carried out for each GAG-
protein pair, and the data were pooled and analyzed using MO. Affinity Analysis 
software v2.2.4 (NanoTemper Technologies) to determine the protein-GAG 
binding constant. For all the analysis, only interactions that produce a binding 





6.1.2 Estimation of biomolecule sizes 
The hydrodynamic radius rh of fluorescein isothiocyanate–dextran (FITC-dextran) 
with varied molecular weights (FD10, FD20, FD70, FD150, and FD2000) 
(Sigma-Aldrich, Germany), was estimated from a previously reported empirical 
relation [270, 271]. 
 𝑟ℎ = 0.015(𝑀𝑤)
0.53±0.02 (15) 
 where the molecular weight Mw is expressed in g/mol and rh in nm.  
On the other hand, the protein size is estimated using a zeta sizer software v.7.11 
(Malvern Instruments Ltd., UK) using the molecular weight of protein as an input 
and the globular protein size as an output. 
6.1.3 Estimation hydrogel mesh sizes 
The mesh size of hydrogels was analyzed based on the rubber-elasticity theory 
considering a full recovery of elastic hydrogels upon a relatively small 
deformation (< 20%) [272]. This theory correlates the number of possible 
covalent cross-links with an average mesh size of the hydrogel networks assuming 
an equal contribution of all polymer chains while neglecting the influence of 
hydrogel network defects. Based on these assumptions, the theoretical hydrogel 
mesh size, ξ is estimated using the following equitation: 








where G´ is the storage modulus, NA is the Avogadro constant, R is the molar gas 







6.1.4 The diffusion of signaling proteins within an affinity-based system 
The mobility of signaling proteins within an affinity-based system with reversible 
binding properties, such as a GAG-based hydrogel system, can be described by 
their effective diffusion coefficient, Deff [166, 184].  
 𝐷𝑒𝑓𝑓 = 𝐷𝑓(1 + 𝑁𝑇/𝐾𝐷)
−1 (17) 
where Df is the free diffusion coefficient of the protein in the gel (which is lower 
than the free diffusion constant of molecules in a buffer because of the steric 
interaction with the gel network), NT  is the total number of protein binding sites in 
the system, and KD (equilibrium dissociation constant) is the strength of affinity 
interaction between the protein and binding ligand. Assuming each GAG 
molecule can bind only to a single molecule of protein, the value of NT  is 
proportional to the GAG concentration within the system. In other words, the 
overall charge density per unit volume of the hydrogel determines the binding 
capacity of the system to given signaling molecules.  This equation is valid under 
several assumptions: 
1. The protein binds and dissociates from the GAG quickly, allowing the 
equilibration between the free and bound protein-GAG complex at a given 
point. 
2. The complex between the GAG and protein is immobile, which is 
applicable as the GAG is covalently crosslinked within the polymer 
network [47].   
3. Binding sites do not reach a saturation point.  In our system, the GAG was 
added (at µM range) in a concentration that is much larger than the typical 
growth factor loading concentration for the cellular stimulations (at a pM-
nM range)  [7].  
4. The binding of the protein to the gel does not interfere with the integrity of 






6.1.5 Mathematical model assumptions 
Several assumptions related to the mathematical model that we used in our 
hydrogel systems: 
1. The polymer network of hydrogel only occupied a small fraction of the 
hydrogel volume. This assumption is particularly valid as the polymer 
content of all hydrogels prepared was within the range of ~2-4%. 
2. The hydrogels remain stable during the experiments as our hydrogels 
system is based on a covalently crosslinked network. For the 
characterization of protein release and gradient experiments, non-MMP 
cleavable starPEG-SH was used, so we did not expect to see a hydrogel 
degradation. Besides, all the hydrogel samples were monitored regularly, 
and no significant changes in their morphology were observed. 
3. Protein transport only happened because of the diffusion, and there is no 
mixing or convective flow in the system. 
4. The free protein, bound, and unbound GAG concentrations are at 
equilibrium at the beginning of each experiment (t= 0 H). 
5. 1:1 binding of the protein to GAG. Single GAG molecule contains only 
one binding site for each protein 
6. There was no resistance in the mass transfer of protein in the release 
medium, and the medium behaved as a sink with unlimited capacity. The 
volume of release media for the release experiment is 40 times of the 
hydrogel volume satisfying Crank’s assumptions for an infinite open 









6.1.6 COMSOL modeling 
6.1.6.1 Protein release from hydrogels loaded within a conical tube. 
Protein release experiments were performed in a 0.5 mL protein low binding 
microcentrifuge tube (Eppendorf Tubes, Germany). The geometry of the tube, as 
provided by the manufacturer, was built in the COMSOL software to simulate the 
release as close as possible to the experimental conditions (Figure 6.1). Due to 
the symmetrical shape of the geometry, a 2D axisymmetric cylindrical coordinate 
system (r, z) was also used. Here, r is the radial distance from the rotational axis, 
and the z is the distance measured from the base of the tube. 
For the quantification of effective diffusion constant of proteins from the release 
experiment (Figure 4.5), the COMSOL numerical simulation was also used 
except that the binding affinity of the GAG to protein (KD) was set to 1 M (no 
affinity), and the amount of protein release at the end of the release study (360 H) 
was considered to be the maximum release. The effective diffusion coefficient 
measured from the FRAP was used as a starting point for the simulation, and the 
best fit to the experimental data was obtained using the least-square method by 
systematic variation of Dgel. Here, as no protein binding/ interaction to the gel 
matrix was assumed, the transport of proteins is controlled only by Fickian 
diffusion. The standard bulk release experiment is the most commonly used 
method to determine the apparent diffusion coefficients of biomolecules within 
the biomaterials. The main reasons for this are primarily for comparing the 
transport properties of different systems where there is no standard method for 








Figure 6.1. Schematic diagram of the protein release from GAG hydrogels within 
a microcentrifuge tube. (A) The geometry of the release experiment set-up. 10 µL 
of hydrogel precursors were loaded at the base of the tube, and after the gel 
polymerization, 400 µL of the medium was added to it to initiate the protein 
release. The hydrogel spans from the z = 0 mm to z = 3.0 mm, and the buffer 
spans from z = 3.0 mm to the z = 17.9 mm. (B) The mass transport dynamic 
within the system. Protein can reversibly bind to the GAG within the hydrogel to 
form immobile protein-GAG complexes. Some of the freely diffusing proteins 
will be released into the medium or rebind to the hydrogel matrix. Z is the height 
from the base of the gel, and r is the radius measured from the vertical axis of the 
tube. 
 
In order to solve the reaction-diffusion equations applied for this geometry, the 
model was divided into two domains: the gel domain and the medium domain. 
Within the gel domain, the initial free protein, free GAG, and the protein-GAG 
complex concentration were determined using set equations as described before 
(Equation 7-10 ). On the other hand, the initial concentration of free protein, 
GAG, and the complex in the release media is set to zero. Finite element analysis 
built in the software with a custom physics-controlled, extra fine, and a free 
triangular mesh was then used to solve the equations. The amount of free protein 






integrated and divided by the initial loading amount to obtain the cumulative 
protein release.   
6.1.6.2 Free and bound protein fraction within a droplet of hydrogels 
The reaction-diffusion model was used to estimate the concentration of free 
VEGF and GAG-bound VEGF, as described in section 3.9. The free VEGF 
concentration in the hydrogel containing different GAG content and GAG-
sulfation pattern (various affinities to the factor) with different initial protein 
loading concentrations was estimated for three days. The details regarding the gel 
geometry and release media are shown in Figure 6.2. Here, the 3D geometry 
model was built in the COMSOL Multiphysics software.  For the simulation, a 
parametric sweep module was applied, and the diffusion coefficient of VEGF in 
hydrogels and solution as determined using the FRAP was used for the input 
parameters. The dissociation rate constant of VEGF from the heparin, as obtained 
by the bio-layer interferometry experiments, was set to 0.0018 s-1. Moreover, the 
KD derived from the curve fitting of the reaction-diffusion model to the 
experimental release was utilized for the simulation (Figure 4.9). The Equations 
11-14 were then solved using the finite element model with a custom physics-
controlled, finer mesh in the hydrogel domain, normal mesh in the medium, and 
free triangular mesh with extra refinement at the gel-buffer interface (maximum 
element size is 100 µm). Surface plot of the free factor concentration with a 
custom manual color and data range from XY plane passing through the middle of 
the gel (at 1000 µm above the gel base) was used to visualize the free factor 







Figure 6.2. A schematic of the protein transport dynamic in a droplet of GAG 
hydrogel.  20 µL of the hydrogel was cast on a hydrophobic glass slide, and 
subsequently, 400 µL of the release medium was added into the surrounding of 
the hydrogel. The hydrogel was modeled as a hemisphere with a radius (R) of 2.1 
mm, and the medium was confined within a block of cell culture chamber with the 
length (L), width (W), and height (H) of 10.7, 9.4, and 4.0 mm, respectively. The 
concentration of free protein and the GAG-bound protein within the hydrogel 
matrix is governed by the ratio of dissociation and association rate constant of the 
protein to the GAG (KD). Freely diffusing protein can also diffuse in the 3D space 
within the hydrogel matrix as well as the release media. 
 
6.1.6.3 Protein gradient formation in hydrogels 
To understand the formation of protein gradient in the gels confined within the 
microfluidic chip described in section 3.3.3, simulation based on the reaction-
diffusion model was applied as described above, implementing one space 
dimension (1D) model of COMSOL software (Figure 6.3). This argument is 
supported by the fact that the hydrogel channel and the nearby growth factor and 
sink channels were designed to be in parallel and have the same height. Therefore, 
we do not expect to see the protein concentration variation across the hydrogel 
matrix's height. As such, the hydrogel region, and the medium (growth factor) 
channels flanking the gel channel, were modeled as a line with a width of 1.3 mm, 






Figure 6.3. Schematic diagram of the protein diffusion through the hydrogel 
integrated within a microfluidic device. The protein transport is modeled utilizing 
one space dimension model of the COMSOL software. The width of the growth 
factor, hydrogel, and medium channel are 0.5, 1.3, and 0.5 mm, respectively. As 
the protein diffuses into the hydrogel, it binds to the immobilize GAG forming the 
protein-GAG complex, which persists depending on the strength of affinity 
interactions between protein and the GAG and the volume density of GAG within 
the 3D polymer matrix. The net protein diffusion occurs from the growth factor 
channel into the medium channel creating a biomolecular gradient within the 
hydrogel. 
 
For the simulation, the diffusion constant of proteins in hydrogels and the pure 
buffer was determined using the FRAP as previously described. Similarly, the 
initial free protein, GAG, and protein-GAG complex concentration were 
determined using the equations described in section 3.9. Besides, the dissociation 
rate constant of the model proteins was fixed to 0.0018/s while the KD was 
obtained from the curve fitting of the experimental release to the reaction-
diffusion model (Table 4.1). The rate constant value was rationally chosen 
according to the literature values for typical protein-GAG interactions. 
Furthermore, it was also demonstrated in a peptide-based affinity controlled 
release system that the values of rate constant (ka & kd) at a given KD did not 
affect the release of protein from the system as long as physically relevant values 
were chosen [52]. Afterward, the finite element analysis built in the COMSOL 
software was used to solve the Equations 11-14, utilizing a user-controlled mesh 
with a maximum element size of 1 µm and free triangular shape. Finally, the 
protein concentration across the hydrogel width was determined at various GAG 
concentrations for up to 72 H.  
For the simulation of non-GAG affine protein gradients, the protein affinity to 
GAG was assumed to be negligible, and thereby, we set the KD value to 1 M. In 





determined using FRAP. To compare the simulated gradient profiles with 
experimental data, the concentration of protein along the width of hydrogels at 
every time point was normalized to the highest protein concentration (at the 
interface between the gel and growth factor source). 
 









CG_Total (µM) Geometry 
Figure 4.6 
(VEGF165-Hep) 




2.69 x 10-4 1.8 x 10-3 6.67 20 64 2.50 1350 Conical 
Figure 4.6 (SDF1α-
Hep) 
8.14 x 10-4 1.8 x 10-3 2.21 81 122 2.50 1350 Conical 
Figure 4.6 (SDF1α-
6ON-DSH) 
3.28 x 10-4 1.8 x 10-3 5.48 81 122 2.50 1350 Conical 
Figure 4.7A 1 x 10-3 1.8 x 10-3 1.8 20 64 1.5, 15, 
150, 1500 
1500, 15 Conical 
Figure 4.7B 8.45 x 10-4 ,4.23 x 
10-4, 2.11 x 10-4, 
8.45 x 10-5 
1.8 x 10-3 2.13, 4.26, 
8.52, 21.3 
20 64 2.50 1500, 15 Conical 
Figure 4.7C 8.45 x 10-10, 8.45 
x 10-6, 8.45 x 10-
5, 8.45 x 10-4, 
8.45 x 10-3 
1.8 x 10-9, 
1.8 x 10-5, 
1.8 x 10-4, 
1.8 x 10-3, 
1.8 x 10-2 
2.13 20 64 2.50 1500, 15 Conical 
Figure 4.7D 8.45 x 10-4 1.8 x 10-3 2.13 20 64 2.50 1500, 150, 
15, 1.5 
Conical 
Figure 4.9A 1.8 x 10-9 1.8 x 10-3 1000000 20 64 1.31 0 droplet 
Figure 4.9B 3.28 x 10-3, 2.59 
x 10-3, 3.31 x 10-3 
1.8 x 10-3 0.548, 
0.695, 0.543 
20 64 1.31 450, 800, 
1000 
droplet 
Figure 4.9C 3 x 10-3, 1.5 x 10-
3, 7.82 x 10-4 
1.8 x 10-3 0.6, 1.2, 2.3 20 64 1.31 1000 droplet 
Figure 4.14B 1.5 x 10-3 1.8 x 10-3 1.2 20  0.25 450 Line 
Figure 4.19B-
SDF1α 
8.14 x 10-4 1.8 x 10-3 2.21 81 122 0.25 1000 Line 
Figure 4.19B-
VEGF165 
1.5 x 10-3 1.8 x 10-3 1.2 20 64 0.25 1000 Line 
Figure 4.19B-EGF 1.8 x 10-9 1.8 x 10-3 1000000 68 133 0.25 1000 Line 
Figure 4.19B-
VEGF121 
1.8 x 10-9 1.8 x 10-3 1000000 20 68 0.25 1000 Line 
Figure 4.20B-
SDF1α 












6.1.7 Vascular network analysis 
Table 6.2. Creation parameters. Parameters used for the Imaris - filament tracer 
module to analyze 3D confocal images of vasculature. 
 
Algorithm  
Name Threshold (loops) 
Track (overtime) false 
Preprocessing  
Channel Index 2 (Phalloidin) 
Enable Preprocessing false 
Approximate Diameter 14.0 µm 
Preserve Edges false 
Segmentation  
Fill Cavities true 
Connected BaseLine true 
Threshold Low 2500 
Threshold High 15000 
Graph Compilation  
Branch Length Ratio 3 
Find Dendrite Beginning Point false 
Finish  
Build all Time Points true 




6.1.8 Metabolic activity assays 
The metabolic activity of HUVECs was evaluated using the PrestoBlue assay 
following the manufacturer’s instructions. Briefly, a PrestoBlue Reagent 
(ThermoFisher Scientific) was mixed with warm media at 1: 10 dilution. 
Following the addition of 400 µL of the mixture, the hydrogel samples were 
incubated at 37°C for 1 H. Subsequently, 150 µl of the solution was transferred in 
duplicate into a black 96 well plate (Greiner) for the fluorescence measurement 
using a Tecan Genios plate reader (Tecan Deutschland GmbH). The excitation 






6.1.9 Bioactivity of VEGF  
To evaluate the bioactivity of VEGF, 10,000 HUVECs/ well were seeded in 96 
wells plate for 24 hours.  Subsequently, the cells were treated with 1, 10, and 100 
ng/mL of freshly prepared VEGF or VEGF pre-incubated for 1-3 days at 37 oC. 
After three days of treatment, cells' metabolic activity was evaluated with 
PrestoBlue assay as described above, except that the total volume of medium and 
PrestoBlue added onto each well was set to 200 L. VEGF's bioactivity was then 























6.2 Supplementary data 
6.2.1 Protein binding to GAGs or- GAG-derivatives  
In this study, four proteins were used as molecular probes representing different 
signaling molecules with varying molecular sizes and heparin affinity. The 
epidermal growth factor (EGF) was selected to represent a relatively small (6.2 
kDa) and (under physiological conditions) negatively charged protein (pI 4.6) 
[273], thus showing no affinity to heparin. The Stromal cell-derived factor 1α 
(SDF1α), with a specific heparin-binding site and cationic excess charge (pI of 
10, the molecular weight of 8 kDa), was used as a structurally similar heparin-
affine factor [78]. The comparison was extended by growth factors of higher 
molecular weight (larger size and hydrodynamic radius) to study the influence of 
molecule size on the diffusion of the weak-heparin binding and weakly acidic 
VEGF121 (28 kDa, pI 6.4) [274] as well as the heparin-binding, cationic 
VEGF165 (38.2 kDa, pI 8.3) [274]. 
MicroScale Thermophoresis (MST) is a sophisticated technique to quantify a 
large variety of biomolecular interactions [120]. The method measures the 
movement of molecules along a temperature gradient (thermophoresis), which 
strongly depends on the size, charge, and conformation of molecules [120, 182]. 
Thus, this technique is quite sensitive to detect the changes in the molecular 
mobility of protein upon binding to a ligand along the temperature gradient. Here, 
MST was used to characterize the binding of heparin or desulfated heparin 
derivatives to the EGF, SDF-1α, VEGF121, and VEGF165 after their 
functionalization with the maleimide moiety (Figure 6.4). Although the 
VEGF165 and SDF1α were already known for their specific binding to heparin 
[167, 190, 193], with the reported KD values of 80-1228 nM [167, 275] and 60 nM 
[275], respectively, the maleimide modifications might alter the structural feature 
of heparin that influences its recognition by the heparin-binding domain of these 
proteins. Therefore, this step is critical to ensure that the binding of heparin affine 
proteins to heparin is preserved. 
The 6O and N sulfate group of heparin can be selectively removed to modulate 





using MST showed that the sulfation pattern of GAGs regulates the binding 
affinity for heparin-binding proteins (SDF1α & VEGF165). As shown here, 
decreasing the sulfate content of heparin by removing 6O sulfate decreases the 
binding affinity of SDF1α from 1.2 µM to 16.7 µM (Figure 6.4A&E). However, 
we could not detect the binding SDF1α to the 6ON-DSH heparin. Similarly, 
removing 6O sulfate from the heparin decreased the affinity of heparin to 
VEGF165 by a factor of four with the strength of interaction (KD) of 0.9 and 4.2 
µM, for Hep and 6O-DSH, respectively. Also, subsequent removal of N sulfate 
from 6O-DSH to generate 6ON-DSH almost ablate its affinity for the VEGF165 
(KD = 33.3 µM) (Figure 6.4B&E).  
Interestingly, in contrast to the smaller affine protein model, the VEGF165 
displayed some weak affinity for the PEG (as shown by the binding curve of 
VEGF165 to the PEG; the binding responses were observed when the PEG 
concentration is 10 µM or higher). Although PEG is considered to be biologically 
inert [213], the functionalization of polymer with the maleimide group could 
probably introduce additional hydrophobic interaction, which is more pronounced 
for a larger protein compared to the smaller ones. Furthermore, as predicted, 
heparin or its derivatives exhibit no affinity to the non-affine proteins (VEGF121 







Figure 6.4. Binding analysis of model proteins to maleimide functionalized-Hep 
or Hep derivatives as determined by microscale thermophoresis (MST). Binding 
curve of (A) SDF1α, (B) VEGF165, (C) EGF, and (D) VEGF121 to Hep, 6O-
DSH, 6ON-DSH, and PEG. The Hep/ Hep derivatives concentration was titrated 
in the range of 15.25 to 500000 nM, whereas the concentration of NT647-labeled 
proteins was kept constant (~2.5 nM). All the measurements were carried out 
using 30% MST Power. (E) The binding constants of proteins to the Hep/ Hep 











6.2.2 Adaptation of FRAP technique to analyze protein mobility in the 
hydrogels  
Several techniques can be used to monitor the diffusion of biomolecules within 
living cells or materials, such as single-particle tracking (SPT), fluorescence 
correlation microscopy (FCS), photoactivation, and fluorescence recovery after 
photobleaching (FRAP) [276, 277]. Of these approaches, FRAP is the most 
applicable one to quantify the mobility of molecules within numerous biological 
systems and biomaterials at a micrometer scale as it does not require specialized 
instruments and analytical tools [202, 278, 279].  In this study, the technique was 
adapted to measure the diffusion coefficient of model proteins in pure buffer or 
GAG-hydrogel matrices (Figure 6.5). As the technique is based on fluorescent 
detection, all the proteins here are labeled with fluorescent using NHS-ester 
chemistry, which specifically reacts with primary amine groups of lysine residues 
or N-terminal end of polypeptides (Figure 6.5A). The reaction rate depends on 
the pH of the buffer and reaches a maximum at a basic pH of ~8.3 [280]. One of 
the key successes of FRAP experiments is choosing the right of fluorescent dyes 
[281]. It is important to note that the chosen fluorescent dye should not 
significantly interfere with the diffusion of original molecules or their interaction 
with other molecules. Besides, the fluorescent probe should also have an 
intermediate photostability to allow for the photobleaching to occur as well as the 
acquisition of post-bleach images with sufficient signal to the noise ratio. Green 
fluorescent probes such as Fluorescein Iso Thio Cyanate (FITC) and the Alexa-
488 are the most commonly used for the FRAP measurements. 
Nevertheless, here, the Alexa-488 was chosen for the labeling of proteins due to 
the significant bleaching of FITC during the post-bleach image acquisitions, 
especially during the diffusion measurement of heparin-affine proteins within 
affine hydrogel systems (data not shown). In our study, both small and large 
proteins can be successfully labeled with Alexa 488, with an average labeling 
degree of 1-2 dyes per protein molecule (Figure 6.5B).  Such a labeling degree 
was shown to be sufficient to produce an optimum fluorescent signal, which is 
essential for the subsequent analysis of the FRAP data to obtain a reliable 





Several diffusion models, which mainly differ on the geometry of the bleach spot 
and the diffusion dimensionality, have been developed to extract the diffusion 
coefficient of proteins within hydrogels or pure buffer from the fluorescence 
recovery curve. However, a uniform disk model for 2D diffusion in a circular 
spot,  which was initially developed by Soumpasis [162], is one of the most 
widely used because it does not require a complicated analytical tool/ program for 
processing the FRAP data. Several assumptions of the uniform disk model need to 
be satisfied to accurately extract the diffusion coefficient from the FRAP curve 
include [270]: 
1. Uniform distribution of fluorescent molecules within the samples. This 
assumption was validated by our confocal microscopy analysis, which 
revealed a uniform distribution of  fluorescently labeled proteins across the 
hydrogel thickness and around the bleach spot (Figure 6.5C-D) 
2. Isotropic diffusion in an infinite medium. This condition can be satisfied as 
the bleach spot was chosen in a region far away from the gel boundary. 
Also, the bleach spot size was approximately less than 10% of the total 
observational area, so a sufficient amount of fluorescent can still diffuse 
into the bleached spot to recover the fluorescent intensity (Figure 6.5D) 
3. 2D diffusion. In our study, a 10X objective with a low NA (0.3) was used. 
Therefore, it could generate a nearly cylindrical bleach profile, which is 
uniform over the entire thickness of the hydrogel (~120 µm) (Figure 6.5E). 
The uniform bleach profile that extends along the optical axis ensures that 
the fluorescent diffusion into the bleached spot effectively occurs only by 
radial diffusion [278].  
4. The diffusion during photobleaching is negligible. In this study, the 
photobleaching took only ~600 ms, which is sufficiently short to avoid 
significant fluorescence recovery during the bleaching process [161, 270, 
282]. 
In addition to these assumptions, to accurately determine the diffusion constant, 
the bleached spot's radius needs to be chosen appropriately. The initial uniform 
disk model developed by Saumpasis [162] employed uniform laser profiles that 





confocal microscopes scan the samples pixel-by-pixel and line-by-line using 
laser beams with Gaussian profiles [278], resulting in bleaching light 
distribution/ radial fluorescence intensity profile across the bleached spot that 
does not follow a discontinuous step function approximation (A sudden 
fluorescence intensity drop at the transition between the bleached and 
unbleached regions). As a result, this model may not be readily applicable to 
measure the diffusion coefficient of proteins using the standard microscopes. 
However, when the radius of the bleached spot is much larger than the effective 
Gaussian resolution, the resulting bleaching illumination profile is equivalent to 
the stationary beam with a uniform radial and Gaussian axial distribution [270]. 
The failure to take this into account can lead to underestimation of the diffusion 
coefficient if the Soumpasis equation (Equation 4) is used to analyze confocal 
FRAP data, especially for fastly diffusing proteins.  
For the confocal microscopes, the effective bleaching resolution rb can be 
approximated as a factor of 2–4 more than the optical resolution [278]. In our 
study, the optical resolution of the 10X objective with an NA of 0.3 is 
approximately ~1 µm. From this, the effective bleaching resolution can be 
approximated to be ~2-4 µm. Therefore, to optimize the size of the bleach spot, 
we analyzed the bleaching intensity distribution of the bleached spot with a 
nominal size in the range of 2.5-20 µm (Figure 6.5 F). As predicted, the 
bleached spot profile was becoming more uniform with increasing bleached spot 
size, justifying the selection of 20 µm bleach spot for further testing 
measurement utilizing biomolecules with known diffusion coefficients. The 
Bovine Serum Albumin, FD 20, and FD 2000 were then chosen as the test 
molecules, and subsequently, the diffusion in PBS was measured utilizing the 
established FRAP protocol.  As expected, the measurement results were shown 
to be comparable with the values obtained from the literature [270, 283, 284] 
(Figure 6.5G), supporting the selection of 20 µm bleach spot size for the 
subsequent studies. This value was in good agreement with Braeckmans and co-
worker's recommendation for using a nominal bleach spot with a radius of at 
least five times larger than the effective bleaching resolution (2-4 µm) to 







Figure 6.5. Optimization of FRAP experimental parameters for the quantitative 
analysis of molecular diffusivity using a uniform disk model. (A) Fluorescence 
labeling of the proteins. Proteins were labeled with fluorescence at their primary 
amines using NHS ester Alexa-488 at pH 8.3. (B) The degree of fluorescence 
labeling. The degree of fluorescence labeling was calculated as a molar ratio of 
dye to protein after the purification step from the unreacted dyes. For each FRAP 
measurements, proteins were fluorescently labeled with Alexa-488 and 
encapsulated into the ATTO-647-labeled hydrogel during the gelation process. 
(C) The XZ section of the FRAP hydrogel sample with a thickness of ~120 µm 
showing a uniform protein distribution within the hydrogel matrix. (D) A circular 
bleached spot was generated just after the photobleaching of fluorescently labeled 
proteins within the middle section of the hydrogel. (E) Uniform bleaching of 20 
µm spot was observed across the thickness of a hydrogel sample. (F) Relative 
bleaching fluorescence intensity distribution of the bleached spot of different sizes 
was measured immediately after the photobleaching. (G) The diffusion coefficient 
(D) of the test samples (FITC-BSA, FIZTC Dextran 20, FITC Dextran 2000) in a 
solution obtained from the literature and FRAP methods using the optimized 












6.2.3 Estimation of hydrogel mesh size 
The mesh size of hydrogels is known to affect the transport signaling molecules 
[16] and the survival and functions of encapsulated cells [285]. The mobility of 
non-charged probe-macromolecules, fluorescently-labeled, FITC-dextran of 
different molecular sizes (MW: 10-200 kDa) was investigated within a set of 
hydrogels prepared with different stiffness (~0.2-6.8 kPa) to investigate the 
potential restriction of the diffusivity of signaling molecules within our GAG 
hydrogels system (Figure 6.6A). The dextran was used as a molecular probe to 
characterize the mesh size of hydrogels in place of proteins/ growth factors 
because of its relatively neutral charge at physiological pH. Thereby, we do not 
expect to see their binding to the hydrogel components. Besides, unlike most 
growth factors, the dextrans are stable and do not form aggregates over time. 
Thus, the immobilization of dextrans within the scaffold is caused only by the 
steric restriction due to the larger molecular size compared to the hydrogel mesh 
size, but not by the binding or aggregate formation.  
While the size of dextrans can be estimated from their molecular weight [270], the 
mesh size of hydrogels was calculated from the rubber elasticity theory [2]. Based 
on our estimation, the size of 10-2000 kDa dextran was approximately within the 
range of ~4-65 nm, while the hydrogels with stiffness ~0.2-6.8 kPa were 
estimated to have a mesh size of ~9-28 nm, covering all possible mesh sizes of 
our in situ cross-linkable hydrogel system [47].  In general, the fraction of 
unrecovered fluorescence/ immobile fraction of all type dextrans in solutions is 
close to zero, indicating a sufficient amount dextran diffused without any 
restrictions from the unbleached region into the bleached spot (Figure 6.6B). 
Besides, their diffusion within the solutions was shown to be inversely 
proportional to their molecular size (Figure 6.6C). In opposite to that, only the 
dextran with molecular weight as large as 70 kDa (Size = 11 nm) exhibited no 
restriction in their mobility within all hydrogels tested. A less than 20% of the 
dextrans with a molecular weight of 10-70 kD were immobile within the 
hydrogels.  Their diffusivity was also inversely correlated to their molecular size 





On the other hand, the mobility of dextran with a molecular weight of 150 kDa or 
larger was severely reduced beyond a specific hydrogel mesh size. For instance, a 
significant immobile fraction (≥ 20%) of the dextran with a molecular weight of 
150 kDa (size = 17 nm) was found in the hydrogel with a mesh size of 9 nm, 
whereas that of the 500 kDa dextran (size = 31 nm)  was observed in the hydrogel 
with the mesh size of 11 nm or lower. Moreover, the mobility of 2000 kDa 
dextran was constrained in all hydrogels type tested, even for the gel with the 
largest mesh size (28 nm). This finding was in good agreement with previous 
studies that showed limited mobility for 2000 kDa dextran within PEG-
chondroitin-sulfate-hydrogels with a mesh size of ∼37 nm [286]. 
Interestingly, the high immobile fractions of the dextran with molecular weight 
150 kDa or larger was also accompanied by the lower diffusion constant (≤ 10 
µm2/s). However, we did not see a significant difference in their diffusivity within 
the hydrogels containing different mesh sizes. This could probably be attributed to 
their large size that exerts a considerable steric hindrance to the hydrogel network, 
which hamper their diffusivity even within the hydrogel with the largest mesh size 
(28 nm). 
Altogether, these results supported that the hydrogel mesh size estimated from the 
rubber elasticity theory corresponds well to the diffusion profile as well as 
molecular size cut off of the hydrogels for the dextrans of different molecular 
sizes. All hydrogels allowed dextrans molecules to freely diffuse if the molecular 
size is smaller than ≤70 kDa. In this case, dextran's mobility was primarily 
governed by the ratio between the molecular size and mesh size of polymer 
networks. As the molecular weights of all proteins we used in our systematic 
study were smaller than 70 kDa, any protein immobility within the hydrogels was 
not expected to be caused by the size filtering of the hydrogel but rather by the 







Figure 6.6. The mobility of FITC-dextrans with different molecular weights 
within the GAG hydrogels of various stiffness. The mobility of FITC-dextran with 
a molecular weight in the range of 10-2000 kDa (FD10-FD2000) was analyzed 
using fluorescence recovery after photobleaching (FRAP). The hydrogel mesh 
size was determined using Rubber elasticity theory [2], and the dextran molecular 
size was estimated as previously described [270]. (A) The post bleach images 
acquired ~120s after the photobleaching. (B) Quantification of an immobile 
fraction within hydrogels at ~120s after the bleaching. (C). The diffusion 
coefficient of dextran within the hydrogels. Data represents mean ± SD (n = 3). 








Figure 6.7. Concentration- and time-dependent VEGF-induced cellular metabolic 
activity. HUVECs on 2D cell culture was incubated with VEGF, and the 
metabolic activities were assessed via Prestoblue assays. HUVECs were seeded in 
96-well plates at 10,000 cells/well in a non-supplemented Basal medium. Results 
are presented as the relative increase in fluorescence intensity compared to the 
untreated control. (A) HUVECs treated with various concentrations of VEGF 
(n=6) showed a dose-dependent stimulatory response. (B) VEGF, which were pre-
incubated for 24 h and 48 h at 37°C before added to the cultured cells, exhibited 





Figure 6.8. The mechanical properties of the binary starPEG-GAG hydrogel 
containing variable GAG content at different crosslinking degree/ molar ratio of 







Figure 6.9. Particle size analysis of the VEGF121 dissolved in the PBS (pH 7.4) 
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